  
 
 
 
Clinical Development  
LCI69 9 (osilodrostat ) 
Oncology Clinical Trial Protocol  CLCI699C2302  / [STUDY_ID_REMOVED]  
 A Phase III, multi -center, randomized, double -blind, 48 
week study with a n initial 12 week placebo -controlled 
period to evaluate the safety and efficacy of osilodrostat in 
patients with Cushing’s disease  
Document type  Amended Protocol Version  
EUDRACT number  2014‐004092‐[ADDRESS_916291] of abbreviations  ................................ ................................ ................................ ............  8 
Glossary of terms  ................................ ................................ ................................ ...............  10 
Amendment 2 (20 -Dec-2019)  ................................ ................................ ............................  11 
Amendment 1 (20 -Nov-2017)  ................................ ................................ ...........................  15 
Protocol summary:  ................................ ................................ ................................ .............  19 
1 Background  ................................ ................................ ................................ ........................  24 
1.1 Overview of disease pathogenesis, epi[INVESTIGATOR_013]  ..............  24 
1.1.1  Epi[INVESTIGATOR_621301]’s syndrome and 
Cushing’s disease  ................................ ................................ ..................  24 
1.1.2  Current treatment modalities  ................................ ................................ . 25 
1.1.3  Unmet medical need  ................................ ................................ ..............  26 
1.2 Introduction to investigational treatment, osilodrostat  ................................ ..........  26 
1.2.1  Overview of osilodrostat  ................................ ................................ ....... 26 
2 Rationale  ................................ ................................ ................................ ............................  33 
2.1 Study rationale and purpose ................................ ................................ ...................  33 
2.2 Rationale for the study design  ................................ ................................ ...............  34 
2.2.1  Overall design  ................................ ................................ .......................  34 
2.2.2  Period 1: Double -blind, placebo -controlled  ................................ ..........  34 
2.2.3  Period 2: Open -label  ................................ ................................ .............  35 
2.2.4  Optional Extension Phase  ................................ ................................ ..... 35 
2.2.5  Steps to ensure reliability of UFC results  ................................ .............  35 
2.2.6  ECG Monitoring ................................ ................................ ....................  36 
2.3 Rationale for dose and regimen selection  ................................ ..............................  36 
2.4 Rationale for choice of combination drugs  ................................ ............................  37 
2.5 Rationale for choice of comparators drugs  ................................ ............................  37 
2.6 Benefit -Risk Asses sment of osilodrostat in study population  ...............................  37 
2.7 Biomarker development ................................ ................................ .........................  39 
  40 
3 Objectives and endpoints  ................................ ................................ ................................ ... 41 
4 Study design  ................................ ................................ ................................ ......................  44 
4.1 Description of study design  ................................ ................................ ...................  44 
4.2 Timing of interim analyses and design adaptations  ................................ ...............  47 
4.3 Definition of end of the study  ................................ ................................ ................  47 

[COMPANY_001]  Confidential  Page 3 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 4.4 Early study termination ................................ ................................ ..........................  48 
5 Population  ................................ ................................ ................................ ..........................  48 
5.1 Patient population  ................................ ................................ ................................ .. 48 
5.2 Inclusion criteria  ................................ ................................ ................................ .... 48 
5.3 Exclusion criteria  ................................ ................................ ................................ ... 49 
6 Treatment  ................................ ................................ ................................ ...........................  51 
6.1 Study drug  ................................ ................................ ................................ ..............  51 
6.1.1  Dosing regimen  ................................ ................................ .....................  52 
6.1.2  Ancillary treatments  ................................ ................................ ..............  52 
6.1.3  Rescue medication for co -morbid conditions  ................................ ....... 52 
6.1.4  Guidelines for continuation of treatment  ................................ ..............  53 
6.1.5  Treatment duration  ................................ ................................ ................  53 
6.2 Dose titration guidelines  ................................ ................................ ........................  54 
6.2.1  Study Period 1: The double -blind, placebo -controlled period 
(Weeks 1 -12). ................................ ................................ ........................  54 
6.2.2  Study Period 2:  The single -arm, open -label dose titration period 
(Weeks 12 -48) ................................ ................................ .......................  56 
6.2.3  Extension phase (Weeks 48 - 96): ................................ .........................  57 
6.3 Dose modifications  ................................ ................................ ................................  57 
6.3.1  Dose modification and dose delay  ................................ ........................  57 
6.3.2  Guidance for evaluation and management of hypocortisolism  .............  61 
6.3.3  Follow -up for toxicities  ................................ ................................ .........  62 
6.3.4  Anticipated risks and safety concerns of the study drug  .......................  63 
6.4 Concomitant medications  ................................ ................................ ......................  63 
6.4.1  Permitted concomitant therapy  ................................ .............................  63 
6.4.2  Permitted concomitant therapy requiring caution and/or action  ...........  [ADDRESS_916292]  ................................ .......................  106 
8.2 Serious adverse events  ................................ ................................ .........................  108 
8.2.1  Definitions  ................................ ................................ ...........................  108 
8.2.2  Reporting  ................................ ................................ .............................  108 
8.3 Emergency unblinding of treatment assignment  ................................ .................  109 
8.4 Pregnancies  ................................ ................................ ................................ ..........  110 
8.5 Warnings and precautions ................................ ................................ ....................  110 
8.6 Data Monitoring Committee  ................................ ................................ ................  110 
8.7 Steering Committee  ................................ ................................ .............................  111 
9 Data collection and management  ................................ ................................ .....................  111 
9.1 Data confidentiality  ................................ ................................ .............................  111 
9.2 Site monitoring  ................................ ................................ ................................ .... 111 
9.3 Data collection  ................................ ................................ ................................ ..... 112 
9.4 Database management and quality control  ................................ ..........................  112 
10 Statistical methods and data analysis  ................................ ................................ ..............  113 
10.1  Analysis sets  ................................ ................................ ................................ ........  114 
10.1.1  Full Analysis Set  ................................ ................................ .................  114 

[COMPANY_001]  Confidential  Page 5 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 10.1.2  Safety Set  ................................ ................................ ............................  114 
10.1.3  Per-Protocol Set  ................................ ................................ ..................  114 
10.1.4  Pharmacokinetic analysis set  ................................ ...............................  114 
10.1.5  Other analysis sets  ................................ ................................ ...............  114 
10.2  Patient demographics/other baseline characteristics  ................................ ...........  114 
10.3  Treatments (study drug, concomitant therapi[INVESTIGATOR_014], compliance)  .............................  114 
10.4  Primary objec tive ................................ ................................ ................................ . 115 
10.4.1  Variable  ................................ ................................ ...............................  115 
10.4.2  Statistical hypothesis, model, and method of analysis  ........................  115 
10.4.3  Handling of missing values/censoring/discontinuations  .....................  115 
10.4.4  Supportive and se nsitivity analyses  ................................ ....................  116 
10.5  Secondary objectives  ................................ ................................ ...........................  116 
10.5.1  Key secondary  objective(s)  ................................ ................................ . 116 
10.5.2  Other secondary efficacy objectives  ................................ ...................  117 
10.5.3  Safety objectives  ................................ ................................ .................  118 
10.5.4  Pharmacokinetics  ................................ ................................ ................  121 
  121 
10.5.6  Resource utilization  ................................ ................................ .............  121 
10.5.7  Patient -reported outcomes  ................................ ................................ ... 121 
  122 
  
 122 
  122 
  122 
  123 
  123 
10.7  Interim analysis  ................................ ................................ ................................ .... 123 
10.8  Sample size calculation ................................ ................................ ........................  123 
10.9  Power for analysis of key secondary variables  ................................ ....................  123 
11 Ethical considerations and administrative procedures  ................................ ....................  124 
11.1  Regulatory and ethical compliance  ................................ ................................ ...... 124 
11.2  Responsibilities of the investigator and IRB/IEC/REB  ................................ ....... [ADDRESS_916293] keepi[INVESTIGATOR_5304]  .....................  126 
11.7  Confidentiality of study documents and patient records  ................................ ..... 127 
11.8  Audits and inspections  ................................ ................................ .........................  127 
11.9  Financial disclosures  ................................ ................................ ............................  127 
12 Protocol adherence  ................................ ................................ ................................ ..........  127 
12.1  Amendments to the protocol  ................................ ................................ ................  127 
13 References (available upon request)  ................................ ................................ ................  128 
14 Appendices  ................................ ................................ ................................ ......................  131 
Appendix 1: List of drugs to be used with caution with osilodrostat  ..............................  131 
Appendix 2: Medications with a “Known ri sk to cause TdP” and with a “Possible 
risk to cause TdP”  ................................ ................................ ................................  134 
Appendix 3:  Normal ranges for cardiovascular risk factors  ................................ .... [ADDRESS_916294] of figures  
Figure 1 -1 Mechanism of action of osilodrostat in Cushing’s Disease  ..................  [ADDRESS_916295] of mUFC (PD analysis 
set) ................................ ................................ ................................ .........  30 
Figure 1 -3 Mean (+ /-SE) mUFC (nmol/24h) over time by [CONTACT_9084]  .........................  [ADDRESS_916296] of tables  
Table 3 -1 Objectives and related endpoints  ................................ ..........................  41 
Table 6 -1 Dose Modification Guidelines for osilodrostat -suspected toxicities  .... 58 
Table 6 -2 Criteria for interruption and re -initiation of osilodrostat for 
abnormal liver function  ................................ ................................ .........  60 
Table 6 -3 Preparation and dispensing  ................................ ................................ ... 67 
Table 6 -4 Packaging and labeling  ................................ ................................ .........  68 
Table 6 -5 Supply and storage of study drugs  ................................ ........................  68 
Table 7 -1a Visit evaluation schedule – Core – Period 1  ................................ .........  70 
Table 7 -1b Visit evaluation schedule – Core (continued) – Period 2  .......................  75 
Table 7 -2 Visit evaluation sched ule – Extension  ................................ ..................  78 
Table 7 -3 Disease and Imaging Assessment collection plan  ................................ . 86 
Table 7 -4 Central Clinical laboratory parameters  ................................ .................  90 
Table 7 -5 Imaging Assessment collection plan  ................................ .....................  91 
Table 7 -6 ECG collection plan  ................................ ................................ ..............  92 
Table 7 -7 Pharmacokinetic blood collection log  ................................ ...................  97 
  99 
  100 
  100 
Table 7 -11 Patient reported outcomes (PROs) collection plan  .............................  [ADDRESS_916297] of medications with potential drug -drug interactions with 
osilodrostat – to be used with caution  ................................ .................  [ADDRESS_916298] of abbreviations  
ACTH  Adrenocorticotropic Hormone  
AE Adverse Event  
ALP Alkaline Phosphatase  
ALT Alanine aminotransferase/glutamic pyruvic transaminase/GPT  
AST Aspartate aminotransferase/glutamic oxaloacetic transaminase/GOT  
BDI Beck Depression Inventory  
b.i.d.  bis in diem /twice a day  
BMI Body Mass Index  
CD Cushing’s disease  
CI Confidence Interval  
CMH  Cochran –Mantel –Haenszel  
CNS  Central Nervous System  
eCRF  Electronic Case Report/Record Form  
CRO  Contract Research Organization  
CS Cushing’s syndrome  
CSR  Clinical study report  
C-SSRS  Columbia Suicide Severity Reporting Scale  
CT Computerized Tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
DBP Diastolic Blood Pressure  
DHEA(S)  Dehydroepi[INVESTIGATOR_2119] (Sulfate)  
DMC  Data Monitoring Committee  
DS&E  Drug Safety and Epi[INVESTIGATOR_677337]-energy X -ray absorptiometry  
ECG  Electrocardiogram  
EDC  Electronic Data Capture  
FAS Full Analysis Set  
FSH Follicle -stimulating hormone  
GFR  Glomerular Filtration Rate  
eGFR  Estimated Glomerular Filtration Rate  
ICH International Conference on Harmonization  
IE  Independent Endocrinologist  
IEC Independent Ethics Committee  
IRB Institutional Review Board  
IRT Interactive Response Technology that includes Interactive Voice Response System and 
Interactive Web Response System  
ITT intent -to-treat 
KOL key opi[INVESTIGATOR_677338]-MS/MS  Liquid chromatography -tande m mass spectrometry  
LFT Liver Function Test  
LH Luteinizing Hormone  
LLN Lower Limit of Normal  
MoA Mechanism of Action  
MRI Magnetic Resonance Imaging  
mUFC  mean Urine Free Cortisol  
[COMPANY_001]  Confidential  Page 9 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 PAS Pharmacokinetic Analysis Set  
PD Pharmacodynamic  
PK Pharmacokinetic  
PPS Per-Protocol Set  
PRO  Patient -Reported Outcomes  
PT Preferred Term  
QoL Quality of Life Questionnaire  
QTc(F)  QT corrected (Fridericia QT formula)  
eSAE  Electronic Serious Adverse Event  
SAS Safety Analysis Set  
SBP Systolic Blood Pressure  
s.c. Subcutaneous  
SC Steering Committee  
SD Standard Deviation  
SEC Safety Event Categories  
SMR  standardized mortality ratio  
SOP  Standard Operating Procedure  
SS Safety Set  
TBIL  Total bilirubin  
TdP Torsades des Pointes  
UFC Urine Free Cortisol  
ULN Upper Limit of Normal  
[COMPANY_001]  Confidential  Page 10 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 Glossary of terms  
Assessment  A procedure used to generate data required by [CONTACT_6551]  A biological specimen including, for example, blood (plasma, serum), saliva, 
tissue, urine, stool, etc. taken from a study subject or study patient  
Baseline value  Value from the last assessment prior to first dosing  
Complete Response  Defined as mUFC ≤ ULN   
Core phase  Includes both Period 1 and Period 2 ; Visits  Day 1 through  Week 48.    
Enrollment  Point/time of patient entry into the study  when informed consent must be 
obtained (i.e. prior to starting any of the procedures described in the 
protocol)  
Escape  Defined as loss of control of mUFC after week 26 (mean UFC > 1.[ADDRESS_916299] tolerated dose of osilodrostat and not 
related to a dose interruption or dose reduction due to safety reasons) after 
prior mUFC normalization  
Optional e xtension phase  Week 48 through Week 96  
Study drug  Osilodrostat or placebo  
Medication number  A unique identifier on the label of each blinded study drug package linked to 
one of the treatment groups of a study  
mUFC  mUFC at a particular visit is the arithmetic mean  of the urinary free cortisol 
(UFC) levels calculated from t hree 24-hour urine samples collected  at 
screening, baseline, Week 12 , Week 36 , Week 48  and Week 12 follow up .  
The arithmetic mean of UFC from two 24 -hour urine  samples will be 
evaluated  at all oth er study visits  
Overall Response  Defined as  either  complete response (m UFC ≤ ULN  ) or partial response 
(mUFC > ULN with ≥ 50% reduction from baseline)  during study treatment  
Partial Response  Defined as  mUFC > ULN with ≥ 50% reduction from baseline  during study 
treatment  
Period  Period 1 : Day 1 through  Week 12.  
Period 2 : Starts immediately after the Week [ADDRESS_916300] Number (Subject No.)  A unique identifying number assigned to each patient/subject/healthy 
volunteer who enrolls in the study  
Study drug discontinuation  Point/time when patient permanently stops taking study drug for any reason  
Variable  Identifier used in the data analysis; derived directly or indirectly from data 
collected using specified assessments at specified time -points  
Withdrawal of Co nsent Withd rawal of co nsent occurs only wh en a patient d oes not want to 
partic ipate in  the study any  longer, a nd does not want  any further visits or 
assessmen ts, and  does not want any further study related cont act 
[COMPANY_001]  Confidential  Page 11 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 Amendment 2  (20-Dec-2019 )  
Amendment rationale  
As of [ADDRESS_916301] 
patient enrolled in the study completes the 48 week core perio d, protocol amendment 02 should 
be locally approved at participating sites.  All remaining patients will then comp lete the study 
as soon as possible after completion of the 48 week core period, rather than after completion of 
the optional 48 week extension period. After local approval of this protocol amendment 02, 
patients who are still receiving treatment in the opt ional extension period (i.e. who have not yet 
reached week 96)  will be asked to come for an end-of-treatment visit within 4 weeks after the 
local amendment approval date (either at their next scheduled visit if the visit is scheduled 
within 4 weeks after t he local amendment approval, or at an unscheduled visit). Patients who 
are still receiving clinical benefit are eligible to join a separate long -term follow -up study.  
At the time when this clinical study was set up, the optional  extension phase was implem ented 
as an initial measure to ensure that all patients benefiting from treatment during the [ADDRESS_916302] a possibility to continue receiving treatment, and to ensure that 
emerging  safety and efficacy  data would be captured. As of the dat e of release of this 
amendment, a separate long -term follow -up study collecting long term efficacy and safety data 
is now open at all sites with ongoing patients . This provides a means for long-term safety and 
efficacy data to be collected within a prospec tive clinical trial setting for all eligible patients , 
without impacting the primary and key secondary objective  of this study.  
Other changes  include : 
• The Beck Depression Inventory (BDI) was removed from Appendix 3 as BDI is  not used 
in the  study. For this study, the BDI -II is used  
• Appendix 3, Patient Quality of Life questionnaires,  deleted for version control.  
Changes to the protocol  
Changes to specific sections for the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.  
• List of abbreviations: the list of abbreviations was updated  
• Protocol Summary table, study design updated language to remove duration of 48 week 
Extension phase.  
• Proto col Summary table study design:  updated to add additional parameters to be blinded  
in period 1 ; urine creatinine,  aldosterone,  renin, estradiol, estrone, androgens (testosterone, 
delta -4 androstenedione, DHEAS), and precursors 11 -deoxycortisol, 11 - 
deoxy corticosterone   
[COMPANY_001]  Confidential  Page 12 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 • Protocol Summary table, extension phase :  defined as optional open label Extension phase 
and patients must end participation in the optional Extension phase within [ADDRESS_916303]  
• Section 1.1.1: Corrected reference  from ‘Amaldi, et al 2003’ to ‘Arnaldi, et al 2003’  
• Section 2.2.4 Optional Extension Phase: updated section title to ‘Optional extension 
phase’ and language added to clarify per Protocol Amendment [ADDRESS_916304]  
• Section 2.2.6 ECG Monitoring: language added to clarify Holter recordings to be 
performed as applicable at Week 72, and at the end of treatment visit in the optional 
Extension phase.   
• Section 4.1.  Description of study design :  deleted language defining optional extension 
period as 48 weeks  
• Section 4.1  Description of study design :  updated to add additional parameters to be 
blinded in p eriod 1; urine creatinine, renin, estradiol, estrone, androgens (testosterone, 
delta -4 androstenedione, DHEAS), precursors 11 -deoxycortisol, 11 - deoxycorticosterone.  
• Section 4.1  Description of study design :  Extension phase updated to clarify patients 
enrolled in the optional extension period must end study participation within [ADDRESS_916305]-Treatment (End  of Study) visit after 30 days off study drug   
• Section 4.1 Description of study design:  Clarified that during the extension phase the dose 
of osilodrostat will be maintained at the established effective dose unless a change is 
required based on mUFC resul ts collected at Weeks 48, and if applicable, at Weeks 60, 72, 
and 84  
• Section 4.3 Definition of end of the study:  updated and clarifiedc ompletion of the study 
as a whole (last patient last visit) will occur once all patients have completed all 
assessments as per Table 7 -1a, Table 7 -1b (Core) and, as applicable, Table 7 -2 (optional 
Extension), or have discontinued from the study, including Post -treatment follow -up or 
transition into the long -term safety follow -up study, whichever occurs first , and patients 
end participation in the optional extension period within [ADDRESS_916306]  
• Section 6.1.5 Treatment duration:  updated to clarify the optional extension phase will end 
when all patients who were eligible , have transition ed into the long -term safety follow -up 
study , or were discontinued from the study.  Patients must end participation in the optional 
extension phase  within [ADDRESS_916307] . Patients participating in the optional  extension phase 
between Week 48 and Week 72, and who are eligible, should transition into the long -term 
safety follow -up study at the next study visit. Patients participating in the optional 
extension phase between Week 72 and Week 96, and who are eligibl e, should transition 
into the long -term safety follow -up study within 4 weeks, at an unscheduled visit, of 
Protocol Amendment 02 approval at the site.  
[COMPANY_001]  Confidential  Page 13 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 • Section 6.2.3 Extension phase (weeks 48 -96):  changed Week [ADDRESS_916308] 
• Section 6 .5.3 Treatment blinding:  updated to add additional parameters to be blinded in 
period 1; urine creatinine, renin, estradiol, estrone, androgens (testosterone, delta -4 
androstenedione, DHEAS), precursors 11 -deoxycortisol, 11 - deoxycorticosterone.  
• Section 7 .1 Study flow and visit schedule:  added language to clarify p atients must end 
participation in the optional extension period within [ADDRESS_916309]  
• Section 7.1.3 Treatment phase:  clarified at Week 48, patients have the option to enter a n 
optional open -label extension phase ; however;  patients currently enrolled in the optional 
Extension phase must end study participation within [ADDRESS_916310] the option to enter a separate long -term safety follow -up 
study or stop study treatment.  Patients not entering the long -term safety follow -up study 
will complete the study with a 30 day follow -up. 
• Section 7.1.4 Discontinuation of Study drug: removed Week 96  
• Table 7 -3 Disease and Imaging Assessment collection plan: added language for 
clarification, DXA scan mandated at End of Treatment Core and End of Treatment 
Extension, unless EOT occurs less than 6 months before the scheduled Week 96 visit.  
• Section [IP_ADDRESS] Bone mineral density assessments: clarified if EOT occurs less than 6 
months before the scheduled Week 96 visit, MRI (or CT) and DXA is not mandatory at 
EOT  
• Section [IP_ADDRESS] Radiological examinations: clarified if EOT occurs less than 6 months 
before the scheduled Week 96 visit, MRI (or CT) and DXA is not mandatory at EOT  
• Table 7 -6 ECG collection plan:  added la nguage  for clarification, Patients  end participation 
in the optional extension period study within [ADDRESS_916311]  
• Section [IP_ADDRESS].1  24-hour Holter Electrocardiogram : Patien ts should  be instructed to return 
their 24 -hour Holter flashcards to the site  at their next study visit in order to facilitate 
timely central reading of the Holter data  
• Table 7 -10 Hair Cortisol sample collection plan : clarified extension phase is optional and 
added language Patients to end study participation once Protocol Amendment [ADDRESS_916312]   
• Section 7.2.6 Patient reported outcomes: removed reference for Appendix 3  
• Table 7 -11 Patient reported outcomes (PROs) collection plan: added language for 
clarification, Patients to end study participation within [ADDRESS_916313]  
• Section 10: Removed  text stating that the results and outcomes of primary analysis will be 
presented in a CSR  
[COMPANY_001]  Confidential  Page 14 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 • Section [IP_ADDRESS] Assess the change in mUFC during the Core and Extension periods of the 
study : updated the section title to optional Extension periods  
• Section 10.5.3 .4 Other safety data: updated to clarify that tumor invasiveness is also 
evaluated  
• Reference:  FDA Guidance for Industry Suicidality corrected from 2015 to 2010 to match 
protocol referenced in Section [IP_ADDRESS]  under the Columbia Suicide Severity Reporting  
Scale (C -SSRS)  
• Reference: added Masri -Iraqi et al, 2014 to match reference in Section 2.6  
• Clarifications were made in the protocol  that extension phase is an optional extension 
phase  
IRBs/IECs  
A copy of this amended protocol will be sent to the Institutio nal Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.  
The changes herein  affect the Informed Consent. Sites are required to upda te and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.  
 
[COMPANY_001]  Confidential  Page 15 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 Amendment 1  (20-Nov-2017)  
Amendment rationale  
As of [ADDRESS_916314]  been enrolled (treated) in the study .  
The main purpose of this amendment is to align the language of all ongoing studies in Cushing’s 
disease indication for prohibited drugs due to TdP risk and to add a statement regarding the risk 
of neutropenia observed in LCI699C2201 and LCI699C2103. These were newly acquired 
information added to the Investigator’s Brochure for transparency, and are thus being added to 
all protocols. New objectives and endpoints on cortisol biomarkers were added to maintain 
consistency between the protocol and data collectio n occurring in the study, as described in the 
VES.   
The duration of the optional extension period was increased in order to collect additional long -
term safety and efficacy data as well as to provide continued access to the study drug for those 
patients b enefitting from the treatment until a separate long -term safety study is set up at 
participating sites.  Based on this extension, the end of study definition has been updated.  
This protocol amendment introduces the following changes:  
• In view of the results  of the thorough QT study CLCI699C2105, which showed that the 
increase in QTcF caused by [CONTACT_677407], the QT -specific concomitant medication guidance for osilodrostat was 
revised to limit t he list of prohibited drugs to medications with a “Known risk to cause 
TdP” and “Possible risk to cause TdP”, instead of all drugs known to prolong QT. This 
change is also in alignment with the terminology used in the QT Drug Lists 
(Credible Meds®).  
• The ri sks section was updated to include neutropenia , which is a known effect related to 
the decrease of cortisol in patients with Cushing’s disease in  line with cases observed in 
clinical trials with osilodrostat.  
• Addition of the following secondary objective  and endpoint  to ensure that analyses related 
to changes in other biomarkers  of hypercortisolism  is part of the protocol. These other 
markers are important to describe changes in disease burden following treatment .  
• Objective: To assess the change from baseline in serum, salivary and  hair cortisol 
levels during the Core and Extension periods of the s tudy.   
• Endpoint: Actual and percentage change in biomarkers  of hypercortisolism  (serum 
cortisol, late night salivary cortisol, morning cortisol and hair cortisol) from baseline 
to each post -baseline visit during the Core and Extension at which cortisol bio markers 
are collected by [CONTACT_677408].   
• Language added to clarify that the study will end once all patients have completed all 
assessments as per Table 7 -1a and Table 7 -1b (Core) and Week  96 visit (extension phase) 
or have discontinu ed from the study early, whichever occurs first.  In addition, visits are 
added for patients who continue to benefit from treatment at Week 96 to continue 
treatment on study  until any of the following occur s: 
(a) they no longer benefit from treatment or  
[COMPANY_001]  Confidential  Page 16 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 (b) a separate long -term safety follow -up study or managed access program becomes 
locally available or  
(c) an alternative treatment option becomes locally available or  
(d) all patients have either reached Week [ADDRESS_916315] discontinued from the study before 
Week 96.  
• Specifying sample collection requirement in the event of suspected hypocortisolism or 
adrenal insufficiency during period [ADDRESS_916316] (IE).  
• Specifying that the screening Thyroid Panel, FSH, and Pre gnancy (serum) tests should be 
done post wash out  during screening period.   
• Columbia Suicide Severity Rating Scale (CSSRS) was removed from Appendix 3 as paper 
CSSRS is not used in the study  (electronic version  is used in the study ) 
• Introduced more flexible wording regarding the description of osilodrostat tablet strengths 
used in the study .  
• The tumor aggressiveness evaluation was added to evaluate the prevalence of tumors with 
extension outside sella tur cica and/or invasion into surrounding structu res at baseline and 
during the study (new onset/disappearance).  
Changes to the protocol  
Changes to specific sections of the protocol are shown in the track changes version of the  
protocol using strike through red font for deletions and red underlined for insertions.  
• Protocol synopsis: edited to be consistent with the changes made throughout the protocol   
• Section 2.2.6: updated to clarify that the 24-hour continuous 12 -lead Holter recordings 
will be performed at baseline, Weeks 2, 12, 14, 36,  72, and at the end of treatment 
Extension visit.   
• Section 2.6: updated to include the possibility of neutropenia based on observed cases 
with osilodrostat .  
• Section 3 , Table 3 -1, and Section [IP_ADDRESS]: addition of the following secondary objective  
and endpoint : 
Objective: To assess the change from baseline in serum, salivary and hair cortisol levels . 
Endpoint: The actual and percentage change from baseline in serum cortisol, late night salivary 
cortisol, morning salivary cortisol and hair cortisol levels for every visit in the Core and 
extension phases at which the biomarkers of hypercortisolism are collected, by [CONTACT_677409].   
• Section 4.1: added the following statement : Three 24 -hr UFC urine samples and two late 
night salivar y cortisol samples  are to be collected after completion of the washout period  
during screening  to assess study eligibility.  
• Section 4.3: Clarified  definition of end of the study  
• Section 6.2.3: added the following statement:  
Patients who continue to benefi t from treatment at Week [ADDRESS_916317] the option to continue 
treatment on study until any of the following occurs:  
[COMPANY_001]  Confidential  Page 17 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 (a) they no longer benefit from treatment or  
(b) a separate long -term safety follow -up study or managed access program becomes locally 
available or  
(c) an alternative treatment option becomes locally available or  
(d) all patients have either reached Week [ADDRESS_916318] discontinued from the study before Week 
96, 
For patients who transition into a separate long -term study or managed access program, th e 
EOS (last dose + 30 days) visit is not applicable, as treatment on osilodrostat will not be 
interrupted, and only the EOT visit will be performed.  
Those patients who will not continue treatment will complete the EOT extension visit and an 
EOS (last dose + 30 days) visit, for details of assessments, please refer to Section 7.1.4.   
• Section 6.3.1 , Table 6 -1, the following statement is added :  
The IE can adjust the dose when sufficient information is provided, i.e., serum cortisol, one or 
more (up to three) 24 -hour UFC result, plasma glucose and electrolytes, (as central lab 
assessment) and completed eCRF pages with clinical signs and symptoms a ssociated with 
hypocortisolism/adrenal insufficiency event.  
• Section 6.3.1, Table [ADDRESS_916319] or ALT 
elevation is > 10.[ADDRESS_916320] : If not resolved after 4 weeks, discontinue from study 
drug  
• Section 6.3.2 : added the following statement:  
In the event of suspected hypocortisolism or adrenal insufficiency during period 1, the site 
should instruct the patient to collect one or more (up to three) 24 -hour urine samples for UFC 
assessment and come to the site for tests for serum cortisol, plasma  glucose and electrolytes 
(sodium and potassium). These samples should be sent to central laboratory immediately to 
allow an appropriate dose modification by [CONTACT_555164]. Physical exam is recommended and a record of 
abnormal findings should be annotated in the CRF.  
• Section 6.4.3, Section [IP_ADDRESS], and Appendix 2: revised to update the QT -specific 
concomitant medication guidance for osilodrostat limiting the list of prohibited drugs to 
medications with a “Known risk to cause TdP” and “Possible risk to cause TdP” inste ad of 
all drugs known to prolong QT , according to (CredibleMeds®).   
• Table 7 -1a: Specifying that the screening Thyroid Panel, FSH, and Pregnancy (serum) 
tests should be done post wash out  during the screening .  
• Table 7 -2, Table 7 -6,  and Table 7 -11: Additional visits are added for patients 
who continue to benefit from treatment at Week 96 to continue treatment on study until 
any of the following occurs:  
(a) they no longer benefit from treatment or  
(b) a separate long -term safety follow -up study or managed access program becomes locally 
available or  
(c) an alternative treatment option becomes locally available or  
(d) all patients have either reached Week [ADDRESS_916321] discontinued from the study before Week 
96. 

[COMPANY_001]  Confidential  Page 18 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 • Section 7.1.4,  amending that hypertension should be defined as office mean supi[INVESTIGATOR_614666] > 180 mmHg or mean supi[INVESTIGATOR_677339] > 110 mmHg (confirmed and 
persistent*).  
• Table 7 -7: updated the blood volume to approximately 3mL  and the following footnote:  
pre-dose sa mple within 0.5 h before dose administration, ±[ADDRESS_916322] dose in th e extension phase  
• Section [IP_ADDRESS]: added the following statement:  
Change in the actual and percentage change from baseline to each post -baseline visit for 
serum cortisol, late night salivary cortisol, morning salivary cortisol and hair cortisol 
levels wi ll be assessed. Descriptive summaries will be provided for every vis it in the Core 
and E xtension phases at which the biomarkers of hypercortisolism are collected. Salivary 
cortisol samples will only be included if they are collected within the correct time  
window. 95% CIs for the percentage change from baseline will also be provided by 
[CONTACT_677410]. • Section 10.5.3 .4: added the following statement: 
The tumor aggressiveness is also evaluated, in terms of the prevalence of tumors with 
extension outside sella tur cica and/or invasion into surrounding structures at baseline and 
during the study (new onset/disappearance).  
• Language “ (depending on availability)” was added in front of all text mentioning 20 mg 
tablet strength.  
• Appendix 3 : Columbia Suicide Severity Rating Scale  (CSSRS) was removed.  
• Editorial changes and clarifications were made at various places in the protocol.  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Commit tee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.  
The changes herein  affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Con sent that takes into account the changes described in this 
protocol amendment.  
[COMPANY_001]  Confidential  Page 19 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 Protocol summary:  
Protocol number  CLCI699C2302  
Title A Phase III, multi -center, randomized, double -blind, 48 week study with a n initial  
12 week placebo -controlled period to evaluate the safety and efficacy of 
osilodrostat in patients with Cushing’s disease  
Brief title  Efficacy and safety evaluation of osilodrostat in Cushing’s disease  
Sponsor and Clinical 
Phase  [COMPANY_001]  
Phase III  
Investigation type  Drug  
Study type  Interventional  
Purpose and rationale  The study aims to confirm  efficacy and safety of osilodrostat for the treatment of 
patients with Cushing’s disease (CD) who are candidates for medical therapy.  
Primary Objective(s) and 
Key Secondary Objective  Primary:  
To demonstrate the superiority of osilodrostat compared to placebo in achieving a 
complete response (mUFC ≤ ULN) at Week 1 2. 
Key secondary:  
To assess the complete response rate in both arms combined at Week 36 in 
patients receiving osilodrostat treatment . 
Secondary Objectives  To assess the proportion of patients with a complete response ( mUFC ≤ ULN ) or 
a partial response ( mUFC decrease ≥50% from baseline  and >ULN ) at Week 1 2, 
Week 3 6, and Week 48. 
To assess the change in mUFC during the Core and Extension period s of the 
study.  (Refer to Table 7 -1a, Table 7 -1b and Table 7 -2 for the study visit and 
evaluation schedule during the  Core and E xtension phase s, respectively ). 
To compare the time -to-first c ontrol of mUFC during the placebo -control led period 
(Weeks 1-12) between the randomized treatment arms.  
To assess the time -to-escape during osil odrostat treatment up to Week 48.  
To assess cardiovascular and metabolic related parameters associated with CD 
(fasting plasma glucose, HbA1c, fasting lipid profile, blood pressure, weight and 
waist circumference ) by [CONTACT_677411] s 12, 36, and 48.  
To assess the change from baseline at Weeks 12, 36, and 48  in physical features 
of CD.  
To assess the change from baseline in bone mineral density (BMD) by [CONTACT_677412][INVESTIGATOR_677340] 48 . 
To determine the safety and tolerability of osilodrostat in the study population.   
To assess the change from baseline  in Health Related Quality of Life, as 
measured by [CONTACT_8671]-specific QoL questionnaire (CushingQoL); by [CONTACT_677413] (BDI -II); and by [CONTACT_677414] -related QoL instrument 
EQ-5D-5L, by [CONTACT_677415] . 
To evaluate pharmacokinetic exposure of osilodrostat in the study population.  
To assess the change in cortisol levels (serum cortisol, late night salivary cortisol, 
morning cortisol and hair cortisol) during the Core and Extension periods of the 
study.  
Study design  This is a Phase III, global, multi -center, randomized, double -blind, placebo -
controlled study.  The study design is placebo -controlled during the first 12 
weeks, followed by [CONTACT_31463] -label treatment with osilodrostat until week 48, and an 
optional Extension phase.  
Screening (up to 8 weeks):   Written in formed consent must be obtained before 
any study specific assessments. Washout of current drug therapy for CD, as well 
as optimization of treatment of co -morbidities is to be completed . Three 24 -hr 
UFC urine samples and two late night salivary cortisol sam ples are to be 
collected after completion of the washout period to assess study eligibility. Other 
assessments needed for eligibility are detailed in Table 7 -1a.  
[COMPANY_001]  Confidential  Page 20 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 Core Phase  
Period 1 ( Weeks 1-12) Double -blind, p lacebo -controlled:  
Study visits are performed at Day 1,  Week 2, Week 5, Week 8 and Week 12. 
The initial dose of study drug (osilodrostat or placebo) is 2 mg b.i.d.  The mean of 
three 24 -hr UFC values (mUFC)  will be done at  screening (prior to Period 1), 
baseline  and Week 12. The mean of two 24 -hr UFC values (mUFC)  is the basis 
for dose titration decisions  (See Section 6.2  for details) . If the mUFC 
remains >ULN, dose escala tion needs to occur according to the following 
sequence: 5 mg b.i.d., 10 mg b.i.d., and 20 mg b.i.d at Weeks 2, 5, or 8, as 
applicable . Dose escalation stops when the mUFC is ≤ ULN.  Doses may be 
down titrated  in both the active control and placebo arms  (to the previous dose , 
or to below 2 mg b.i.d.) if mUFC is below the LLN or close to the lower limit of 
the normal range  and/or the patient has signs or symptoms of adrenal 
insufficiency . Down -titration to doses  less than 2  mg b .i.d. (with mock down -
titration in the placebo arm to maintain the treatment blind) could also be used 
(Section 6.2.1  for further details). Intermediate doses may only be used in 
specifi c circumstances  (see Section [IP_ADDRESS]  for details ). Dose adjustments will be 
done between study visits to allow the next UFC assessment to reflect the 
impact of the new dose of study drug (see Sections 4.1 ). In patients 
discontinuing study drug before We ek 12 , every effort should be made to 
continue visits and assessments up to and including Week 12  (see Section 4.1 ). 
To maintain the treatment blind , the UFC, urine creatinine, serum and salivary 
cortisol, Adrenocorticotropic Hormone ( ACTH ), aldosterone, renin, estradiol, 
estrone, androgens (testosterone, delta -4 androstenedione, DHEAS), and 
precursors  11-deoxycortisol, 11 -deoxycorticosterone  will be kept blinded to 
patients, inv estigators and the [COMPANY_001] Clinical Trial Team during Period 1  (see 
Section 6.5.3 ). A group of independent endocrinologists (IEs) is responsible for 
managing dose titrations during th is period. The IE  will have access  to relevant 
data including UFC, serum cortisol , ACTH and chemistry results, the treatment 
assignment , and clinical signs and symptoms at the most recent study visit .  The 
IE is responsible for determining the dose of study drug as soon as the mUFC 
results are available for individual patients . The IE communicates instructions 
regarding the dose of  study drug in a blinded manner via Interactive Response 
Technology ( IRT) to the appropriate site . 
 
Period 2 ( Weeks 12-48): Open-label treatment :  
All patients receive active , open label  drug, osilodrostat,  during Period 2. 
Immediately after the Week 1 2 visit, all patients that were receiving  doses of 2 
mg b.i.d. or above , regardless of treatment assignment (active drug or placebo) 
during Period 1, will receive osilodrostat 2 mg b .i.d. Patients treated with either 
osilodrostat or matching placebo at doses less than 2 mg b .i.d. during Period 1 
will receive open label osilodrostat  at the same dose .  
As in Period 1, dose escalat ion in Period 2 will be based on mUFC results 
(mUFC > ULN).  All dose adjustments will be made by [CONTACT_677416] 14 onwards. The I E 
does not participate in dose decisions beyond Week 12. The investigator should 
be vigilant for signs or symptoms  of adrenal insufficiency or gluco corticoid 
withdrawal  between Week 12 and the receipt of Week 14 UFC results , and may 
reduce  or temporarily withhold osilodrostat if clinically indicated . The dose 
escalation sequence  in all patients in Period 2, regardless of Period 2 starting 
dose (either 2 mg b .i.d. or doses less than 2 mg b .i.d.), is 2 mg b.i.d.,  5 mg b.i.d. , 
10 mg b .i.d., 20 mg b .i.d., and 30 mg b .i.d (see Section 6.2.2 ). 
During Period 2 , three 24 -hr UFC values will be used to calculate mUFC at 
Week 36 and Week 48 ; the mean of two [ADDRESS_916323] reached a stable efficacious dose  when , mUFC 
remains ≤ ULN . The dose may be up -titrated for mUFC > ULN, or down -titrated 
for mUFC values < LLN or close to  the lower limit of the normal range and/or if 
the patient has signs or symptoms of adrenal insufficiency.  Intermediate doses 
[COMPANY_001]  Confidential  Page 21 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 may be used only in specific circumstances. Please see Section [IP_ADDRESS]  for 
details.  
 
Optional Extension phase  (Weeks 48 -96):  
At Week 48, patien ts have the option to enter a n optional open -label Extension  
phase . Patients must end participation in the optional Extension phase within [ADDRESS_916324]. Doses can be adjusted in this phase  of the study as 
described above and in Section 6.2.3  
Population  The study population will be comprised of approximately 69 adult male and 
female patients with Cushing’s disease who are candidates for medical therapy  
(see Section 5.1).  
Inclusion criteria  Key inclusion criteria are listed below; please refer to Section [ADDRESS_916325] of 
inclusion criteria.  
• Confirmed CD that is persistent or recurrent as evidenced by  [CONTACT_677417]  (i.e., a, b and c) : 
a. mUFC > 1.[ADDRESS_916326] (Mean of three 24 -hour urine samples collected 
preferably on 3 consecu tive days , during screening after washout of prior 
medical therapy for CD (if applicable),  confirmed by [CONTACT_677418] 1) , with ≥2 of the  individual UFC  values being > 1.[ADDRESS_916327].  
b. Morning plasma ACTH above Lower Limit of Normal  
c. Confirmation (based on medical history) of pi[INVESTIGATOR_677341]:  
i. Histopathologic confirmation of an ACTH -staining adenoma in patients 
who have had prior pi[INVESTIGATOR_221370].  
OR 
ii. MRI confirmation of pi[INVESTIGATOR_296953] > 6 mm  
OR 
iii. Bilateral inferior petrosal sinus sampling (BIPSS) with either CRH or 
DDAVP stimulation for patients with a tumor ≤ 6mm. The criteria for a 
confirmat ory BIPSS test are any of the following:  
• Pre -dose central to peripheral ACTH gradient > 2;  
• Post -dose central to peripheral ACTH gradient > 3 after either CRH or 
DDAVP stimulation  
• Patients that received glucocorticoid replacement therapy must have 
disco ntinued such therapy for at least seven days or 5 half -lives prior to 
screening, whichever is longer.  
• Patients with de novo  CD can be included only if they are not considered 
candidates for surgery (e.g., poor surgical candidates due to co -morbidities, 
inoperable tumors, patients who refuse to have surgical treatment, or 
surgical treatment is not available).  
• For patients with a history of pi[INVESTIGATOR_585643]: at least 2 years for 
stereotactic radiosurgery (SRS), and 3 years for conventional (fractionated)  
radiation, respectively, must have elapsed from the time of the most recent 
radiation treatment to the time of enrollment into this study.  
• Washout of any current drug therapy for CD. The following minimum washout 
periods must be completed before baseline  efficacy assessments are 
performed:  
a. Steroidogenesis inhibitors (ketoconazole, metyrapone): 1 week  
b. Pasireotide s.c. (immediate release formulation): 1 week  
c. Mifepristone : 3 weeks  
d. Dopamine agonists (e.g., cabergoline), or PPAR -gamma agonists (e.g., 
rosiglita zone, pi[INVESTIGATOR_051]): 4 weeks  
[COMPANY_001]  Confidential  Page 22 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 e. Pasireotide LAR: 8 weeks.  Rescreening can be used as needed to 
ensure washout is complete.  
f. Mitotane: 6 months. Rescreening can be used as needed to ensure 
washout is complete.  
Exclusion criteria  Key exclusion criteria are listed below; please refer to Section 5.[ADDRESS_916328] 
of exclusion criteria.  
• Patients with pseudo -Cushing’s syndrome . This may be diagnosed by [CONTACT_677419] s collected during the screening 
period and after washout of prior CD medication.   
• Patients with risk factors for QTc prolongation or Torsade de Pointes, 
including: patients with a baseline QTcF > 450 ms for males and QTcF > 
460 ms for females; personal or  family history of long QT syndrome; 
concomitant medications known to prolong the QT interval; patients with 
hypokalemia, hypocalcaemia, or hypomagnesaemia, if not corrected before 
pre-dose Day 1.  
• Patients likely to require adrenalectomy, pi[INVESTIGATOR_221370] , or radiation 
therapy during the placebo -controlled period (Weeks 1-12) for the treatment 
of severe hypercortisol ism or pi[INVESTIGATOR_677342].   
• Patients with compression of the optic chiasm due to a macroadenoma or  
patients at high risk of compression of the optic chiasm (tumor within 2 mm 
of optic chiasm).  
• Patients who have a known inherited syndrome as the cause for hormone 
over secretion (i.e. Carney Complex, McCune -Albright syndrome, MEN -1, 
AIP).  
• Patients with C ushing’s syndrome due to ectopic ACTH secretion or ACTH -
independent (adrenal) Cushing’s syndrome.  
• Patients who have undergone any major surgery within 1 month , or 
undergone transsphenoidal pi[INVESTIGATOR_677343] 3 months, prior to 
screening . 
• Hypertensive  patients with uncontrolled blood pressure defined as SBP > 
180 and/or DBP > 10 5 or not optimally treated for hypertension as judged by 
[CONTACT_093].  
• Diabetic patients with poorly controlled diabetes as evidenced by [CONTACT_13505]1c > 
9 % or not optimally treated  for diabetes mellitus as judged by [CONTACT_1275].  
• Patients who are not euthyroid as judged by [CONTACT_093].  
• Patients with liver disease such as cirrhosis, chronic active hepatitis, or 
chronic persistent hepatitis, or patients with serum ALT and/or AST > [ADDRESS_916329], or total bilirubin > 1.[ADDRESS_916330] of study inclusion and 
exclusion criteria, respectively.  
Investigational and 
reference therapy  Osilodrostat 1 mg, 5 mg, 10 mg  and (depending on availability) 20 mg  film-coated 
tablets,  and matching placebo film -coated tablets , for oral administratio n. Each 
tablet strength is provided in a separate bottle.  
Efficacy assessments  24-hour Urine Free Cortisol for the primary and key secondary endpoints.  Other 
assessments for secondary endpoints include: weight , waist circumference, blood 
pressure, fasting plasma glu cose, HbA1c, fasting lipid p rofile, Health -related 
Quality of L ife questionnaires ( CushingQoL, Beck Depression Inventory -II, and 
EQ-5D-5L), physica l features of Cushing’s disease , biomarkers of 
hypercortisolism , BMD at lumbar spi[INVESTIGATOR_390066] ( by [CONTACT_11324]) . 
Safety assessments  Adverse events  
Laboratory evaluations (chemistry, hematology, coagulation, Thyroid Panel, FSH, 
LH, fasting plasma glucose, urinalysis and pregnancy test) ;  
ECG, Holter recordings , MRI of pi[INVESTIGATOR_2117], vital signs , physical exam  and C -SSRS .  
[COMPANY_001]  Confidential  Page 23 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 Data analysis  The primary efficacy variable is the proportion of randomized patients in each 
treatment arm that are complete responders at Week 1 2. A complete responder 
is defined as a patient who has mUFC ≤ ULN (based on central laboratory result) 
at Week 1 2. The primary analysis will be based on a Cochran –Mantel –Haenszel 
(CMH) exact test stratified by [CONTACT_677420][INVESTIGATOR_585643] (yes/no) using the 
FAS. Following the ITT principle, patients are analyzed according to the d rug 
and stratum they were assigned to at randomization.  
The statistical null hypothesis states that the complete response rates at the end 
of the 1 2-week placebo -controlled period (i.e., at Week 1 2) are the same 
between the two randomized arms. If the 1 -sided p -value is ≤ 0.025, and the 
odds ratio (osilodrostat vs. placebo) is > 1, the null hypothesis will be rejected 
and the complete response rate in the osilodrostat arm is considered higher than 
that in the placebo arm.  
The key secondary objective is to assess the complete response rate (proportion 
of patients with mUFC ≤ ULN)  in both arms combined at Week 36 in patients 
receiving osilodrostat treatment , i.e., patients randomized to placebo who do not 
switch to osilodrostat will not be included. In this analysis, patients with missing 
mUFC assessments at Week 36 will be considered as non -responders.  
For the key secondary objective, the statistical null hypothesis states that the 
complete response rate at Week 36 is < 30%. The analysis of the key secondary  
objective will be based on the 2 -sided 95% exact confidence interval (CI) 
constructed using the Clopper -Pearson method  in FAS patients receiving 
osilodrostat treatment . If the lower bound of this 95% confidence interval is ≥ 
30%, the null hypothesis will be rejected and the complete response rate will be 
considered at least 30%  at Week 36 .  
The above testing on the key secondary objective will only be carried out if the 
null hypothesis for the primary objective is rejected.  This sequential procedure 
will ensure preservation of the overall 2 -sided type 1 error at 5%.  
The analysis of the key secondary endpoint will be performed in FAS patients 
receiving osilodrostat treatment and will be repeated using PPS patients  
receiving osi lodrostat treatment  as supportive analysis.  In addition, the key 
secondary endpoint will also be analyzed using the patients randomized to the 
osilodrostat arm only.  
Key words  Cushing’s disease, LCI699, osilodrostat, Pi[INVESTIGATOR_677344], Adrenocorticotropic 
Hormone, ACTH, UFC 

[COMPANY_001]  Confidential  Page 24 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 1 Background  
1.1 Overview of disease pathogenesis, epi[INVESTIGATOR_540714]  
1.1.1  Epi[INVESTIGATOR_621301]’s syndrome and 
Cushing’s disease  
Endogenous Cushing’s syndrome (CS) is rare (estimated prevalence of less than 1 in 10,000 
inhabit ants)  (Feelders, et al 2012 ). The causes of endogenous Cushing’s syndrome are classified 
into ACTH -dependent and ACTH -independent etiologies. The most common cause of 
Cushing’s syndrome is Cushing’s dise ase (CD) , which occurs in about 70% of cases, and is due 
to an ACTH -secreting pi[INVESTIGATOR_677345]. Cushing’s disease most commonly 
affects adults aged 20 -50 years, with a marked female preponderance. The other main cause of 
ACTH -dependent Cushin g’s syndrome is ectopic ACTH secretion from non -pi[INVESTIGATOR_44079] 
(e.g., small cell lung cancer). The ACTH -independent etiologies of Cushing’s syndrome are 
adrenal diseases such as adrenal tumors (adenomas or carcinomas) or bilateral adrenal 
hyperplasia.  
Endogenous Cushing’s syndrome is characterized by [CONTACT_621341], which results 
in a variety of metabolic abnormalities and co -morbidities that collectively lead to an overall 4 -
fold higher mortality rate than age - and gender -matched subjects in the general population 
(Arnaldi , et al 2003 ). The increased cardiovascular risk is related to the following clinical 
manifestations of Cushing’s syndrome: metabolic syndrome, insulin resistance, visceral  
obesity, glucose intolerance, hypertension, dyslipi[INVESTIGATOR_035], and hypercoagulation. Other clinical 
signs and symptoms of Cushing’s Syndrome include: supraclavicular and dorsal fat pads; 
proximal muscle weakness; osteoporosis with increased risk of fractures; skin changes (wide 
purple striae, hirsutism, acne); impaired immune function with increased risk of infection; 
neuropsychiatric disorders (depression, mood changes, and cognitive impairment), 
hypogonadism  in both gender , and menstrual disorders in women ( Newell -Price, et al 2006 ). 
At the time of diagnosis of Cushing’s disease, the prevalence of co -morbidities has been 
reported as follows: 58 –85% of patients have hypertension, 32 –41% have obesity, 20 –47% 
have diabetes mellitus, 50 –81% have major depression, 31 –50% have osteoporosis, and 38 –
71% have dyslipi[INVESTIGATOR_035] ( Feelders, et al 2012 ). 
Correction of hypercortisolism in patients with Cushing’s disease is ex pected to improve or 
reverse the increased morbidity and mortality associated with untreated disease. Recently 
published data have suggested that recovery from the co -morbidities does occur, but may be 
delayed or incomplete ( Valassi, et al 2012 ; Arnaldi, et al 2012 ). The duration and severity of 
chronic hypercortisolism may impact the reversibility of the co -morbidities associated with 
Cushing’s disease  (Feelders, et al 2012 ). 
However, mortality studies have consistently shown that the mortality rate is significantly 
impacted by [CONTACT_621342], i.e., persistent/recurrent hypercor tisolism 
compared to biochemical remission of the disease. A recent meta -analysis of published 
mortality studies ( Clayton, et al 2011 ) showed that the standardized mortality ratio (SMR) is 
[COMPANY_001]  Confidential  Page 25 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 much higher in  Cushing’s disease patients with persistent hypercortisolism (SMR=5.5) than 
those in remission (SMR=1.2).  
1.1.2  Current treatment modalities  
In the International Consensus Statement on the treatment of ACTH -dependent Cushing’s 
syndrome ( Biller, et al 2008 ), the goals of treatment are stated as: reversal of clinical features; 
normalization of biochemical changes with minimum morbidity; and long -term control without 
recurrence.  
The treatment options for CD includ e pi[INVESTIGATOR_221370], pi[INVESTIGATOR_585643], medical therapy 
and bilateral adrenalectomy. The primary treatment is surgical removal of the pi[INVESTIGATOR_677346]. Second -line treatments include: more 
radical  pi[INVESTIGATOR_221370] (re -operation), radiation therapy, medical therapy, and bilateral 
adrenalectomy. This categorization of primary and secondary therapi[INVESTIGATOR_677347] 32 academic experts from 9 countries ( Biller, et al 2008 ). 
Post-surgical remission rates of 70 -80% have been reported. However, a 25% incidence of 
recurrent hypercortisolism has been reported at 10 years of follow -up (Bochicchio et al 1995 ; 
Sonino et al 1996 ). With second pi[INVESTIGATOR_221370] (re -operation), success rates are lower and 
complications are higher than with primary pi[INVESTIGATOR_221370]; therefore patients should be 
carefully selected ( Fleseriu, et al 2007 ; Friedman, et al 1989 ). 
Pi[INVESTIGATOR_677348] o ption for patients who are not surgical candidates or have persistent 
or recurrent hypercortisolism following primary pi[INVESTIGATOR_221370]. However, the response to 
pi[INVESTIGATOR_621312]. The two mo st 
commonly used radiation modalities are stereotactic radiosurgery (SRS), which consists of a 
single high -dose treatment (e.g. proton beam, gamma knife or cyber knife), and conventional, 
fractionated radiation (linear accelerator). SRS is not only more co nvenient to the patient; it 
also has a faster onset of biochemical remission  median of 17 months (Sheehan, et al 2013 ), 
than with conventional fractionated radiation , with an onset of 2-3 years  (Loeffler and Shih, 
2011 ). In some cases  of conventional fractionated radiation , remission may be delayed until 10 
years or longer ( Losa, et al 2010 ; Minniti, et al 2007 ). The long term complications include 
hypopi[INVESTIGATOR_297] (Newell -Price, et al 2006 ), secondary malignant tumors ( Sedney, et al 2012 ), 
and possibly an increased risk of death from cerebrovascular disease post -radiation ( Ayuk 
2012 ). 
Medical therapy is an attractive option for patients with Cushing’s disease who have persistent 
or recurrent hypercortisolism after primary pi[INVESTIGATOR_621310], and 
patients with de novo CD who are not surgical candidates for medical reasons, refuse to undergo 
surgery, or do not have acces s to a specialized center with experience in pi[INVESTIGATOR_221370].  
Pasireotide (Signifor®), a second generation somatostatin analogue, is currently approved in the 
US and in EU for the treatment of Cushing’s disease. In the pi[INVESTIGATOR_30338] 3 trial, pasireotide 
was effective in normalizing or reducing by > 50% urinary free cortisol in 34% to 41% of 
patients, in study groups randomized to 0.[ADDRESS_916331], is approved in the US for the treatment of 
hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's 
syndrome who have type [ADDRESS_916332] been used with or without regulator y approval for the treatment of 
Cushing’s disease, including: ketoconazole and metyrapone (steroidogenesis inhibitors), 
mitotane (adrenolytic agent), and cabergoline (dopamine agonist).  
Bilateral adrenalectomy is deferred until all other options have been exhausted ( Biller, et al 
2008 ). A consequence of bilateral adrenalectomy is immediate and permanent primary adrenal 
insufficiency, which requires life -long glucocorticoid and mineralocorticoid replacemen t 
therapy and monitoring. Part of the management of primary adrenal insufficiency includes 
emergency treatment for situations of acute stress such as sepsis or trauma. These events can 
be life -threatening if not treated with high “stress doses” of these ho rmones intravenously. 
Additionally, Nelson’s syndrome is a potential complication of bilateral adrenalectomy that is 
marked by [CONTACT_677421][INVESTIGATOR_677349]. This can be a 
serious complication because it may result in com pression of structures adjacent to the pi[INVESTIGATOR_677350], and pi[INVESTIGATOR_321547] , although this ultimate 
complication should not occur in the modern era when close follow -up with pi[INVESTIGATOR_677351]  (Assie, et al 2007 ). 
1.1.[ADDRESS_916333] adverse 
reactions from the medical therapy . 
Therefore , there is an unmet medical need to develop new drugs with improved safety and 
efficacy. Based on the data from study LCI699C2201 in patients with Cushing’s disease, 
osilodr ostat shows promise in fulfilling this unmet medical need.  
1.2 Introduction to investigational treatment , osilodrostat  
1.2.1  Overview of osilodrostat  
Osilodrostat  (company research code: LCI699)  is a new chemical entity with the chemical 
structure  4-[(5R) -6,7-Dihydro -5H-pyrrolo[1,2 -c]imidazol -5-yl]-3-fluorobenzonitrile  
phosphate .  
Osilodrostat  is a potent, oral inhibitor of 11β -hydroxylase (CYP11B1 ), the enzyme that 
catalyzes the last step in the biosynthesis of cortisol. This provides the rationale for invest igating 
the use of osilodrostat in endogenous causes of Cushing’s syndrome. The current development 
activity of osilodrostat is focused on the treatment of patients with Cushing’s disease 
(hypercortisolism due to a pi[INVESTIGATOR_677345]), because it is the most common 
cause  of Cushing’s syndrome and it is a relatively homogeneous  patient group . This drug also 
inhibits aldosterone synthase (CYP11B2 ), and therefore is a dual inhibitor of both cortisol and 
aldosterone synthesis.   It is manufactured as  a phosphate salt and available in film -coated tablets 
of 1 mg, 5 mg, 10 mg and 20 mg for this phase III study.  
The mechanism of action of osilodrostat is depi[INVESTIGATOR_6517] 1 -1 below.  
[COMPANY_001]  Confidential  Page 27 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 Figure 1-1 Mechanism of action of osilodrostat in Cushing’s Disease  
 
[IP_ADDRESS]  Non-clinical experience  
For detailed non -clinical pharmacokinetics and toxicity findings, please refer to the 
[Investigator Brochure ].  
[IP_ADDRESS].[ADDRESS_916334]. The plasma half -life of osilodrostat  in rat and dog was 
short (~ 2 h). Ex posure was dose -proportional within the dose range investigated in the rat but 
over-proportional in dogs and mice. No accumulation or gender differences were observed in 
either species. Protein binding of osilodrostat  in animals and humans was low (26.6 –36.4%). 
Osilodrostat rapi[INVESTIGATOR_677352]. The highest tissue -to-blood ratios 
(≥ 9) were observed in the uveal tract, skin, eye, glandular stomach, small intestine, liver, and 
adrenal cortex. Drug -related radioactivity showed a significant affinity to melanin in the skin 
and uveal tract. Drug -related radioactivity showed a moderate distribution to brain, spi[INVESTIGATOR_677353] -to-blood concentration ratio of 0.73 -1.7. The elimination of 
osilodrostat  is mainly thro ugh metabolism and excretion in urine (~79% in rats and ~90% in 
dogs; unchanged osilodrostat  ~ 5-10% in urine and < 3% in feces).  
Based on the in vitro  CYP P450 inhibition profile and predicted steady state maximum 
concentration of 1.54 μM at 30 mg twice daily in humans, there is potential of drug - drug 
interaction for osilodrostat . Results from a clinical drug -drug intera ction study [LCI699C2102]  
are su mmarized in Section [IP_ADDRESS].1 . It is unlikely that osilodrostat  will increase the systemic 
exposure of co -medications whose clearance is mediated by P -gp, BCRP, OAT1, OAT3,  OCT1, 
and OCT2 transport activi ty. 

[COMPANY_001]  Confidential  Page 28 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 [IP_ADDRESS].2  Preclinical Safety  
Safety pharmacology:  
In safety pharmacology studies, proarrhythmic indices and QTc interval prolongation were 
observed in an in vitro  study in isolated rabbit heart and in vivo  studies in dog and monkey with 
osilodrostat . Proarrhythmic indices were observed at 10 µM in an isolated rabbit heart assay.  
QTc interval prolongation was noted at 50 mg/kg after 2 weeks of intravenous dosing in dogs, 
at 30 mg/kg oral (gavage) after sing le dose, and at 10 mg/kg/day i n a two week study in 
monkeys.  
Toxicology:  
No acute toxicity was observed in mice following administration of oral doses up to 125  mg/kg. 
In repeated dose general toxicity studies up to 26 -weeks in duration in the rat, and up to 39 -
weeks in the dog, the main target organs were central nervous system (CNS), liver,  female 
reproductive organs, and adrenal gland. Reversible CNS effects were seen at very high  doses 
in dogs (≥10 mg/kg) and mice (doses ≥ 30 mg/kg). Hepatocellular h ypertrophy and  vacuolation 
were seen in 13 -week and 26 -week rat studies at doses ≥ 5 mg/kg and in a 13 -week study in 
mice at doses ≥ 10 mg/kg (partially reversible). In female dogs, transient  increases in ALT and 
AST were observed at week 5 during the 13 -week study at 0.1 and 10  mg/kg. Effects on female 
reproductive organs (ovary, uterus and vagina) were seen in rats at  doses ≥ 5 mg/kg (reversible) 
and in mice at doses ≥ 30 mg/kg. Male reproductive organ  changes were limited to a decrease 
in prostate weight s (no microscopic correlate) in the 26 -week rat study at 20 mg/kg. No effects 
on female or male reproductive organs were found in  dogs. In the adrenal cortex, morphological 
alterations were observed in dogs (zona  glomerulosa) and at much higher exposure in  rats (zona 
fasciculata/glomerulosa). They may  be a result of the inhibition of adrenocortical steroid 
biosynthesis leading to an adaptive  induction of the aldosterone/cortisol synthase pathway. In 
the chronic toxicity studies, the  NOAEL was 2 mg/kg in the  rat (26 -week), and was 10 mg/kg 
in the dog (39 -week).  
In genetic toxicology studies, no evidence of mutagenic activity was observed in the Ames test, 
and no evidence of chromosomal damage in the in vitro  micronucleus test. Clastogenic effects 
at high conc entrations with and without metabolic activation were reported in cultured human 
peripheral blood lymphocytes. In vivo  genotoxicity tests in rats (micronucleus test and comet 
assay) were clearly negative and it is therefore concluded that osilodrostat has no relevant 
genotoxic potential in humans.  
In reprotoxicity studies (EFD in rats and rabbits, FEED study in rats), embryo/fetal toxicity was 
observed at doses that produced maternal toxicity in the rat and the rabbit, and increased 
incidence of fetal malfo rmation was observed in rats (only occurred at the maternally toxic 
dose).  
[IP_ADDRESS]  Clinical experience  
[IP_ADDRESS].1  Clinical pharmacokinetics  
The pharmacokinetics of osilodrostat has been studied in healthy volunteers, patients with 
hypertension, and patients with hyperaldoste ronism, as well as in an ongoing proof -of-concept 
[COMPANY_001]  Confidential  Page 29 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 study in Cushing’s disease patients. For detailed information, please refer to the [Investigator’s 
Brochure ]. 
Following single oral doses of 0.5 mg to 200 mg to healthy volunteers under fasting conditions, 
osilodrostat was rapi[INVESTIGATOR_19627] a Tmax of approximately 1 hour. The elimination half -
life of osilodrostat was 3 -5 hours across all doses examined. The pharmacokinetics of 
osilodrostat were over -dose proportional in the dose range of 0.5 to 200 mg (s ingle dose); for a 
2-fold increase in dose, the AUC increase would be about 2.4 -fold, and Cmax increase would 
be 2.1 -to 2.4 -fold [LCI699A2101] . Metabolism was the major clearance pathway for 
osilodrostat in humans with renal clearance making only a minor c ontribution. Metabolism of 
osilodrostat was extensive in humans via multiple pathways (and combination of pathways) 
[LCI699C2101].  Results from a cocktail drug -drug interaction study [LCI699C2102]  showed 
that at a single dose of [ADDRESS_916335] therapeutic dose of 30 
mg b .i.d. at steady state, osilodrostat is a moderate  inhibitor of CYP1A2, a weak to moderate 
inhibitor of CYP2C19, and a weak inhibitor of CYP2D6 and CYP3A4/5 .  
[IP_ADDRESS].2  Results of LCI699C2201 study in Cushing’s disease  
The purpose of the LCI699C2201 study was to determine whether the ability of osilodrostat  to 
inhibit 11β -hydroxlase could safely reduce urinary free cortisol (UFC) in patients with 
Cushing’s disease. This was initially studied over a 10 -week treatment durat ion Proof -of 
Concept (Part I). Part II of the study aim ed to further evaluate  the observations from the Part I 
by [CONTACT_79323] a cohort of patients who participated in Part I and a new cohort (Expansion cohort) 
of patients , and evaluating the long -term efficacy and safety of osilodrostat  treatment.  
In Part I, o silodrostat was effective in controlling cortisol production in all 12 patients studied. 
At daily osilodrostat doses between 2 mg b.i.d. and 50 mg b .i.d., 24-hour mean  UFC ( mUFC ) 
decreased rapi[INVESTIGATOR_677354]. In general at 5 mg b.i.d. 
patients showed mUFC reduction after 2 weeks (at first mUFC measurement after dose 
titration).  
The primary endpoint, defined as mUFC ≤ ULN or ≥ 50 % decrease from baseline at Day 70, 
was achieved by [CONTACT_16983]. Overall, the mean time to response (UFC normalization or ≥ 50% 
reduction from baseline) was 34.3±14.1 days. The mean daily dose (± SD) of osilodrostat 
required to reach the primary endpoint was 13.5±13.9 mg b.i.d. with 75% of patients 
normalizing mUFC on ≤ 10  mg b.i.d. At Day 84, two weeks after osilodrostat was withdrawn, 
mUFC levels increased to a mean of 4 -fold above upper limit of normal (ULN) ( Figure 1 -2). 
[COMPANY_001]  Confidential  Page [ADDRESS_916336] of mUFC (PD analysis set)  
 
Source:  In-text Figure 11 -2, 10-week interim CSR study [LCI699C2201]  
Significant decreases in mean plasma cortisol and aldosterone from baseline ( -60% and -70%, 
respectively) and marked increases in their precursors from baseline (11 -deoxycortisol [13 -
fold] and 11 -deoxycorticosterone [42-fold], respectively) and ACTH [2.4 -fold] were observed  
at Day 70 . These biochemical changes were as expected based on the mechanism of action of 
the drug, i.e., primarily related to hypocortisolism, hypoaldosteronism, accumulation of their 
precursors, and increase in ACTH from baseline.  
In Part II, 17 out of 19 patients  completed 22 weeks of treatment  and 15 had normal mUFC 
levels at week 22 (79%).  During treatment with osilodrostat, the mean mUFC levels decreased 
quickly and stabilized to a normal level (11 to 138 nmol/24h) at Week 4 (Figure 1 -3). After 
Week 4, normal mean mUFC levels were observed through the study up to Week 22. All 
patients attained UFC normalization at least once during the study, and no patient “escaped” 
UFC control.  

[COMPANY_001]  Confidential  Page 31 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 Figure 1-3 Mean (+/ -SE) mUFC (nmol/24h) over time by [CONTACT_677422] : In-text Figure 11 -1, 22 -week interim CSR study [LCI699C2201]  
[IP_ADDRESS].3  Overview of safety  
In the clinical trials for the treatment of hypertension or primary hyperaldosteronism, 
osilodrostat was tolerated with the overall incidence of adverse events being similar to placebo. 
Adverse events ( AEs) were generally of mild to moderate intensity. Bot h SAEs and 
discontinuations due to AE were infrequent, and were reported at a rate similar to placebo in 
the hypertension studies. The most common AEs across these studies were: headache, dizziness 
(including postural dizziness), nausea, diarrhea and fatig ue.  There were also AEs of 
hyperkalemia and impaired ACTH -stimulated cortisol response in these trials, which are 
consistent with the potential for hypocortisolism and hypoaldosteronism.  
In Study [CLCI699C2201 ], in patients with Cushing’s disease, safety  data from the 10 -week 
analysis also showed that osilodrostat was well tolerated with similar common adverse events 
to those in the hypertension trials, including: fatigue, nausea, vomiting, diarrhea, headache,  
dizziness, hypokalemia and muscle spasms.  
In Part I of the study [LCI699C2201] , all 12 patients (100%) experienced adverse events but 
these were generally mild to moderate in severity (NCI CTC grade 1 or grade 2). Fatigue, 
muscle cramps, dizziness and gastrointestinal events were the most common even ts suspected 
to be drug related. Four patients reported AEs consistent with cortisol and/or aldosterone 
withdrawal; dose reductions or temporary dose interruption in these patients improved the 
symptoms. There were no discontinuations related to study drug  and no serious adverse events 
of suspected drug relationship.  
In Part II, osilodrostat was generally well tolerated throughout the study. Of the 19 enrolled 
patients, 17 patients completed the 22 weeks treatment period with a median duration of 
exposure of 25.1 and 38.9 weeks in the Expansion cohort and Follow -up cohort, respectively.  
The safety findings identified in the interim analysis (data cut -off date: 23 -Dec-2013) that was 

[COMPANY_001]  Confidential  Page [ADDRESS_916337] patient had completed 22 weeks of treatmen t in this ongoing study are 
summarized below.  
Except for one patient in the Expansion cohort, all patients experienced AEs , grade 1/[ADDRESS_916338] common AEs suspected to be drug 
related (by [CONTACT_6214]).  
Two patients experience d a total of [ADDRESS_916339] grade 3 pi[INVESTIGATOR_2117] -dependent Cushing's syndrome ( preferred 
term [ PT]). The SAE resulted i n hospi[INVESTIGATOR_059]/prolonged hospi[INVESTIGATOR_677355] . This SAE was continuing at the time of the data cut -
off date.  
Another patient experienced 2 SAEs concurrently: grade 3 gastroenteritis ( Preferred Term ( PT)) 
and grade 1 Electrocardiogram QT prolong ation  (PT). The gastroenteritis resulted in 
hospi[INVESTIGATOR_059]/prolonged hospi[INVESTIGATOR_059], was not suspected to be related to the study drug and 
resolved with concomitant medication. The Electrocardiogram QT prolong ation  was suspected 
to be related to the study drug by [CONTACT_093], but causality is not clear. There were no 
cardiac symptoms or arrhythmia reported. The electrocardiogram QT prolong ation  SAE was 
ongoing at the time of the data cut -off date.  
One patient discontinued the study drug due to AEs. This patient reported (by [CONTACT_6214]) grade [ADDRESS_916340] with adrenal insuffici ency, acne, and hirsutism  
(female only)  being the most commonly reported. The majority of AEs of special interest were 
suspected to be related to study drug, were mainly grade 1/[ADDRESS_916341] result outside the normal range 
at some point , changes were grade 1/[ADDRESS_916342] been i dentified that 
are consistent with the mechanism of action of the drug as an inhibitor of both cortisol and 
aldosterone synthesis.  These can be summarized as follows:  
[COMPANY_001]  Confidential  Page 33 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 • Changes in adrenal hormones: cortisol decreased, aldosterone decreased, and their 
precur sors (11 -deoxycortisol, 11 -deoxycorticosterone) increased  
• Change in pi[INVESTIGATOR_460788]: ACTH increased  
• Changes in electrolytes: potassium increased or decreased  
• Changes in body weight and blood pressure: potentially increased by [CONTACT_677423] 11 -deoxycorticosterone  
• Changes in sex hormones: testosterone and estradiol increased (testosterone more than 
estradiol)  
A more detailed list of potential AEs related to the mechanism of action of osilodrostat can be 
found in Section 8.1.[ADDRESS_916343].  For a comprehensive review of clinical safety 
data with osilodrostat , see the [Investigator’s Brochure].  
[IP_ADDRESS].4  Osilodrostat : QT/QTc in healthy volunteers  
The cardiac repolarization liability of osilodrostat  was assessed in the definitive ICH E14 
compliant thor ough QT Study (TQT) study CLCI699C2105 in 86 healthy male and female 
subjects. A  maximum  mean ∆∆QTcF of 25.4 ms was observed on osilodrostat 150 mg (5 -fold 
higher than the maximum clinical dose of 30 mg), with absence of a relevant QT effect on 
osilodrosta t 10 mg (∆∆QTcF 0.3 ms;  90% CI −1.50, 2.16).   No s ubject experienced  QTcF 
values >500 ms, or increases from baseline >[ADDRESS_916344] was observed at Tmax 
([ADDRESS_916345] -dose). No dose -related effects were observed for the cardiac intervals (QRS, P R, 
or HR), or on blood pressure on osilodrostat 10 mg or 150 mg. No new safety concerns were 
identified in this study.  
A population -PK analysis was performed to estimate the peak exposure (Cmax) of the highest 
planned clinical doses of osilodrostat (20 mg and 30 mg), based on the pooled PK data from the 
osilodrostat  studies A2101, C2105, and C2201 (total N=178). The predicted arithmetic mean 
and geometric mean Cmax,ss of osilodrostat 20 mg was 174 and 168 ng/mL, and on osilodrostat 
30 mg  was  284 and 275 ng /mL, respectively.    
The concentration -QTcF effect model from study LCI699C2105 was then applied to the 
predicted Cmax values for osilodrostat 20 mg and 30 mg from the Population -PK 
analysis.   Based on the predicted exposure levels, the predicted maximum m ean QTcF on 
osilodrostat 20 mg is 4.1 ms (CI 2 .98, 5.28), and the predicted maximum mean QTcF on 
osilodrostat 3 0 mg is 6.3 ms (CI 5.13, 7.42).  
The results remained below the QTcF effect of regulatory concern (i.e., an upper boundary of 
the 90% CI  < 10 ms) and fully support the use of osilodrostat doses up to 30 mg.  
2 Rationale  
2.1 Study rationale and purpose  
Osilodrostat is a potent, oral inhibitor  of 11β-hydroxylase (CYP11B1), the enzyme that  
catalyzes the last step in the biosynthesis of cortisol. This provides the rationale for investigating 
the use of osilodrostat in endogenous causes of Cushing’s syndrome (CS)  of which  the most 
common cause is an ACTH -secreting pi[INVESTIGATOR_296953] (Cushing’s disease [C D]).  
[COMPANY_001]  Confidential  Page 34 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 This is a pi[INVESTIGATOR_22735] , Phase III , global, multi -center, randomized, double -blind, placebo -controlled 
study to confirm the results of the phase II [LCI699C2201 ] study and intended to support the 
registration of osilodrostat for the treatment of patients w ith CD who are candidates for medical 
therapy.  
2.2 Rationale for the study design  
2.2.1  Overall design  
The study aims to demonstrate the superiority  of osilodrostat compared to placebo in achieving 
a complete response (mUFC ≤ ULN) at Week 12, to evaluate the safety of osilodrostat 
compared to placebo, and to evaluate  the long-term safety and efficacy of osilodrostat .   
2.2.2  Period 1: Double -blind, placebo -controlled  
At the  beginning of the 1 2-week placebo -controlled period, eligible patients will be randomly 
assigned in a double -blinded fashion, either to osilodrostat treatment or to placebo (2:1 ratio).  
The duration of the placebo -controlled period in the current study is optimized to allow for 
appropriate dose titration and collection of placebo -controlled data, while minimizing the 
duration of time without cortisol -lowering therapy to protect patient safety.  Furthermore, over 
75% of patients in the Phase II study [LCI699C2201]  had UFC controlled by [CONTACT_10585] [ADDRESS_916346] 1 2 weeks  of the study : 
1. UFC and related laboratory tests obtained during Period 1 that may disclose treatment 
assignment  will remain blinded  (as described in Section 6.5.3 ) to patients, investigators 
and [COMPANY_001] Clinical Trial Team  until after the 48 -week Core database lock .   
2. Matching placebos will be provided for all tablet strengths used during Period 1 
(osilodrostat 1 mg, 5 mg, 10 mg, and (depending on availability) 20 mg ).   
3. Patients randomized to placebo will undergo mock titration (simulating both up and down -
titrations)  consistent with what may occur in patients treated with active drug  during 
Period 1 . Please see Section 6.2.1  for details .  
In addition, to reduce the risk of premature discontinuation during the placebo -controlled  
period, comorbidities (such as hypertension, hyperglycemia, hyperlipi[INVESTIGATOR_677356] ), 
should be optimally treated prior to study entry  and during the entire study . Rescue therapy for 
co-morbid conditions should also be implemented  before a decision is made to discontinue a 
patient from study drug (see rescue plan in Section 6.1.3 ). During this period, the investigator 
may temporarily interrupt study drug in the event of an AE of suspected adrenal insufficiency, 
or any AE that requires replacement or stress doses of glucocorticoid therapy (for additional 
information, see Section 6.2 , Section 6.3.1  and Section 6.3.2 ). 
[COMPANY_001]  Confidential  Page 35 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 2.2.3  Period 2: Open -label  
The objective of the open -label period , during which all patients receive active drug , is to 
elucidate the long -term efficacy and safety profile of osilodrostat while allowing for dose 
titration as needed by [CONTACT_677424].  
To maintain the integrity of the blind during Period 1 (do uble-blind period), at the begi nning of 
Period 2 ( Week 12, open -label period) all patients will start open -label osilodrostat 2 mg b.i.d., 
except those treated with doses < [ADDRESS_916347] been titrated 
to doses of > [ADDRESS_916348] been 
down -titrated to doses lower tha n 2 mg b.i.d. by [CONTACT_5875] 1 2.  At the start of Period 2  (after Week 
[ADDRESS_916349] been co mpleted ), these patients will continue  or start  treatment with open -
label osilodrostat at their last dose of Period 1  with dose titrations based on mUFC at Week 14 
onwards (as described in Section 6.2 ).  
2.2.4  Optional Extension Phase  
At the end of the Core study (Week 48) patients receiving clinical benefit from osilodrostat 
have the option to enter a 48 -week optional Extension phase (Weeks 48 to  96). Additional safety 
and efficacy data will be collected during this period. Patients currently enrolled in the optional 
extension phase must end study participation within [ADDRESS_916350]. Refer to  Section 4.1  for more 
details.  
2.2.5  Steps to ensure reliability of UFC results  
As UFC , measured in a 24 -hour urine collection  is the biomarker used for both the primary and 
key secondary assessment s, special care is taken to ensure that the results are reliable ( Section 
[IP_ADDRESS] ).  The [ADDRESS_916351] be within defined upp er and lower limits for urine 
volume (>500mL - <3000mL) and urine creatinine (see Laboratory Manual for the most current 
reference range s). These limits are intended to avoid the reporting of misleading results because 
of incomplete urine collections or ex tremes of urine concentration from under -treatment or 
overtreatment of central diabetes insipi[INVESTIGATOR_677357]. In addition, patients with eGFR < 60 
mL/min are excluded because reduced urine free cortisol excretion has been reported in patients 
with moderate  or severe renal impairment ( Chan, et al 2004 ; Issa, et al 1999 ; and Sharp, et al 
1996 ).  Additio nally,  the method used for measurement of UFC at the central laboratory is liquid 
chromatography -tandem mass spectrometry (LC -MS/MS). In contrast to immunoassays, LC -
MS/MS has the advantage of measuring cortisol accurately and exclusively, without concern of 
[COMPANY_001]  Confidential  Page 36 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 interference by [CONTACT_12783] -reactivity of accumulating cortisol precursors (e.g., 11 -DOC) with 
osilodrostat therapy ( Trainer, et al 2014 ; Monaghan, et al  2011 ). 
2.2.6  ECG Monitoring  
Cardiac monitoring will include 12 -lead Safety ECGs at pre -dose (Day 1)  and 1.[ADDRESS_916352] -
dose at each visit the patient receives study drug. The Safety ECGs are the primary cardiac 
safety assessment, and their rationale is to assess the maximum change in QTcF in each 
individual patient each time they receive study drug at t he site. The 12 -lead safety ECGs are 
read in real -time on -site by [CONTACT_978] [INVESTIGATOR_677358] (e.g., cardiologist), and if there 
is QT prolongation (QTcF > 480 ms or increase > 60 ms from baseline assessment), patients 
are to be managed according t o the QT Monitoring Flow Chart in Figure 7 -2. 
In addition, 24 -hour continuous 12 -lead Holter recordings will be performed at baseline, W eeks 
2, 12, 14, 36 , and as applicable at Week  72 and at the end of treatment visit in the optional 
Extension phase .  The 24 hour Holter assessments are not intended to provide real -time 
assessment of cardiac intervals and cardiac rhythm; the recordings are read centrally.  
2.3 Rationale for dose and regimen selection  
The rati onale for b.i.d. dosing of osilodrostat is based on its half -life of 3 -5h. This dosing 
regimen was used in study [LCI699C2201].   The original modeling of PK exposure estimated 
that a dose of 4 -5 mg b.i.d. was expected to achieve a plasma concentration abov e the in vitro  
IC50 for CYP11B1 (2.5 nM) for a full 24 hours for efficacy; however, 2 mg b.i.d was chosen 
to be the starting dose in the proof -of-concept study based on safety considerations.  
In the Phase II study [LCI699C2201] , Part I, evaluating osilodro stat in patients with 
uncontrolled CD  over a 10 week period (N=12) , osilodrostat was initiated at [ADDRESS_916353] once during the study and 11/12 patients had a normal UFC 
at week 10.  The mean dose at  the time of response was 13.5 mg/day (SD = 13.9 mg), and the 
mean time to response was 34.3 days (SD = 14.1 days). The daily dose required to first reach 
UFC normalization was ≤ 20 mg/day in 75% of the patients, with at least 50% of the patients 
requiring  10-20 mg/day (5 -10 mg, b.i.d).   
In Part II  (N=19) , osilodrostat was initiated at [ADDRESS_916354] once during the study; 16/19 (84%) patients had a normal UFC at 
Week 10, and 1 5/19 (79%) had a normal UFC at W eek 22.  The distribution of total daily doses 
was similar to t hat of study Part I.  The mean total daily dose for the 17 patients that remained 
in the study at Week 22 was 16 .9 mg; the total daily dose at W eek 22 was ≤ 20mg in 14/17 
(82.3%) of patients.  
Hypocortisolism was reported in 4 patients in Part I of study [LCI699C2201 ], and in 6 patients 
in Part II (Core).  Hypocortisolism resolved in all patients with dose reduction and/or 
interruption.  In addition, during Part II of study [LCI699C2201], one patient had biochemical 
evidence of hypocortisolism on 2 mg b.i.d ., and the dose was reduced to 1 mg b.i.d. Therefore, 
the individual dose titration starting at 2 mg b.i.d. is an appropriate method to assess the efficacy 
[COMPANY_001]  Confidential  Page 37 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 and safety of osilodrostat. In the event that hypocortisolism (24 -hour mUFC < LLN , or mUFC 
in the lo wer part of the normal range with signs and symptoms of adrenal insufficiency ) is 
observed on a dose of 2 mg b.i.d. , the dose may be reduced to < 2 mg b.i.d. (i.e., 1 mg b.i.d., 1 
mg q.d., or 1 mg q.o.d. (every other day)) to mitigate the risk of persisten t hypocortisolism.  
In both parts of this study, the interpatient variability in dose requirements to normalize cortisol 
is broad (e.g. 2 mg b .i.d. to 30 mg b .i.d.). Fixed -dose comparisons of treatment groups with 
various doses of osilodrostat are not appr opriate because this would carry the potential risk of 
acute adrenal insufficiency if a relatively high dose is administered to a patient that is sensitive 
to osilodrostat.  
This study will start individual dose titration with [ADDRESS_916355] 12 weeks of the study. The double -
blind design minimizes the risk of potential bias.   
2.6 Benefit -Risk Assessment of osilodrostat in study population  
Potential patient benefits  
There is an unmet medical need in patients with Cushing’s disease which is a rare and serious 
disease with limited options for medical therapy. Phase 2 data demonstrated normalization of 
mean UFC in 11/12 patients after 10 weeks of therapy (LCI699C2201, Pa rt 1) and 15/19 
patients after 22 weeks of therapy ((LCI699C2201, Part II C ore). There was a trend toward 
improved fasting glucose and HbA1c in patients with diabetes at baseline, and an improved 
fasting lipid profile in patients with dyslipi[INVESTIGATOR_677359]. Based on these results osilodrostat 
is a promising potential new therapy in patients with uncontrolled Cushing’s disease . 
Study -specific risks  
Study -specific risks in study LCI699C2302 include the potential for prolonged periods of 
uncontrolled hyperc ortisolism during washout, blinded placebo and dose titration with a 
maximum combined duration of under -treatment of  [ADDRESS_916356] to blood pressure and diabetes control  are used .  For patients who 
require washout periods of 4 weeks or longer, treatment with drugs that require a short washout 
period (e.g., 1 week) is recommended (see Section 5.2 ). 
To reduce the probability of treatment with placebo, a 2:1 randomization ratio (osilodrostat: 
placebo) has been implemented. In additio n, close clinical monitoring of co -morbidities during 
[COMPANY_001]  Confidential  Page [ADDRESS_916357] been implemented.  In addition, the threshold for mUFC 
to enter  the study is > 1.[ADDRESS_916358] (compared to > 1.[ADDRESS_916359] in other studies) allowing patients 
with less severe Cushing’s disease to participate in the study. Furthermore, the placebo -
controlled period has been kept to a minimum at [ADDRESS_916360] of cortisol reduction, as reported in the literature. During 
hormonal cont rol, a significant decrease of neutrophil count, which is commonly elevated in 
patients with Cushing’s disease, has been reported demonstrating the effect of glucocorticoids 
on these blood cells ( Masri -Iraqi et al, 2014 ). This effect has also been observed with 
osilodrostat in the Cushing’s disease trials and has included cases of neutropenia which were 
associated with mUFC levels that were either below normal or have had a rapid and substantial 
decline f rom baseline. In the cases observed, neutropenia has rapi[INVESTIGATOR_677360], and has also reversed when osilodrostat was continued, t ypi[INVESTIGATOR_677361].  
Potential risks of osilodrostat treatment in study populatio n 
Potential risks of treatment with osilodrostat in patients with Cushing’s disease include: QT 
prolongation, adrenal insufficiency, AEs related to the accumulation of precursor molecules, 
including: increased or decreased blood pressure, hypokalemia or hy perkalemia, hyponatremia, 
weight gain, edema, and increase in the synthesis of sex steroids (primarily adrenal androgens 
in women) that may lead to menstrual changes and hirsutism in women and acne in men and 
women. Corticotroph tumor progression, with or without compressive symptoms, is another 
potential risk.  Skin rash has also been observed.   
Mitigation of the potential risks related to osilodrostat treatment include: frequent study visits 
with careful monitoring for adverse events and toxicities inclu ding those that have been 
observed in previous studies with osilodrostat ; vital signs, blood chemistry including urine, 
serum, and salivary cortisol levels, plasma ACTH, electrolytes, renal and liver function, fasting 
lipid profiles, HbA1c, sex steroid lev els (testosterone, estradiol, adrenal androgens), aldosterone 
and immediate precursor levels, safety ECGs at the time of Cmax, pi[INVESTIGATOR_677362], and 
bone mineral density.   
In addition, t he protocol provides specific guidance for safety follow -up for li ver toxicity 
(increased transaminases, increased total bilirubin) and an algorithm for monitoring and 
management of QT prolongation.  PK sampling will be conducted in all patients to measure 
osilodrostat plasma concentrations and assess for any correlation  with adverse events or for 
potential drug -drug interaction.  
Oversight Committees  
A Steering Committee has been established comprising investigators who are Cushing’s disease 
experts, whose role is to contribute to the study design, oversee the conduct of  the study and to 
ensure the transparent management of the study according to the protocol. An independent data 
monitoring committee (DMC) comprising external endocrinologists with expertise in 
Cushing’s disease, a cardiologist and a statistician will be e stablished before FPFV to monitor 
[COMPANY_001]  Confidential  Page 39 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 
 unblinded safety data periodically as the study proceeds, and to oversee the functioning of the 
IEs. A [COMPANY_001] Safety Management Team (SMT) exists to review and evaluate all emerging 
safety data for potential new safety s ignals on a regular basis and to evaluate safety management 
across the program.  
Conclusion  
Based on current data, and the planned risk mitigation processes, the overall benefit -risk of trial 
participation is expected to be positive for all trial subjects, including those randomized to the 
placebo arm.   
2.[ADDRESS_916361] for screening and monitoring Cushing’s disease. 
Since cortisol is not uniformly secreted during the day, a quantitatively exact collection and 
measurement of [ADDRESS_916362] abnormal cortisol levels.  
Although this method has been used in routine clinical practice for many years, there are several 
practical/methodological difficulties accompanying the collection and analyses of 24 -hour UFC 
samples. For instance, patient education and compliance is essential  to ensure that 24 -hour urine 
samples are collected correctly, and consequently the UFC results are reliable. UFC levels could 
be elevated by [CONTACT_677425]’s disease (pseudo -
Cushing’s syndrome, e.g., due to maj or depression or chronic alcoholism).  Multiple UFC 
collections are required to assess the possibility of cyclic hypercortisolism.  Salivary cortisol 
may allow an easier method of assessing cortisol that reflects the concurrent free cortisol level 
in serum . Hair cortisol levels may be useful to assess longer -term overall cortisol secretion.  
This study will assess the value of additional pharmacodynamic markers such as the  
 salivary cortisol, and hair cortisol.   

[COMPANY_001]  Confidential  Page 40 
Amended Protocol Version 0 2  Clean   Protocol No. CLCI699C2302  
 

[COMPANY_001]  Confidential  Page 41 
Amended Protocol Version 02 Clean   Protocol No. CLCI699C2302  
 
 3 Objectives and endpoints  
Objectives and related endpoints are described in Table 3 -1 below.  
Table 3-1 Objectives and related endpoints  
Objective  Endpoint  Analysis  
Primary   Refer to Section 10.4  
To demonstrate the superiority of osilodrostat compared to placebo 
in achieving a complete response (mUFC ≤ ULN) at Week 1 2.   The proportion of randomized patients with a complete response, 
i.e. mUFC ≤ ULN at Week 1 2.    
Key secondary   Refer to  Section 10.5.1  
To assess the complete response  rate in both arms combined at 
Week 36 in patients receiving osilodrostat treatment .  The proportion of patients with mUFC ≤ ULN at Week 36 for  
combined randomized patients  who receiv e osilodrostat treatment .  
Other secondary   Refer to Section 10.5.2  
To assess the proportion of patients with a complete response 
(mUFC ≤ ULN ) or a partial response ( mUFC decrease ≥ 50% from 
baseline  and > ULN ) at Week 12, Week 3 6, and Week 48.  
 The overall response rate defined as proportion of complete 
responders (mUFC ≤ ULN) plus partial responders (≥ 50% 
reduction in mUFC from baseline  and > ULN ) at Week 1 2, Week 
36, and Week 48 by [CONTACT_677408] .  
To assess the change in mUFC during the Core and E xtension 
periods of the study.  (Refer to Table 7 -1a and Table 7 -2 for the 
study visit and evaluation  schedule during the  Core and optional 
Extension phase s, respectively ). Actual and percentage change in mUFC from baseline to each 
post-baseline visit during the Core and E xtension at which UFC is 
collected  by [CONTACT_677408].   
To compare the time -to-first control of mUFC during the placebo -
control led period ( Weeks 1-12) between the randomized treatment 
arms . 
 Time -to-first control of mUFC, which is defined as the time (in days) 
from randomization to the first mUFC collection that was ≤ ULN 
before completion or discontinuation of placebo -controlled period, 
whichever is earlier.   
To assess the time -to-escape during osilodrostat treatment up to 
Week 48.  
 Time -to-escape is defined as the time (in weeks) from the first 
collection of normal mUFC (≤ ULN) to the first mUFC > 1.[ADDRESS_916363] 2 6 weeks.   
[COMPANY_001]  Confidential  Page 42 
Amended Protocol Version 02 Clean   Protocol No. CLCI699C2302  
 
 Objective  Endpoint  Analysis  
To assess cardiovascular and metabolic related parameters 
associated with CD (fasting plasma glucose, HbA1c, fasting lipid 
profile, blood pressure, weight and waist circumference ) by 
[CONTACT_677426] s 12, 36, and 48 . The actual and percent change from baseline in fasting plasma 
glucose (FPG), HbA1c, fasting lipid profile, blood pressure (BP), 
weight and waist circumference at Week12, Week 36, and Week 48 
by [CONTACT_2939] s and for the overall patient population.  
  
To assess the change from baseline at Weeks 12, 36, and 48 in 
physical features of CD.  Mean change from baseline to Week 12, Week 36, and Week 48 in 
each of the following clinical signs of Cushing’s disease, captured 
by: a semi -quantitative Likert scale for facial rubor, striae, 
supraclavicular fat pad, dorsal fat pad, proximal muscle wasting 
(atrophy), central (abdominal) obesity, and ecchymoses (bruises) 
by [CONTACT_677427] .    
To assess the change from baseline in bone mineral density (BMD) 
by [CONTACT_677428][INVESTIGATOR_677340] 48 .   The change from baseline in bone mineral density, and BMD T -
score, at the lumbar spi[INVESTIGATOR_050] (L1 -L4) and total hip at Week 48 by 
[CONTACT_677429] .   
To determine the safety and tolerability of osilodrostat in the study 
population . Adverse events and laboratory abnormalities.  Assessed events 
include: AEs of special interest, laboratory evaluati on, ECG, Holter 
recording, and pi[INVESTIGATOR_299446].   
To assess the change from baseline in Health Related Quality of Life, 
as measured by [CONTACT_8671]-specific QoL questionnaire (CushingQoL); 
by [CONTACT_262098] (BDI -II); and by [CONTACT_677414] -
related QoL instrument EQ -5D-5L, by [CONTACT_677430].  
 Change in standardized score of CushingQoL, Beck Depression 
Inventory -II, and EQ -5D-5L, from baseline to Week [ADDRESS_916364] measurement prior to early discontinuation, whichever 
occurs ear lier.   
To evaluate pharmacokinetic exposure of osilodrostat in the study 
population . Plasma concentrations ( pre-dose, [ADDRESS_916365] -dose ) of osilodrostat .  
To assess the change from baseline in serum, salivary and hair 
cortisol levels  The actual and percentage change from baseline in serum cortisol, 
late night salivary cortisol, morning salivary cortisol and hair cortisol 
levels for every visit in the Core an d extension phases at which the 
biomarkers of hypercortisolism are collected , by [CONTACT_677431].    
[COMPANY_001]  Confidential  Page [ADDRESS_916366] 1 2 weeks, followed by [CONTACT_31463] -label 
treatment with osilodrostat until week 48, and an optional Extension  phase .  
Screening period  (up to 8 weeks) : 
The screening period will have a maximum duration of 8 weeks to enable patients to washout 
their current treatment for Cushing’s disease . Patients will be evaluated for trial eligibility after 
the washout period is completed.  
During washout, some patients may have loss of control of co -morbidities such as hypertension 
and diabetes. Therefore the screening period should be viewed as a “run -in” period in which 
the treatment of co -morbidities is optimized. Patients should be close ly monitored and treated 
accordingly, aiming ideally for normalization of blood pressure, fasting glucose and potassium. 
Control of co -morbidities in this “run -in” is important  for patient safety and to ensure the 
majority of patients can complete the 1 2-week placebo -control period and therefore minimize 
loss of data.  Three 24 -hr UFC urine samples and two late night salivary cortisol samples are to 
be collected after completion of the washout period to assess study eligibility . 
Period 1 ( Weeks 1-12): double -blind, placebo -controlled period  
This is the randomized, double -blind, placebo -controlled period (Weeks 1-12).  Eligible 
patients are randomized in a 2:1 ratio to treatment with study drug (osilodrostat or placebo , 
respectively ). Patients are strati fied at randomization according to history of pi[INVESTIGATOR_585643] 
(yes/no).   
Figure 4-1 Schematic of Period 1  
 
Study visits occur at Day 1, and Week s 2, 5, 8, and 1 2 (Figure 4 -1).  Study drug  is started on 
Day [ADDRESS_916367] the patient to implement the dose to patients.  
Figure 4-2 Timing of study visits, UFC collection, and dose adjustments during 
Period 1  
 
Legend:  During Period 1, study visits are at  Day [ADDRESS_916368] or at a visit if the patient needs to receive new study drug supplies or for safety issues . 
See text for additional detail s.   
Three 24 -hour urine samples will be collected by [CONTACT_1962] , preferably on consecutive days at 
screening, immediately  prior to Day 1 and the Week 12 visit  (primary endpoint)  during this 
study period . Two 24 -hour urine samples will be collected preferably on consecutive days 
immediately prior to each of the other visits  (i.e. at Weeks 2, 5, and 8) .  
In order to maintain the treatment blind during Period 1, all laboratory results obtained during 
Period 1 that may disclose the randomized treatment assignment are blinded to patients, 
investigators and the [COMPANY_001] Clinical Trial Team (see Section 6.5.3  for further details) . The 
relevant laboratory results that are blinded include: UFC, urine creatinine , serum and salivary 
cortisol, ACTH, aldosterone,  renin, estradiol, estrone, androgens (testosterone, delta -4 
androstenedione, DHEAS), and precursors 11 -deoxycortisol, 11 - deoxycorticosterone . 
A group of independent endocrinologists (IEs) is responsible for managing  dose titrations 
during Period 1  between visits . Titrations for patients assigned to placebo will aim to simulate 
the active arm. Refer to Section 6.2  for details on dose titratio n. The IE communica tes study 
drug dosing instructions to the site for all patients (active and placebo) in a blinded manner  
through the IRT system . If a dose adjustment is required , sites may inform patients of a dose 
change by [CONTACT_100841] a visit if the c hange can be managed with the patients’ current supplies. 
If a different tablet strength is needed to implement the dose change, patients need to return to 
the site to collect the required study drug supplies and instructions on how to administer the 
dose.  To minimize dosing errors  for patient safety , it is very  important  that these instructions 
are clear, simple and written  legibly  (see Section [IP_ADDRESS] . and Section 6.6  for further details).   
If patients discontinue study drug treatment before the Week 12 visit, investigators should make 
reasonable efforts to follow patients and perform assessments for all sch eduled visits up to and 

[COMPANY_001]  Confidential  Page 46 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 including the Week 12 visit (as listed in Table [ADDRESS_916369]-treatment Follow -up), even if 
alternative cortisol lowering therapy has been initiated.  
During Period  1, the investigat or may temporarily  interrupt study drug in the event of an AE of 
suspected adrenal insufficiency, or any AE that requires replacement or stress doses of 
glucocorticoid therapy (for additional information, see Section [IP_ADDRESS]  and Section 6.3.1 ).  
Period 2 (Weeks 12-48): single arm, open -label treatment period  
Period [ADDRESS_916370] dose titration with active drug , while patients 
randomized to  osilodrostat continue this treatment and undergo a “second” dose titration.   
• All p atients on doses of ≥2 mg b.i.d.  at the Week 1 2 visit will receive open -label 
osilodrostat at a starting dose of 2 mg b.i.d. at the beginning of Period 2, regardless of 
treatment assignm ent in Period 1.  
• Patients on <2 mg b.i.d. at the Week 1 2 visit will continue the same dose they were on at 
the end of  Period 1 , regardless of treatment assignment during Period 1 .  
• Placebo -treated  patients on a dose of < 2 mg b.i.d. at the end of Period 1 , will continue this 
dose but with active drug at the beginning  of Period 2 .   
During Period 2, the investigator is responsible for dose titration , which will be based on mUFC 
and other relevant patient data (as described in Section 6.2.2 ). Osilodrostat can be titrated up to 
a maximum dose of [ADDRESS_916371].   The IE does not participate in dose decisions 
beyond Week 12.  
Three 24 -hour urine samples will be collected by [CONTACT_1962], preferably on consecutive days 
immediately prior to the Week 36  visit ( key secondary endpoint)  and Week 48 (end of C ore 
phase ). Two 24-hour samples will be collected prior to all other visits in Period 2.   A patient is 
considered to have reached a stable efficacious dose when mUFC remains ≤ ULN. This dose is 
continued, unless a change is needed (see Section 6.2.2  for details).  As in Period [ADDRESS_916372] the new supplies.  
Optional Extension phase : 
 
At Week 48, patients have the option to enter a n optional  open -label Extension  phase .  Patients 
who do not enter the optional extension discontinue osilodrostat at Week [ADDRESS_916373] -Treatment (End of Study) visit after [ADDRESS_916374] -Treatment (End of Study) 
visit after 30 days off study drug. Refer to  Section 6.1.5  for more details.  During the optional 
extension phase the dose of osilodrostat will be maintained at the established effective dose 
[COMPANY_001]  Confidential  Page 47 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 unless a change is required based on mUFC results  collected at Weeks 48, and if applicabl e, at 
Weeks 60, 72, and 84  (see Section 6.2.3  for details on dose adjustment) .  
Additionally, patients are allowed to have unscheduled visits at any time in the study if needed, 
e.g. if they report signs  and/or symptoms of hypercortisolism, adrenal insufficiency, other AEs , 
or need additional study drug supplies.  
For more details on dos ing titration , Independent Endocrinologist s (IE) and Investigator 
intervention s, please refer to Section 6.[ADDRESS_916375] periodic safety 
data reviews as outlined in Section 8.6 . 
4.3 Definition of end of the study  
Completi on of the study as a whole (last patient last visit) will occur once all patients have 
completed all assessments as per Table 7 -1a, Table 7 -1b (Core) and, as applicable, Table 7 -2 
(optional Extension), or have  discontinued from the study , including Post -treatment follow -up 
or transit ion into the long -term safety follow -up study , whichever occurs first .  
Patie nts to end participation in the  optional Extension period within [ADDRESS_916376].  Refer  to Section 
6.1.5  for details.  

[COMPANY_001]  Confidential  Page 48 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 4.4 Early study termination  
The study can be terminated at any time for any reason by [CONTACT_5343]. Should this be necessary, 
the patient will be contact[CONTACT_33981]/her des ignee. The patient should be seen 
as soon as possible and the assessments should be performed as described in Section 7  for a 
discontinued or withdrawn patient. The investigator may be informed of additi onal procedures 
to be followed in order to ensure that adequate consideration is given to the protection of the 
patient’s interests. The investigator will be responsible for informing IRBs and/or ECs of the 
early termination of the trial.  
5 Population  
5.1 Patien t population  
The study population will be comprised of approximately 69 adult male and female patients 
with Cushing’s disease who have persistent or recurrent hypercortisolism after primary pi[INVESTIGATOR_677363]/or irradiation, and patients with de novo  Cushing’s disease who are not surgical 
candidates for medical reasons, or refuse to undergo surgery or do not have access to a 
speci alized center with experience in pi[INVESTIGATOR_221370].   
The investigator or designee must ensure that only patients who meet all the following inclusion 
and none of the exclusion criteria are randomized to treatment in the study.  
5.[ADDRESS_916377] to meet all of the following criteria:  
1. Written informed consent obtained before any assessment is performed.  
2. Male or female patients aged 18 - 75 years . 
3. Confirmed CD that is persistent or recurrent as evidenced by  [CONTACT_677432] (i.e., a, b, a nd c) : 
a. mUFC > 1.[ADDRESS_916378] (Mean of three 24 -hour urine samples collected  preferably on 3 
consecutive days  during screening after washout of prior medical therapy for CD (if 
applicable) , confirmed by [CONTACT_677433] 1), with ≥ 2 
of the individual UFC values being > 1.[ADDRESS_916379] . 
b. Morning plasma ACTH above Lower Limit of Normal  
c. Confirmation (based on medical history) of pi[INVESTIGATOR_677364]:  
i. Histopatho logic confirmation of an ACTH -staining adenoma in patients who have 
had prior pi[INVESTIGATOR_221370].  
OR 
ii. MRI confirmation of pi[INVESTIGATOR_296953] > 6 mm  
OR 
iii. Bilateral inferior petrosal sinus sampling (BIPSS) with either CRH or DDAVP 
stimulation for patients with a tumor ≤ 6mm. The criteria for a confirmatory BIPSS 
test are any of the following:  
• Pre-dose central to peripheral ACTH gradient > 2;  
[COMPANY_001]  Confidential  Page 49 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 • Post-dose central to peripheral ACTH gradient > [ADDRESS_916380] seven days or 5 half -lives prior to screening , whichever is longer . 
5. Patients with de novo  CD can be included only if they are not considered candidates for 
surgery (e.g., poor surgical candidates due to co -morbidities, inoperable tumors, patients 
who refuse to have surgical treatment, or surgical treatment is not available)  
6. For patients with a  history of pi[INVESTIGATOR_585643]: at least 2 years for stereotactic 
radiosurgery (SRS), and 3 years for conventional (fractionated) radiation, respectively, must 
have elapsed from the time of the most recent radiation treatment to the time of enrollment 
into this study.   
7. Able to communicate well with the investigator, to understand and comply with the 
requirements of the study.  
8. Washout of any current drug therapy for CD. The following minimum washout periods must 
be completed before baseline efficacy asses sments are performed:  
a. Steroidogenesis inhibitors (ketoconazole, metyrapone): 1 week  
b. Pasireotide s.c. (immediate release formulation): 1 week  
c. Mifepristone : 3 weeks  
d. Dopamine agonists (e.g., cabergoline), or PPAR -gamma agonists (e.g., rosiglitazone, 
pi[INVESTIGATOR_677365]): 4 weeks  
e. Pasireotide LAR: 8 weeks .  Rescreening can be used as needed to ensure washout is 
complete.  
f. Mitotane : [ADDRESS_916381] not meet any of the following criteria:  
1. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half -
lives at the time of enrollment, whichever is longer; or longer if required by [CONTACT_13125], and for any other limitation of participation in an investigational trial based on 
local regulations.  
2. Patients with pseudo -Cushing’s syndrome . This may be diagnosed by [CONTACT_677434] p eriod and after washout of 
prior CD medication.  
3. History of hypersensitivity to drugs of the same or similar chemical classes as osilodrostat . 
4. History of malignancy of any organ system (other than localized basal cell carcinoma of the 
skin), treated or untr eated, within the past 5 years, regardless of whether there is evidence 
of local recurrence or metastases.  
5. Patients with risk factors for QTc prolongation or Torsade de Pointes, including:  
• patients with a baseline QTcF > 450 ms for males and QTcF > 460 ms for females  
• personal or family history of long QT syndrome  
• concomitant medications known to prolong the QT interval  
[COMPANY_001]  Confidential  Page 50 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 • patients with hypokalemia, hypocalcaemia, or hypomagnesaemia, if not corrected 
before pre -dose Day 1.  
6. Patients who have a history of: congestive heart failure (NYHA Class III or IV), unstable 
angina, sustained ventricular tachycardia, clinicall y significant bradycardia, advanced heart 
block, acute myocardial infarction less than one year prior to study entry, or clinically 
significant impairment in cardiovascular function.  
7. Pregnant or nursing (lactating) women.  
8. Women of child -bearing potential, defined as all women physiologically capable of 
becoming pregnant, unless they are using highly effective methods of contraception during 
dosing and for 1 week after completion of dosing. Highly effective contraception methods 
include:  
A. Total abstinence (wh en this is in line with the preferred and usual lifestyle of the subject. 
Periodic abstinence (e.g., calendar, ovulation, symptothermal, post -ovulation methods) 
and withdrawal are not acceptable methods of contraception.  
B. Female sterilization (have had surg ical bilateral oophorectomy with or without 
hysterectomy) or tubal ligation at least six weeks before taking study drug. In case of 
bilateral oophorectomy, documentation is required (e.g. operative report, pelvic 
ultrasound or other reliable imaging method ). 
C. Male sterilization (at least 6 months prior to screening). For female subjects on the study 
the vasectomized male partner should be the sole partner for that subject.  
D. Combination of any two of the following (a+b or a+c, or b+c):  
a. Use of oral*, injected, or implanted hormonal methods of contraception or other 
forms of hormonal contraception that have comparable efficacy (failure rate <1%), 
for example hormone vaginal ring or transdermal hormone contraception  
b. Placement of an intrauterine device (IUD) or int rauterine system (IUS)  
c. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or 
cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository.  
*In the case of use of oral contraception, women should have been stable on the sa me pi[INVESTIGATOR_6522] a 
minimum of [ADDRESS_916382] had 12 
months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e., age 
appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with 
or without hysterectomy) , total hysterectomy,  or tubal ligation at least six weeks ago. In the 
case of oophorectomy alone, only when the reproductive status of the woman has been 
confirmed by [CONTACT_6492] -up hormone level assessment is she considered not of child bearing 
potential.  
9. Patients likely to require adrenalectomy, pi[INVESTIGATOR_221370], or radiation therapy during the 
placebo -controlled period ( Weeks 1-12) for the treatment of severe hypercortisolemia or 
pi[INVESTIGATOR_677366].    
10. Patients with compression of the optic chiasm due to a macroadenoma or patients at high 
risk of compression of the optic chiasm (tumor within 2 mm of  optic chiasm).  
11. Patients who have a known inherited syndrome as the cause for hormone over secretion 
(i.e. Carney Complex, McCune -Albright syndrome, MEN -1, AIP).  
[COMPANY_001]  Confidential  Page 51 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 12. Patients with Cushing’s syndrome due to ectopic ACTH secretion or ACTH -independent 
(adrenal) C ushing’s syndrome.  
13. Patients who have undergone any major surgery within 1 month , or undergone 
transsphenoidal pi[INVESTIGATOR_677343] 3 months,  prior to screening .  
14. Hypertensive patients with uncontrolled blood pressure defined as SBP > 180 and/or DBP > 
105 or not optimally treated for hypertension as judged by [CONTACT_093] . 
15. Diabetic patients with poorly controlled diabetes as evidenced by [CONTACT_13505]1c > 9 % or not 
optimally treated for diabetes mellitus as judged by [CONTACT_093] . 
16. Patients who are not euthyroid  as judged by [CONTACT_093].  
17. Patients with moderate to severe renal  impairment (estimated GFR < 60 mL/min by [CONTACT_677435] ). 
18. Patients with liver disease such as cirrhosis, chronic active hepatitis, or chronic persistent 
hepatitis, or patients with serum ALT  and/or AST > [ADDRESS_916383], or total bilirubin > 1.[ADDRESS_916384], recent surgery, 
or pregnancy.  
23. History of psychiatric hospi[INVESTIGATOR_677367] 6 months .      
24. Score “yes” on item 4 or item 5 of the Suicidal Ideation section of the Colombia Suicide 
Severity rating Scale (C -SSRS), if this ideation occurred in the past 6 months, or “yes” on 
any item of the Suicidal Behavior sect ion, except for the “Non -Suicidal Self -Injurious 
Behavior” (item also included in the Suicidal Behavior section), if this behavior occurred 
in the past 2 years.  
6 Treatment  
6.1 Study drug  
The s tudy drug consists of osilodrostat (LCI699) and matching placebo, in the form of film -
coated tablets for oral administration, in the following tablet strengths: 1 mg, 5 mg, 10 mg, and 
(depending on availability) 20 mg . 
Each strength has a unique size , imprint  and color ( Figure 6 -1). The osilodrostat 1 mg, 5 mg, 
10 mg and 20 mg film coated tablets are approximately 6 mm, 7 mm, 9 mm, and 11 mm 
respectively in diameter and pale yellow, yellow, pale orange brown and light brown 
respectively in color.  
[COMPANY_001]  Confidential  Page 52 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 Figure 6-1 Appearance of osilodrostat tablets by [CONTACT_677436]:  Each strength of osilodrostat (and matching placebo) has a unique size and color to aid in 
recognition. The appearance of the actual tablets may vary slightly from the pi[INVESTIGATOR_1103].   
6.1.1  Dosing regimen  
Study drug should be taken  twice a day (b.i.d.). For example a p atient on a [ADDRESS_916385] to food.  The patient will 
maintain a diary of each drug self -administration in order to track compliance. If vomiting 
occurs during the course of treatment, patients should not take the study drug again before the 
next scheduled dose. Patients should be instructed not to make up missed doses. A missed dose 
is defined as a case when the dose is not taken within 4  hours after the usual dosing time.  
On study visit days, patients should be reminded not to take the study drug prior to the site visit 
to ensure compliance with the ECG and pre-dose PK sampling procedure. The morning dose  of 
study drug on the visit days should be administered at the site after the ECG and pre-dose PK 
sampling  has been completed . 
6.1.2  Ancillary treatments  
Not applicable.  
6.1.3  Rescue medication  for co -morbid conditions  
Patients should receive optimal treatment for co -morbidities (hyperglycemia, hypertension, 
dyslipi[INVESTIGATOR_035], hypokalemia) both during the screening period and study treatment period.  
During the placebo -controlled period (Weeks 1-12), if patients’ comorbidities for CD worsen , 
rescue treatment for co -morbidities should be initiated and optimized to retain the patient in the 
study if possible, before a decision is made to discontinue  study  medication .    
It is suggested that the following glycemic thresholds be used for initiation or intensification of 
glucose -lowering therapy:  
• Fasting plasma glucose > 200 mg/dL ( 11.1 mmol/L) from baseline to Week 6  

[COMPANY_001]  Confidential  Page 53 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 • Fasting plasma glucose > 160 mg/dL ( 8.88 mmol/L) from Week [ADDRESS_916386] and the dose increased, if tolerated, to 
the maximally effective dose  (i.e., ≥1500 mg daily) prior to adding another agent.    
For the treatment of hypertension, ACE inhibitors should be used over diuretics known to cause 
hypokalemia (e.g., hydrochlorothiazide) and dose should be optimized.  Mineralocorticoid 
receptor antago nists (e.g., spi[INVESTIGATOR_8407]) should be used as second line agent s for hypertension 
and to prevent hypokalemia ; however the concomitant use of ACE inhibitors and 
spi[INVESTIGATOR_677368] . Serum potassium should be monitored closely and 
hypokalemia should be  treated promptly if it occurs.  Oral or intravenous potassium supplements 
can be used to treat hypokalemia, and spi[INVESTIGATOR_677369]/or hypertension.  It is suggested that o ral potassium 
supplementation be initiated if the serum potassium level is even mildly decreased (e.g., ≤ 3.3 
mg/dL [≤ 3.3 mEq/L]), and more aggressively treated (e.g., consider intravenous potassium 
replacement) if the patient is symptomatic or serum pota ssium level falls to < 3.0 mg/dL [< 3.0 
mEq/L]).  
Serum lipid levels should be monitored and treated as appropriate.    
Thresholds for considering discontinuation of patients from study drug or from the study are 
discussed in Section 7.1.4 . 
6.1.4  Guidelines for continuation of treatment  
Osilodrostat therapy (or matching placebo) is continued unless it must be interrupted or 
discontinued for safety or other reasons. See Section 6.3  ‘Dose modifications’ for details.  
6.1.5  Treatment duration  
The treatment duration is 48 weeks in the C ore study (Periods 1 and 2 ), and up to an additional 
48 weeks for patients who agree  to continue on the optional extension phase . Patients may 
continue treatment with the study drug until unacceptable toxicity has been experienced, and/or 
treatment is discontinued at the discretion of the investigator or withdrawal of consent.   In the 
absence of study drug discontinu ation, patients will receive osilodrostat for a minimum of [ADDRESS_916387].  Patients participating in the 
optional extension phas e between Week 48 and Week 72, and who are eligible, should transition 
into the long -term safety follow -up study at the next study visit. Patients participating in the 
optional extension phase between Week 72 and Week 96, and who are eligible, should trans ition 
into the long -term safety follow -up study within 4 weeks , at an unscheduled visit  if needed , of 
Protocol Amendment 02 approval  at the site . 
[COMPANY_001]  Confidential  Page 54 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 6.2 Dose titration guidelines  
6.2.1  Study Period 1: The double -blind, placebo -controlled period (Weeks 1 -
12). 
For patien ts on osilodrostat arm,  the IE is responsible for study drug dose titrations during 
Period 1, as the Investigators will not have access to UFC, serum cortisol, and other related 
laboratory results (as described in Section 4.1 ) that could disclose the randomized treatment 
assignment. The IE will determine the study drug dose once the mUFC level is available from 
scheduled study visits at Week 2, Week 5 and Week 8, and has access to following data:  
• treatm ent allocation  
• mUFC and individual [ADDRESS_916388] recent study visit (see Table 7 -
1a), and mUFC values since the beginning of the trial (as reported by [CONTACT_11378])  
• other rel evant laboratory data (i.e., serum cortisol, ACTH , and chemistry ) 
• data on the presence or absence of clinical signs and symptoms of adrenal insufficiency 
(AI; as recorded on the clinical signs and symptoms of AI eCRF page from the most 
recent study visit) (see Section 7.2. 2.1.1  for details).  
• vital signs as recorded in the eCRF  
• study  drug doses since the beginning of the trial (as recorded on the Drug Administration 
Record (DAR) eCRF).  
In order to maintain the study blind, communication from the IE to the investigator must be 
limited to communication of study drug dose decisions throu gh the IRT system .   
For patients in the placebo arm,  a simulated dose titration sequence will  be used to maintain 
the blind.  
[IP_ADDRESS]  Dose up -titration during Period 1  
The initial study drug dose in Period 1 is osilodrostat or placebo 2 mg b.i.d.   The dose escala tion 
sequence is: 5 mg b.i.d., 10 mg b.i.d. and 20 mg b.i.d. The IE will up -titrate the osilodrostat 
dose to the next dose in the sequence, based on the mUFC value until mUFC is normalized.  
While the goal is to normalize mUFC, decision to up -titrate dose will take into consideration 
the totality of the data available on each patient e.g. level of mUFC, rate of decrease of mUFC 
and tolerability of study drug (see Section 6.3 ). 
Once mUFC is in the normal range  (i.e., mUFC ≤ ULN and ≥ LLN), the dose should be 
maintained, provided there are no safety concerns requiring a dose reduction or interruption (as 
described below and in Section 6.3 ).  
[IP_ADDRESS]  Dose down -titration during Period 1   
The dose of study drug may be down -titrated or interrupted by [CONTACT_677437] < LLN or  close to LLN together with signs and/or symptoms o f adrenal insufficiency. 
However, it is expected that the investigator will take immediate action to temporarily withhold 
study medication, without waiting for instructions from the IE, if their patient had suspected 
adrenal insufficiency,  or any AE that r equires replacement therapy with glucocorticoids (see 
[COMPANY_001]  Confidential  Page 55 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 Section 6.3.1  for details) . In the event the investigator interrupts study drug, this information 
must be recorded in the eCRF as soon as possible, s o that the IE can take this into account when 
selecting the next scheduled study drug dose.  
[IP_ADDRESS]  Intermediate doses for dose adjustment  
The preferred doses for either up or down -titration are the standard recommended doses of 2, 
5, 10 and 20 mg b.i.d. during P eriod 1. The preferred intermediate doses are: 3, 7, and 15 mg 
b.i.d., but other doses may be selected if necessary.  
Examples of the appropriate use of intermediate study drug doses are described below:     
• A patient previously down titrated from a higher dose for signs and symptoms of adrenal 
insufficiency to the next lower standard dose (e.g., down titrated from 10 mg b.i.d. to 5 mg 
b.i.d.), and who experienced an increase in mUFC > ULN, or developed signs and 
symptoms of hypercortisolism at the lower dos e, may be up titrated to an intermediate 
dose (e.g. 7 mg b.i.d., or, if needed, another intermediate dose between 5 mg and 10 mg 
b.i.d.) to optimize control.  
• A patient who had mUFC > ULN, with or without signs and symptoms of 
hypercortisolism at one dose,  and subsequently had mUFC < LLN or close to the LLN, 
accompanied by [CONTACT_677438] 
(e.g., after up -titration from 5 mg b.i.d. to 10 mg b.i.d.)  may be down titrated to an 
intermediate dose (e.g., 7 mg  b.i.d., or, if needed, other doses between 5 mg and 10 mg 
b.i.d.) to optimize control.  
In patients treated with either osilodrostat or placebo, the study drug could be down -titrated to 
a dose lower than 2 mg b.i.d., if indicated.  In addition, d oses of 1  mg b.i.d. or lower can be 
used, e.g., 1 mg q.d. or 1mg q.o.d. (every other day), if needed for patients that are sensitive to 
osilodrostat. Importantly, only placebo -treated patients with mUFC < 1.[ADDRESS_916389] doses 
increases the complexity o f dispensing drug to the patient, and self -administration of drug by 
[CONTACT_102] (see Section 6.6  for details).  
[IP_ADDRESS]  Communication and implementation of dose changes  
As soon as possible (e.g. within 48 hours, if feasible) after the receipt of UFC values for each 
patient:  
1. The IE must determine the next study drug dose (as described in the dosing guidelines, 
above)  
2. The IE must communicate the dose decision for each patient to the corresponding site, 
throu gh the IRT system in a blinded manner.  
3. If a dose change is needed and can be accommodated with the patients’ current supplies, 
the IRT system will provide instructions for the new dose,  with the option for this dose 
change communication to be either via the phone or during an unscheduled visit (per 
investigator judgment). If a different tablet strength is needed to implement the dose 
change, the IRT system w ill recommend that the patient returns to the site (unscheduled 
[COMPANY_001]  Confidential  Page 56 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 visit) for a dose change. The follo wing need to be completed during both at scheduled and 
unscheduled site visit s:  
a. Patients should return all unused tablets to the site for drug accountability  
b. Patients will receive adequate quantities of medication at the new dose  to last until the 
next scheduled visit.   
c. Patients must receive written instructions regarding the new dose and dosing schedule.    
Phone contact: [CONTACT_677439] a patient contact [CONTACT_677440] 2 -5 days 
after a visit, regardless of whether a dose change was made to assess the following:  
1. verify the dose the patient is taking   
2. assess the presence or absence of signs and symptoms of adrenal insufficiency or 
glucocortic oid withdrawal .  
Note: If the dose is maintained without change, the  patient does not need to return to the site 
until the next scheduled study visit.  
As a general rule, the patient must be on a dose of study medication for at least [ADDRESS_916390] adequate 
exposure to the dose. Therefore, if the time interval between availability of the new dose and 
next scheduled visit is less than 6 days (when 2 x 24 -hour urine collections are required for dose 
titration) or 7 days (when 3 x 24-hour urine co llections are required, e.g. Week  12 visit), patients 
should not be requested to change their dose until the next scheduled visit when new dosing 
instructions will be provided and study drug dispensed .  
The above guidance is not applicable when urgent dose  changes need to be made to ensure 
patient safety.  All study drug dose changes must be documented in the eCRF . 
6.2.2  Study Period 2:  The single -arm, open -label dose titration period 
(Weeks 12 -48) 
Immediately after the Week 12 visit, all patients (in both treatm ent groups) will receive open -
label osilodrostat (as described in Section 4.1 ).  
Investigators will up -titrate osilodrostat doses to achieve mUFC normalization, according to the 
following dose escalation sequence: 2 mg b.i.d., 5 mg b.i.d., 10 mg b.i.d., 20 mg b.i.d., and then 
30 mg b.i.d.. For any patients on less than 2 mg b.i.d. at t he beginning of Period 2, the 
investigator can increase the dose to 2 mg b.i.d. when the results of the Week 14 visit are 
available, and then follow the above dose escalation sequence as needed to normalize mUFC. 
The investigator will follow the same dosin g guidelines as described above for the IE (Section 
6.2.1 : Study Period 1).   
The investigator must remain vigilant to signs and symptoms of adrenal insufficiency and 
glucocorticoid withdrawal between Wee k [ADDRESS_916391] to the osilodrostat dose,  if needed.  An unscheduled visit during 
this time may facilitate assessment of the patient.    
Osilodrostat treatment continues until the Week 48 v isit with dose -titration to the minimum 
effective dose that maintains UFC ≤ULN. This dose is continued unless a change is required 
based on mUFC results, or an AE occurs that requires dose reduction or temporarily 
[COMPANY_001]  Confidential  Page 57 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 withholding osilodrostat. Dose adjustments  are to be performed by [CONTACT_677441] (Section 6.2.1 : Study Period 1).  
6.2.3  Extension phase (Weeks 48 - 96): 
Osilodrostat treatment continues for  up to [ADDRESS_916392] the 
option to continue treatment on study until any of the following occur s: 
a) they no longer benefit from treatment or  
b) managed access program becomes locally available or  
c) an alternative treatment option becomes locally available or  
d) within [ADDRESS_916393]. Refer to 
Section 6.1.5  for details  
For patients who transition into a separate long -term study or managed access program, the 
EOS (last dose + 30 days) visit is not ap plicable, as treatment on osilodrostat will not be 
interrupted, and only the EOT visit will be performed.  
Those patients who will not continue treatment will complete the EOT extension visit and an 
EOS (last dose + 30 days) visit, for details of assessments, please refer to Section 7.1.4 . 
6.3 Dose modifications  
6.3.1  Dose modification and dose delay  
Please refer to Section 4.1  “Description of study design” and Section 6.2   “Dos e titration  
guidelines ” for further i nformation about dose and dosing regimen during various periods of 
the trial.  
In the event of a major safety issue, the investigator may order any laboratory, radiology, or 
other diagnostic testing required in the safety assessment. In the case of suspecte d acute adrenal 
insufficiency  or adrenal crisis , the investigator may order and see the results of an urgent serum 
cortisol level  during the double -blind phase of the trial (Weeks 1-12).  However, since 
knowledge of the serum cortisol level could, in effect, unblind the investigator, this action 
should be reserved for situations in which the clinical diagnosis is in doubt, and the serum 
cortisol level is considered necessary in the evalu ation and treatment of the patient.  
For patients who do not tolerate the protocol -specified dosing schedule, dose adjustments are 
permitted in order to allow the patient to continue the study drug. The followin g guidelines 
(Table 6 -1 and Table 6 -2) need to be applied .  These changes must be recorded in the eCRF s. 
[COMPANY_001]  Confidential  Page [ADDRESS_916394]  
Symptomatic adrenal 
insufficiency  
See Section 6.3.2  for 
additional detail.  If the investigator at any time suspects adrenal insufficiency, they can 
immediately  interrupt study drug and initiate replacement with glucocorticoids . 
Upon recovery  as assessed by [CONTACT_093] *, glucocorticoid therapy can be 
tapered as tolerated, and  study drug can be re -started . The decision to restart 
study drug will be made by [CONTACT_093] . The AE and associated treatments 
with changes to study drug need to be appropriately documented in the eCRF.   
*Recovery is assessed clinically by [CONTACT_093].  A general guideline is that 
glucocorticoid taper can begin when mUFC is in the upper part of the normal 
range or > ULN, and study drug can be re -started if the patient is clinically 
stable off glucocorticoid therap y for at least one week, and the mUFC is 
normal or > ULN.   
The IE can adjust the dose when sufficient information is provided, i.e., serum 
cortisol, one or more (up to three) 24 -hour UFC result, plasma glucose  and 
electrolytes  (as central lab assessment) and completed eCRF pages  with 
clinical signs and symptoms associated with hypocortisolism/ adrenal 
insufficiency event .  
Persistent asymptomatic 
hypocortisolism ( mUFC < 
LLN) at the lowest dose of 
osilodrostat  (1 mg every 
other d ay) 
See Section 6.3.2  for 
additional detail.  The IE can interrupt study drug  and 
restart at the same dose as clinically 
indicated  (based on information in the 
eCRF ).  The investigator can interrupt study 
drug and restart at the same dose as 
clinically indicated.  
Glucocorticoid withdrawal 
syndrome  
See Section 6.3.[ADDRESS_916395] improved . 
*Hypotension (mild, 
reversible)  The investigator can interrupt dose 
until blood pressure le vels have 
improved . The investigator can reduce or 
interrupt dose until blood pressure 
levels  have improved . 
*Hypertension  The investigator can interrupt dose 
until blood pressure levels have 
improved; consider ACE inhibitors for 
treatment of hypertension , or 
spi[INVESTIGATOR_677370], particularly if hypokalemia 
is present.  ACE inhibitors and 
spi[INVESTIGATOR_677371].  The investigator can reduce or 
interrupt dose until blood pressure 
levels have improved; consider ACE 
inhibitors for treatment of 
hypertension , or spi[INVESTIGATOR_677372], particularly if 
hypokalemia is present.  ACE 
inhibitors and spi[INVESTIGATOR_677373].  
*Weight gain, edema  The investigator can interrupt dose 
until improved; consider 
spi[INVESTIGATOR_677374].  The investigator can reduce or 
interrupt dose until improved; 
consider spi[INVESTIGATOR_677375].  
*Hypokalemia  The investigator can interrupt dose 
until improved; replace potassium; 
consider spi[INVESTIGATOR_677376] ; replace 
potassium; consider spi[INVESTIGATOR_677377] [ADDRESS_916396]  
*Hyperkalemia  The investigator can interrupt dose 
until improved; if on spi[INVESTIGATOR_571545], reduce or interrupt ; treat 
with kayexalate and other potassium 
lowering therapi[INVESTIGATOR_242478].   The investigator can reduce or 
interrupt dose until improved; if on 
spi[INVESTIGATOR_256813], reduce 
or interrupt ; treat with kayexalate and 
other potassium lowering therapi[INVESTIGATOR_485819].  
*Hirsutism (women only)  The investigator can interrupt dose 
until improved; review testosterone 
level; consider treatment with 
spi[INVESTIGATOR_8407], cyproterone acetate 
or finasteride per local guidelines  The investigator can reduce or 
interrupt dose until improved; review 
testosterone level; consider treatment 
with spi[INVESTIGATOR_8407], cyproterone 
acetate or finasteride  per local 
guidelines  
*Acne (women or men)  The investigator can interrupt dose 
until improved; review testosterone 
level; consider treatment with 
spi[INVESTIGATOR_8407], cyproterone acetate 
or finasteride  per local guidelines  The investigator can reduce or 
interrupt dose until improv ed; review 
testosterone level; consider 
spi[INVESTIGATOR_8407], cyproterone acetate 
or finasteride per local guidelines  
* Treatment of co-morbidities should be optimized during the screening period and ma y be considered in these  
situations and throughout the study treatment period (see Section 6.1.3  for details ).   
Instructions for monitoring liver function, and the criteria for withholding, re -initiating,  
reducing  dose or discontinuation of study medication are provided in Table 6 -2 below.  
[COMPANY_001]  Confidential  Page 60 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 Table 6-2 Criteria for interruption and re -initiation of osilodrostat  for abnormal 
liver function  
Isolated total Bilirubin elevation  
> ULN – 1.[ADDRESS_916397]  Maintain dose level  
> 1.[ADDRESS_916398]  lnterrupt study drug  dose . Monitor LFTs  weekly , or more frequently if clinically 
indicated, until resolved to ≤ 1.[ADDRESS_916399]:  
If resolved in ≤ 14 days, restart study drug and  maintain dose level  
If resolved in > 14 days, restart study drug and decrease by [CONTACT_132435] . 
> 3.[ADDRESS_916400]*  Interrupt study drug . Monitor LFTsa  weekly, or more frequentl y if clinically indicated, 
until resolved to ≤ 1.[ADDRESS_916401]:  
If resolved in ≤ 14 days, restart study drug and decrease by [CONTACT_30560].  
If resolved in > 14 days, then discontinue pat ient from study drug treatment.  The 
patient should be monitored weekly (including LFTsa), or more frequently if clinically 
indicated, until total bilirubin ha s returned to baseline or stabilized  over 4 weeks.  
> 10.[ADDRESS_916402]*  Discontinue patient from study drug treatment  
The patient should be monitored weekly (including LFTsa), or more frequently if 
clinically indicated, until total bilirubin ha s returned to baseline or stabilized  over [ADDRESS_916403] or ALT elevation  
> ULN - 3.[ADDRESS_916404]  Maintain dose level  
> 3.[ADDRESS_916405]  
  
 
 Maintain dose level.  Repeat  LFTsa as soon as possible, preferably within 48 -72 hours 
from awareness of the abnormal results ; if abnormal lab values are confirmed upon 
the repeat test, then monitor LFTsa weekly, or more frequently if clinically indicated , 
until resolved to ≤ 3.[ADDRESS_916406]  
> 5.[ADDRESS_916407]  
 
 
 
 
 Interrupt study drug .  Repeat LFTsa as soon as possible, preferably within 48 -72 hours 
from awareness of the abnormal results; monitor LFTsa weekly, or more frequently if 
clinically indicated, until resolved to ≤ 3.[ADDRESS_916408] .  Then : 
If resolved in ≤ 14 days,  restart study drug and  maintain dos e level  
If resolved in > 14 days, restart study drug and decrease dose by [CONTACT_621353] 4 weeks, discontinue patient from study drug 
> 10.[ADDRESS_916409]  Interrupt study drug . Repeat  LFTsa as soon as possible, preferably within 48-72 hours 
from awareness of the abnormal results ; monitor LFTsa weekly, or more frequently if 
clinically indicated, until resolved to ≤ [ADDRESS_916410] . Then  restart study drug and decrease 
dose  by [CONTACT_677442].  
If not resolved after 4 weeks, discontinue patient fr om study drug  
> 20.[ADDRESS_916411]  
 
 
 Discontinue patient from study drug treatment .  
Repeat LFTsa as soon as possible, preferably within 48 -72 hours from awareness of 
the abnormal results; monitor LFTsa weekly, or more frequently if clinically indicated, 
until returned to baseline or stabilized  over [ADDRESS_916412] 
and total bilirubin value:  
AST or ALT >3.[ADDRESS_916413] combined  with total 
bilirubin >2.[ADDRESS_916414] or ALT or  
total bilirubin value : 
[AST or ALT>2x baseline AND > 3.[ADDRESS_916415]] OR 
[AST or ALT > 8.[ADDRESS_916416]], combined with [total 
bilirubin >2x baseline AND >2.[ADDRESS_916417]  Permanently discontinue patient from study drug treatment.  
 
Repeat as soon as possible, preferably within 48 hours 
from awareness of the abnormal results,  then with weekly 
monitoring of  LFTsa), or more frequently if clinically 
indicated, until AST, ALT, or bilirubin  have returned  to 
baseline or stabilized  over 4 weeks.   
Refer to Section [IP_ADDRESS]  for additional follow -up evaluations 
as applicable.  
[COMPANY_001]  Confidential  Page [ADDRESS_916418], GGT, total bilirubin (fraction ated [direct and indirect], if total bilirubin > 2.[ADDRESS_916419]), and alkaline phosphatase (fractionated [quantification of isoforms], if alkaline phosphatase > 2.[ADDRESS_916420].)  
b. “Combined” defined as: total bilirubin increase to the defined threshold concurrently  with ALT/AST increase to 
the defined threshold . 
If combined elevations of AST or ALT and total bilirubin do not meet the defined thresholds, please follow the 
instructions for isolated elevation of total bilirubin and isolated elevation of AST/ALT, and ta ke a conservative 
action based on the degree of the elevations (e.g. discontinue study drug at the situation when interrupt study 
drug is needed for one parameter and discontinue study drug is required for another parameter).   After all 
elevations resolve to the defined thresholds that allow treatment re -initiation, re -start the treatment either at the 
same dose or at one dose lower if meeting a criterion for dose reduction  
c. “Cholestasis” defined as: ALP elevation  (>2xULN and R value (ALT/ALP  in x ULN) < 2).   
Note: The R value is calculated by [CONTACT_6612], using multiples of the ULN for both values. 
It  denotes whether the relative pattern of ALT and/or ALP elevation is due to cholestatic (R ≤ 2), hepatocellular 
( R ≥ 5), or mixed (R >2 an d < 5) liver injury  
* Note: If total bilirubin > 3.[ADDRESS_916421] (non -conjugated) component only, and hemolysis as the 
etiology has been ruled out as per institutional guidelines (e.g., review of peripheral blood smear and haptoglobin 
determination), then ↓ 1 dose level and continue treatment at the discretion of the investigator.  
In addition, any AE  per investigator judgment , regardless of suspected drug causality, may 
require interruption of study drug and replacement therapy with glucocorticoids until 
improvement  of the event.  These events, associated treatments along with changes to the dosing 
regimen of study drug need to  be documented in the eCRF as soon as possible to enable the IE 
(up to Week 12) to make the appropriate dose decisions.  
If the patient has interruption of study drug for more than [ADDRESS_916422] udy drug. Patients who had interruption of study drug 
and mUFC remains ≤ ULN off study drug should remain on study . 
6.3.2  Guidance for evaluation and management of hypo cortisolism  
Patients with Cushing’s disease treated with osilodrostat may experience a broad range of 
symptoms , signs, and/or lab abnormalities associated with relative or absolute hypocortisolism .  
Glucocorticoid withdrawal syndrome may occur with the rapid fall of c ortisol levels, even while 
the patient’s serum and/or urine cortisol levels are normal or elevated.  Patients may also present 
with serum and/or urine cortisol levels that are below normal or in the lower part of the normal 
range, in the absence of symptom s. Non-specific symptoms that may be suggestive of 
hypocortisolism or glucocorticoid withdrawal  are described in Section [IP_ADDRESS].[ADDRESS_916423] one or more (up to three) 24 -hour urine  samples  for UFC 
assessment and come to the site for tests for  serum cortisol, plasma glucose  and electrolytes  
(sodium and potassium ). These samples should be sent to central laboratory immediately to 
allow the appropriate dose modification by [CONTACT_555164].  Physical exam is recommended and record of 
abnormal findings  to the CRF.   
[COMPANY_001]  Confidential  Page 62 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 6.3.3  Follow -up for toxicities  
Table 6 -1 and Table 6 -2 outline the follow -up evaluation recommended for toxicities of specific 
types.  
[IP_ADDRESS]  Follow -up on potential drug -induced liver injury (DILI) cases  
Transaminase increase combine d with TBIL increase may be indicative of potential DILI, and 
should be considered as clinically important event.  
The threshold for potential DILI may depend on the patient’s baseline AST/ALT and TBIL 
value; patients meeting any of the following criteria will require further follow -up as outlined 
below:  
• For patients with normal ALT and AST and TBIL value at baseline: AST or ALT > 3.[ADDRESS_916424] combined with TBIL > 2.[ADDRESS_916425]  
• For patients with elevated AST or ALT or TBIL value at baseline: [AST or ALT > 2 x 
baseline AND > 3.[ADDRESS_916426]] OR [AST or ALT > 8.[ADDRESS_916427]], combined with [TBIL > 2 x 
baseline AND > 2.[ADDRESS_916428]]  
Medical review needs to ensure that liver test elevations are not caused by [CONTACT_15014], defined 
as ALP elevation > 2.[ADDRESS_916429] with R value < 2 .  
Note: (The R value is calculated by [CONTACT_6612], using multiples of the ULN 
for both values. It denotes whether the relative pattern of ALT and/or ALP elevation is due to 
cholestatic (R ≤ 2), hepatocellular (R ≥ 5), or mixed (R >2 and < 5) liver injury ). 
In the absence of cholestasis, these patients should be immediately discontinued from study 
drug treatment, and repeat LFT testing as soon as possible, preferably within 48 hours from the 
awareness of the abnormal results. The evaluation sho uld include laboratory  tests, detailed 
history, physical assessment and the  possibility  of liver lesions, obstructions/compressions, etc.  
• Laboratory  tests should include ALT, AST, albumin, creatine kinase, total bilirubin, direct 
and indirect bilirubin, G GT, prothrombin time (PT)/  international normalized ratio ( INR) 
and alkaline phosphatase.  
• A detailed histo ry, including relevant information, such as review of ethanol,  concomitant 
medications, herbal remedies, supplement consumption, history  of any pre -existing liver 
conditions or risk factors, should be collected.   
• Further testing for acute hepatitis A, B, C or E infection and liver imaging (e .g. biliary 
tract) may  be warranted.  
• Obtain PK sample, as close as possible to last dose of study drug.  
• Additio nal testing for other hepatotropic viral infection (CMV, EBV or HSV), 
autoimmune hepatitis or liver biopsy may be considered as clinically indicated or after 
consultation with specialist/hepatologist.  
All cases confirmed on repeat testing meeting the laboratory criteria defined above, with no 
other alternative cause for LFT abnormalities identified should be considered as “medically 
significant”, thus, met the definition of SAE ( Section 8.2.1 ) and reported as S AE using the term 
“potential drug -induced liver injury”. All events should be followed up with the outcome clearly  
documented  (Section [IP_ADDRESS]  and Section [IP_ADDRESS] ). 
[COMPANY_001]  Confidential  Page 63 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 6.3.4  Anticipated risks and safety concerns of the study drug  
Many of the anticipated drug -related safety concerns and recommendations for actions are 
reviewed in Section 6.3.1  “Dose modification and dose d elay.”  
In case of placebo treatment it is possible that patient s will present symptoms related to high 
cortisol.  
Additional anticipated risks are summarized in Section 8.1.3  “Adverse events of special 
interest.”  
For a comprehensive review of safety, see the [Investigator’s Brochure] . 
6.4 Concomitant medications  
Stable doses of concomitant medications (except those for hypercortisolism) are allowed during 
the study. All pre -exist ing concomitant medications should be recorded at study start. The 
investigator should instruct the patient to notify the study site about any new medications he/she 
takes after the start of the study. All medications and significant non -drug therapi[INVESTIGATOR_014] (in cluding 
physical therapy and blood transfusions) administered after the patient signs the informed 
consent must be listed on the Concomitant medications/Significant non -drug therapi[INVESTIGATOR_677378].  
All prescription medications and over -the-counter drugs taken within the timeframe defined in 
the entry criteria prior to the start of the study and during the study, must be recorded on the 
Prior and Concomitant Medications page of the eCRF. Medication entries should be specific to 
trade name, the s ingle dose and unit, the frequency and route of administration, the start and 
discontinuation dates and the reason for therapy.  
Medications used for the treatment of hypertension, diabetes or impaired glucose tolerance, and 
hyperlipi[INVESTIGATOR_035], in particular, r equire this detailed information as part of th e efficacy 
assessment.  
6.4.1  Permitted concomitant therapy  
Spi[INVESTIGATOR_621320] -
related edema or hypokalemia. The use of these drugs should be done  with close monitoring for 
the potential risk of severe hyperkalemia, which is further increased if renal insufficiency is 
present. Eplerenone may be used if required in acute myocardial infarction management.  
Spi[INVESTIGATOR_8407], cyproterone acetate or finaste ride for the prevention and/or treatment of 
hirsutism are approved in some countries and are not prohibited  in this study . ACE inhibitors 
can be used for the treatment of hypertension, but cannot be used concomitantly with 
spi[INVESTIGATOR_256813].  
6.4.2  Permitted concomitant therapy requiring caution and/or action  
Medications that are metabolized by [CONTACT_097]450 enzymes  
The clinical inhibitory potential of osilodrostat on CYP450 enzymes was assessed with a drug -
drug interaction study using a cocktail of CYP1A2, CYP2C19, CYP2D6, and CYP3A4/5 probe 
substrates (caffeine, omeprazole, dextromethorphan, and midazolam respective ly). Results 
[COMPANY_001]  Confidential  Page 64 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 showed that at a single dose of 50 mg, which covers the maximum extent of interaction of 30 
mg b.i.d., osilodrostat is a moderate inhibitor of CYP1A2 (2.5 -fold increase in substrate 
exposure), a weak to moderate inhibitor of CYP2C19 (1.9 -fold increase in substrate exposure), 
and a weak inhibitor of CYP2D6 and CYP3A4/5 (1.5 -fold increase in substrate exposure).  
In addition,  in vitro  drug metabolism studies show that osilodrostat is a potential inhibitor of 
CYP1A2, CYP2C19, CYP2D6, CYP3A4/5 and CYP2E1, and may consequently increase 
exposure to drugs metabolized by [CONTACT_36918].  
Therefore concomitant medications that are known substrates of these enzymes (see Appendix 
1) should be used with caution.  
The patient and the Investigator should be aware of potential signs of overdose of the 
concomitant medication and in the event of suspected toxicities; administration of either the 
substrate or osilodrostat should be discont inued according to Investigators’ judgment.  
6.4.3  Prohibited concomitant therapy  
Use of the following concomitant medication is prohibited during the study:  
- Other drug treatments for Cushing’s disease;  
- Medications with a “known risk to cause Torsades des Po intes (TdP)” and “possible risk to 
cause TdP”  
- Eplerenone and glucocorticoids, except under certain conditions:  
• Eplerenone may be used if necessary in acute post -myocardial infarction 
management, and in the event of refractory hypokalemia in patients with  hypertension 
or edema; glucocorticoids may be used as required for the short -term treatment of 
hypocortisolism or adrenal insufficiency.  
- Glucocorticoids (except under certain conditions as explained below  in Section [IP_ADDRESS] ). 
[IP_ADDRESS]  Concomitant medications  with a “Known risk to cause TdP” and with 
a “Possible risk to cause TdP”.  
Preclinical data and preliminary clinical data indicate that there is a risk of QTc prolongation in 
humans (see Section [IP_ADDRESS] ). Therefore, the use of medications with a “Known risk to cause 
TdP” and with a “P ossible risk to cause TdP”  concomitantly with osilodrostat is prohibited.  
If a patient requires a long -term medication  from the two  categories mentioned above , and there 
is no appropriate alternative medication available, they should be discontinued from the study.  
However, if a patient requires such a drug for short -term therapy, e.g., antibiotics for active 
infection, then osilodros tat may be interrupted temporarily while this drug is administered  after 
a thorough risk -benefit assessment . This does not require the patient to discontinue from the 
study prematurely. Washout periods for osilodrostat and the short -term prohibited  drug in  many 
cases may not be possible; this is acceptable if the benefit of the drug outweighs the risk of 
withholding osilodrostat therapy in the investigator’s judgment. In such cases, a discussion with 
the [COMPANY_001] Medical Monitor is recommended.  
Please refer  to Appendix [ADDRESS_916430] a “ Known risk to cause 
TdP” and “ Possible risk to cause TdP”. Investigators are advised to utilize this website when 
considering the addition of a new concomitant medication, as the lists are periodically updated. 
[COMPANY_001]  Confidential  Page 65 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 If necessary, a discussion can be held with the [COMPANY_001] Medical Monitor whe n considering the 
use of medications with a “Known risk to cause TdP” and with a “Possible risk to cause TdP”   
[IP_ADDRESS]  Glucocorticoids  
Glucocorticoids may be used as required for the short -term treatment of adrenal insufficiency  
(See Section 6.3.2  for a detailed discussion) . If glucocorticoids are used in stress doses, or as 
replacement therapy, for > [ADDRESS_916431] Number (Subject No.), that is assigned when 
the patient is first enrolled for screening and is retained as the primary identifier for the patient 
throughout his/her entire participation in the trial. The Subject No. consists of the Center 
Number (Center No.) (as assigned by [CONTACT_5359]) with a sequential patient 
number suffixed to it, so that  each subject is numbered uniquely across the entire database. 
Upon signing the informed consent form, the patient is assigned to the next sequential Subject 
No. available to the investigator through the  Oracle Clinical RDC interface.  
The investigator or d esignated staff will contact [CONTACT_677443]. Once assigned, the Subject No. must 
not be reused for any other subject and the Subject No. for that individual must not b e changed, 
even if the patient is re -screened. If the patient fails to be randomized or start treatment for any 
reason, the reason will be entered into the Screening Disposition  page.  
IRT must be notified within 2 days that the patient was not randomized.  
6.5.2  Treatment assignment or randomization  
Eligible patients will be assigned to one of the 2 treatment arms ( Section 4.1  and Section 6.1 ) 
in a ratio of 2:1 (osilodro stat: placebo respectively).  
Randomization will be stratified at Day 1 according to history of pi[INVESTIGATOR_585643] (yes/no).  
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and co ncealed from patients and investigator staff. A patient 
randomization list will be produced by [CONTACT_15017] (IRT) provider 
using a validated system that automates the random assignment of subject number  to 
randomization numbers. Thes e randomization numbers are linked to the different treatment 
arms, which in turn are linked to medication numbers. A separate medication randomization list 
will be produced by [CONTACT_90181] a 
validate d system that automates the random assignment of medication numbers to medication 
packs containing each of the study drugs . 
Prior to dosing, all patients who fulfill all inclusion/exclusion criteria will be randomized via 
IRT to one of the 2 treatment arms. The investigator or his/her delegate will call or log on to 
the IRT and confirm that the patient fulfills all the inclusio n/exclusion criteria. The IRT will 
[COMPANY_001]  Confidential  Page [ADDRESS_916432] package of study drug 
to be dispensed to the patient. The r andomization number will not be communicated to the 
caller.  
6.5.3  Treatment blinding  
Patients, investigators, other site personnel, and the [COMPANY_001] Clinical Trial Team will remain 
blinded to the identity of the randomized treatment assignments until after the 48-week C ore 
study database lock, using the following methods:  
(1) randomization data are kept strictly confidential until the time of treatment unblinding. The 
bioanalyst and the pharmacokineticist will be unblinded to avoid the unnecessary analysis of 
placebo samples . [COMPANY_001] Drug Supply Management department members will be unblinded 
in order to prepare the study drug supplies. The Independent Endocrinologists  will have access 
to treatment assignment to determine dose titrations during Period [ADDRESS_916433] access to treatment assignment, if needed , because they are overseeing the dose 
decisions of the IEs.   
(2) The identity of the randomized treatment assignments will be concealed by [CONTACT_677444]. Each dose of osilodrostat will have 
a matching placebo identical in packaging, labeling, schedule of administratio n, and appearance 
(color, size, and weight).   
(3) The Period 1 laboratory results that could disclose the randomized treatment assignment 
(UFC, urine creatinine , serum and salivary cortisol, ACTH, aldosterone, renin, estradiol, 
estrone, androgens (testoste rone,  delta -4 androstenedione, DHEAS), precursors 11 -
deoxycortisol, 11 - deoxycorticosterone )) from this period of the trial, will be kept blinded  from 
patients, investigators and other site personnel  until the 48-week C ore study database lock is 
complete.  Blinded laboratory data (e.g. UFC , serum cortisol , ACTH , etc. ) will however be 
available to IEs responsible for  dose titration during Period 1, as well as  the DMC if needed.  
Unblinding before database lock will only occur in the case of emergencies ( Section 8.3  
“Emergency unblinding”), for regulatory reporting purposes and at the conclusion of the study.  
6.[ADDRESS_916434] the patient or caregiver to take the 
study drugs as per protocol. Study drug(s) will be dispensed to the patient by [CONTACT_5361]. All dosages prescribed to the patient and all dose changes during the study must 
be record ed on the Dosage Administration Record eCRF.  
Study drug use in this study includes 1 mg, 5 mg, 10 mg and (depending on availability) 20 mg 
tablets and matching placebo tablets. There is a unique size and color for each tablet strength 
(see Figure 6 -1).  Study drug is dispensed in a unique set of kits (bottles) for each patient at 
each visit.  Osilodrostat (or matching placebo) is dispensed in separate bottles for each tablet 
strength.  The label on each b ottle indicates the dose strength.    
Patients may be dispensed bottles of more than one tablet  strength at the same visit.  For 
example, if a patient is on the preferred intermediate dose of [ADDRESS_916435] be provided to the patient at the visit; these 
instructions must include the dose and the number of tablets of each strength to be taken in the 
morning and in the evening. The IRT system ensures t hat enough study drug is dispensed to 
treat the patient until the next scheduled visit by [CONTACT_677445] (bottles) for 
each patient at each visit . A minimal  number of strengths will be dispensed at any one visit , as 
feasible . 
At each stu dy visit during Period 1 (Weeks 1-12), Period 2 (Weeks 12-48) and in Extension, 
the site will contact [CONTACT_185686] (IRT) for identification of the specific 
drug supply to be used by [CONTACT_677446].   IRT will provide the site with 
study drug kit number(s) specific to the patient and the visit . For dose changes, IRT will indicate 
if a patient visit to the site is needed to collect study drug supplies to implement the dose change 
or if it may be implemented via  a phone  contact . Patients requiring a different tablet strength to 
implement a dose change between scheduled study visits, will need to return to the site 
(unscheduled visit) to collect the new study drug supplies. The site pharmacist will dispense the 
corresponding kit(s) to the patient, to provide drug supply until the next study visit.  
Table 6-3 Preparation and dispensing  
Study drug s Dispensing  Preparation  
Osilodrostat (LCI699)  
or placebo (1 mg, 5 mg, 
10 mg and 20 mg)  Tablets including instructions for administration are 
dispensed by [CONTACT_230774].  
Patients will be provided with adequate supply of study drug 
for self -administration at home until at least their next 
scheduled study visit (including any dose change required 
in between visits).  More than one tablet strength may be 
dispensed to patients at the same visit.    Not applicable  
6.6.1  Study drug packaging and labeling  
Osilodrostat /placebo will be supplied as film coated tablets  packaged in bottles . 
The study medication packaging has a 2 -part label. A unique medication number is printed on 
each part of this label which corresponds to one of the treatment arms and a dose. Responsible 
site personnel will identify the study drug package(s) to dispense to  the patient by [CONTACT_677447](s). Site personnel will add the subject number on to the 
label. Immediately before dispensing the package to the patient, site personnel will detach the 
outer part of the label from the packa ging and affix it to the source document (Drug Label Form) 
for that patient’s unique subject number.  
Medication labels will be in the local language and comply with the legal requirements of each 
country. They will include storage conditions for the drug a nd the medication number but no 
information about the patient.  
[COMPANY_001]  Confidential  Page 68 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 Table 6-4 Packaging and labeling  
Study drug s Packaging  Labeling (and dosing frequency)  
Osilodrostat (LCI699) or placebo  
(1 mg, 5 mg, 10 mg and 20 mg)  Tablets in bottles with 
labels  LCI699, LCI699/ Placebo (b.i.d. , o.d., once 
every other day ) 
6.6.[ADDRESS_916436] access. Upon receipt, the study drug should be stored acc ording to the 
instructions specified on the drug labels and in the [Investigator’s Brochure].  
Table 6-5 Supply and storage of study drug s 
Study drug s Supply  Storage  
Osilodrostat (LCI699)  or 
placebo  Centrally supplied by [CONTACT_677448]  
6.6.3  Study drug compliance and accountability  
[IP_ADDRESS]  Study drug compliance  
Compliance will be assessed by [CONTACT_1755]/or study personnel at each patient visit and 
information provided by [CONTACT_5363]/or caregiver will be captured in the Drug 
Accountability Form. This information must be captured in the source document at each patient 
visit.  
[IP_ADDRESS]  Study drug accountability  
The investigator or designee must maintain an a ccurate record of the shipment and dispensing 
of study drug in a drug accountability log. Drug accountability will be noted by [CONTACT_677449]. Patients will be asked to return all unused 
study drug and packaging on a regular basis, at the end of the study or at the time of study drug 
discontinuation.  
At study close -out, and, as appropriate during the course of the study, the investigator will return 
all used and unused study drug, packaging, dru g labels, and a copy of the completed drug 
accountability log  to the [COMPANY_001] monitor or to the [COMPANY_001] address provided in the investigator 
folder at each site.  
[IP_ADDRESS]  Handling of other study treatment  
Not applicable.  
6.6.[ADDRESS_916437] party, as appropriate . 
1RYDUWLV &RQILGHQWLDO 3DJH
$PHQGHG3URWRFRO9HUVLRQ&OH DQ  3URWRFRO1R&/&,&

 9LVLWVFKHGXOHDQGDVVHVVPHQWV
 6WXG\IORZDQGYLV LWVFKHGXOH
7DEOHD 7DEOHE DQG7DEOH OLVWDOORIWKHDVVHVVPHQWV DQGLQGLFDWHWKHYLVLWVDWZKLFK
WKH\ DUH SHUIRUPHG ZLWK DQ ³;´ IRU WKH &RUH DQG ([WHQVLRQ SKDVH V UHVSHFWLYHO\ 9LVLW
DVVHVVPHQWVZLQGRZLVGD\VH[FHSWIRU'D\ZKLFKKDVD GD\ZLQGRZ
$OO GDWD REWDLQHG IURP WKHVH DV VHVVPHQWV PXVW EH VXSSRUWHG LQ W KH SDWLHQW¶V VRXUFH
GRFXPHQWDWLRQ7KHWDEOHLQGLFDWHVZKLFKDVVHVVPHQWVSURGXFHGD WDWREHHQWHUHGLQWRWKH
FOLQLFDOGDWDEDVH'RUUHPDL QLQVRXUFHGRFXPHQWVRQO\6³ &DWHJRU\´FROXPQ
1RH&5)ZLOOEHXVHGDVDVRXUFHGRFXPHQW7DEOH 7DEOH 7DEOH 7DEOH 7DEOH 
DQG
7DEOH OLVWDOORIWKHDVVHVVPHQWVUHTXLUHGIRUWKHFROOHFWLRQSODQIR U'LVHDVHDQG,PDJLQJ
$VVHVVPHQW&OLQLFDO/DERUDWRU\SDUDPHWHUV,PDJLQJ(&*3.V DPSOHV%LRPDUNHUVVDPSOHV
DQG3DWLHQW5HSRUWHG2XWFRPH UHVSHFWLYHO\ 
3DWLHQWVPXVWHQGSDUWLFLSDWLRQLQ WKHRSWLRQDOH[WHQVLRQSHULR GZLWKLQZHHNVDIWHU3URWRFRO
$PHQGPHQWLVDSSURYHGDWWK HVLWHRUE\:HHNZKLFKHYHU RFFXUVILUVW[COMPANY_003]
[COMPANY_001]  Confidential  Page 70 
Amended Protocol Version 02 Clean   Protocol No. CLCI699C2302  
 
 Table 7-1a Visit evaluation schedule  – Core  – Period [ADDRESS_916438] 
dose 
+30d  
Week    from -[ADDRESS_916439]  S  x   x x x x x    x  
IRT Randomization  S     x          
Patient history                 
 Demography  D [IP_ADDRESS]  x           
 Inclusion/Exclusion criteria  D 5.2 & 5.3   x           
Relevant medical history/Current medical 
conditions  D [IP_ADDRESS]  x           
 Cushing's Disease history  D [IP_ADDRESS]  x           
 Prior/concomitant medication  D [IP_ADDRESS]      As required  
Physical examination  S [IP_ADDRESS]  x x x x x x x x x x x 
 Body height  D [IP_ADDRESS]  x             
 Body weight  and Waist Circumference  D [IP_ADDRESS]  x   x x x x x x x x x x 
Physical features of Cushing’s disease  D [IP_ADDRESS]  x     x    x  
  Signs and symptoms of adrenal insufficiency  D [IP_ADDRESS].1     x x x x x x x x x x 
Vital signs                 
Body temperature/ Blood pressure/Pulse rate  D [IP_ADDRESS]  x   x x x x x x x x x x 
Laboratory assessments                 
[COMPANY_001]  Confidential  Page [ADDRESS_916440] 
dose 
+30d  
Week    from -8 up to  
-3 -2 to -1 1 2 5 8 12 2 5 8 12  
 Hematology  D [IP_ADDRESS].1   x  x x x x x x x x x x 
Chemistry  D [IP_ADDRESS].2   x  x x x x x x x x x x 
 Thyroid Panel, FSH  D [IP_ADDRESS].5   x  x  x  x  x  x  
 LH D [IP_ADDRESS].7     x  x  x  x  x  
 Coagulation  D [IP_ADDRESS].4     x    x    x  
 Urinalysis  D [IP_ADDRESS].[ADDRESS_916441] (serum)  D [IP_ADDRESS].[ADDRESS_916442] (urine)  D [IP_ADDRESS].8     x x x x x x x x x x 
Efficacy Assessment                 
24-hour Urinary Free Cortisol and creatinine  D [IP_ADDRESS]   x  x x x x x x x x x x 
 Serum testosterone and estradiol  D [IP_ADDRESS].6     x x  x x x  x x x 
 Plasma ACTH and serum cortisol  D [IP_ADDRESS].6   x x x x x x x x x x x 
 Serum aldosterone and serum 11 -
deoxycortisol  D [IP_ADDRESS].6     x x x x x x x x x x 
Serum Androstenedione, DHEAS, Estrone  D [IP_ADDRESS].6     x x  x x x  x x x 
  Plasma Renin  D [IP_ADDRESS].6     x x  x x x  x x x 
Salivary Cortisol (morning and late night)  D [IP_ADDRESS].6   x  x x x x x x x x x x 
 Serum 11 -Deoxycorticosterone  D [IP_ADDRESS].6     x x x x x x x x x x 
Fasting serum Insulin, plasma glucose and 
lipi[INVESTIGATOR_805]  D [IP_ADDRESS].[ADDRESS_916443] 
dose 
+30d  
Week    from -8 up to  
-3 -2 to -1 1 2 5 8 12 2 5 8 12  
 HbA1C  D [IP_ADDRESS].[ADDRESS_916444] 
dose 
+30d  
Week    from -8 up to  
-3 -2 to -1 1 2 5 8 12 2 5 8 12  
Safety                 
 Adverse Events  D 8.1     As required  
 12 Lead safety ECG assessment  D [IP_ADDRESS].2   x x x x x x x x x x x x 
 12-Lead 24 -hour Holter ECG recording  D [IP_ADDRESS].1    x  x   x x   x  
Biomarkers                 
  Hair Cortisol  D [IP_ADDRESS]     x          
Imaging                 
 Pi[INVESTIGATOR_299446] (or CT)  D [IP_ADDRESS]  x           
 DXA scan  D [IP_ADDRESS]  x           
Patient Reported Outcomes                 
 C-SSRS  D 7.2.[ADDRESS_916445]  S [IP_ADDRESS]     x x x x x      

[COMPANY_001]  Confidential  Page [ADDRESS_916446] 
dose 
+30d  
Week    from -8 up to  
-3 -2 to -1 1 2 5 8 12 2 5 8 12  
PK sampling  D 7.2.3     x x x x x      
End of Phase disposition  D    x         x 
[COMPANY_001]  Confidential  Page 75 
Amended Protocol Version 02 Clean   Protocol No. CLCI699C2302  
 
 Table 7 -1b Visit evaluation schedule – Core (continued) – Period [ADDRESS_916447] dose 
+30d  
Week    [ADDRESS_916448]  S  x x x x x x x x x x x  
Patient history  
 Prior/concomitant medication  D [IP_ADDRESS]  As required   
Physical examination  S [IP_ADDRESS]  x x x x x x x x x x x x 
 Body weight  and Waist  Circumference  D [IP_ADDRESS]  x x x x x x x x x x x x 
Physical features of Cushing’s disease  D [IP_ADDRESS]      x   x   x  
Signs and symptoms of adrenal insufficiency  D [IP_ADDRESS].1  x x x x x x x x x x x x 
Vital signs                
Body temperature/ Blood pressure/Pulse rate  D [IP_ADDRESS]  x x x x x x x x x x x x 
Laboratory assessments                
Hematology  D [IP_ADDRESS].1  x x x x x x x x x x x x 
Chemistry  D [IP_ADDRESS].2  x x x x x x x x x x x x 
 Thyroid Panel, FSH  D [IP_ADDRESS].5  x  x  x   x   x  
 LH D [IP_ADDRESS].7  x  x  x   x   x  
 Coagulation  D [IP_ADDRESS].4  x  x  x    x   x  
 Urinalysis  D [IP_ADDRESS].[ADDRESS_916449] (serum)  D [IP_ADDRESS].[ADDRESS_916450] (urine)  D [IP_ADDRESS].[ADDRESS_916451] dose 
+30d  
Week    14 17 20 23 26 29 32 36 40 44 48  
Efficacy Assessment                
24-hour Urinary Free Cortisol and creatinine  D [IP_ADDRESS]  x x x x x x x x x x x x 
Serum testosterone and estradiol  D [IP_ADDRESS].6  x  x  x   x   x x 
Plasma ACTH and serum cortisol  D [IP_ADDRESS].6  x x x x x x x x x x x x 
Serum aldosterone and serum 11 -
deoxycortisol  D [IP_ADDRESS].6  x  x  x   x   x x 
Serum Androstenedione, DHEAS, Estrone  D [IP_ADDRESS].6  x  x  x   x   x x 
Plasma Renin  D [IP_ADDRESS].6  x  x  x   x   x x 
Salivary Cortisol (morning and late night)  D [IP_ADDRESS].6  x x x x x x x x x x x x 
Serum 11 -Deoxycorticosterone  D [IP_ADDRESS].6  x  x  x   x   x x 
Fasting serum Insulin, plasma glucose and 
lipi[INVESTIGATOR_805]  D [IP_ADDRESS].7  x  x  x   x   x x 
 HbA1C  D [IP_ADDRESS].7      x   x   x x 
Safety                
 Adverse Events  D 8.1  As required  
 12 Lead safety ECG assessment  D [IP_ADDRESS].2  x x x x x x x x x x x x 
 12-Lead 24 -hour Holter ECG recording  D [IP_ADDRESS].1  x       x     
Biomarkers  
  Hair Cortisol  D [IP_ADDRESS]      x      x x 

[COMPANY_001]  Confidential  Page [ADDRESS_916452] dose 
+30d  
Week    14 17 20 23 26 29 32 36 40 44 48  
Imaging                
 Pi[INVESTIGATOR_299446] (or CT)  D [IP_ADDRESS]      x      x  
 DXA scan  D [IP_ADDRESS]             x  
Patient Reported Outcomes  
 C-SSRS  D 7.2.[ADDRESS_916453]  S [IP_ADDRESS]  x x x x x x x x     
PK sampling  D 7.2.3  x x x x x x x x x x x  
End of Phase disposition  D            x x 
[COMPANY_001]  Confidential  Page 78 
Amended Protocol Version 02 Clean   Protocol No. CLCI699C2302  
 
 Table 7-2 Visit evaluation schedule – Extension  
  
Category  
Protocol 
Section  Extension -Treatment  Post -
Treatment 
Follow -up    EOT 
Extension  
Day     [ADDRESS_916454] dose 
+30d  
Week      [ADDRESS_916455] / Drug Dispensing  S     x x x x x x x x x x  
Prior/concomitant medication  D [IP_ADDRESS]  As required  
Physical examination  S [IP_ADDRESS]    x x x x x x x x x x x 
Body weight and Waist Circumference  D [IP_ADDRESS]    x x x x x x x x x x x 
Physical features of Cushing’s disease  D [IP_ADDRESS]        x  x x x  
Signs and symptoms of adrenal 
insufficiency  D [IP_ADDRESS].1  x x x x x x x x x x x x 
Vital signs                              
Body temperature / Blood pressure / Pulse 
rate D [IP_ADDRESS]    x x x x x x x x x x x 
Laboratory assessments                              
Hematology  D [IP_ADDRESS].1    x x x x x x x x x x x 
Chemistry  D [IP_ADDRESS].2    x x x x x x x x x x x 
 Thyroid Panel, FSH  D [IP_ADDRESS].5        x     x x x x x   
 LH D [IP_ADDRESS].[ADDRESS_916456] dose 
+30d  
Week      48 52 56 60 64 68 72 84 96 108, 
then 
every 
24 
weeks   
 Coagulation  D [IP_ADDRESS].4        x     x x x x x   
 Urinalysis  D [IP_ADDRESS].[ADDRESS_916457] (serum)  D [IP_ADDRESS].[ADDRESS_916458] (urine)  D [IP_ADDRESS].8    x x x x x x x x x   x 
Efficacy Assessment                              
24-hour Urinary Free Cortisol and 
creatinine  D [IP_ADDRESS]        x     x x x x x x 
Serum testosterone and estradiol  D [IP_ADDRESS].6        x     x x x x x x 
Plasma ACTH and serum cortisol  D [IP_ADDRESS].6        x     x x x x x x 
Serum aldosterone and 11 -deoxycortisol  D [IP_ADDRESS].6        x     x x x x x x 
Serum androstenedione, DHEAS, estrone  D [IP_ADDRESS].6        x     x x x x x x 
Plasma Renin  D [IP_ADDRESS].6     x   x x x x x x 
Salivary cortisol (morning and late night)  D [IP_ADDRESS].6        x     x x x x x x 
Serum 11 -Deoxycorticosterone  D [IP_ADDRESS].6        x     x x x x x x 
Fasting serum Insulin, plasma glucose and 
lipi[INVESTIGATOR_805]  D [IP_ADDRESS].7        x     x x x x x x 
HbA1C  D [IP_ADDRESS].[ADDRESS_916459] dose 
+30d  
Week      48 52 56 60 64 68 72 84 96 108, 
then 
every 
24 
weeks   
Safety                             
Adverse Events  D 8.1 As required  
12 Lead safety ECG assessment  D [IP_ADDRESS].2  x     x     x x x x x x 
12-Lead 24 -hour Holter ECG recording  D [IP_ADDRESS].1              x     x   
Biomarkers                
Hair Cortisol  D [IP_ADDRESS]        x         x  x  x 
Imaging                             
 Pi[INVESTIGATOR_299446] (or CT)  D [IP_ADDRESS]              x   x  x   
 DXA scan  D [IP_ADDRESS]                  x  x   
Patient Reported Outcomes                             
 CushingQoL  D 7.2.[ADDRESS_916460] undergone washout of any current drug therapy for CD 
according to washout pe riods described in the Inclusion criteri a (Section 5.2 ).  During washout, 
some patients may have loss of control of co -morbidities such as hypertension and diabetes. 
Therefore the screening period should be viewed as a “run -in” period in which the treatment of 
co-morbidities is optimized. Patients should be closely monitored and treated accordingly, 
aiming ideally for normalization of blood pressure, fasting glucose  and potassium . 
Information on the most recent prior medical therapy for CD will be collected including the  
drug name , dose, duration of therapy and outcome , provided such data are available . 
The three 24 -hour urine samples for the mUFC value eligibility assessment should  be collected . 
In addition, two late night salivary cortisol sample s need to be collected to exclude pseudo -
cushing’s disease  (Alwani et al 2014 ). These urine and saliva samples should be collected after 
the washout period is over , in order to avoid any interference with the washed out  therapy . It is 
highly recommended to send them to  the central laboratory at least [ADDRESS_916461] repeated laboratory result (s) meet the 
criteria, th ose result s may be used to determine eligibility. If the latest repeated laboratory 
result (s) do not meet the criteria, the patient will be considered a screening failure.  
Patients who do not meet eligibility criteria are allowed to be rescreened  up to a maximum of 
two times . The rescreening should be documented in the source files  and re -registered in IRT.  
If a patient is re -screened the patient should retain their study Subject Number.  
If rescreening is within [ADDRESS_916462] to be repeated: pi[INVESTIGATOR_299446]  (or CT)  and DXA scan . All other 
assessments must  be repeated.  
If rescreening is done more than [ADDRESS_916463]  be repeated.  
For details of assessments  and day windows , refer to Table 7 -1a. 
An additional biomarker informed consent will be proposed to the patient for optional 
participation. For details, refer to Section [IP_ADDRESS] .  
[COMPANY_001]  Confidential  Page 82 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 [IP_ADDRESS]  Eligibility screening  
While the investigator is responsible to ensure that each patient meets all inclusion/exclusion 
criteria prior to randomization, a subset of those criteria have been identified as key eligibility 
criteria and will also be verified by [CONTACT_677450] T prior to permitting the patient to 
be randomized . Patient’s eligibility is checked in IRT. The eligibility checklist form must be 
completed in IRT by [CONTACT_677451] [ADDRESS_916464] dose of study drug (osilodrostat/placebo). Verification 
of all eligibility criteria must be done prior to contact[CONTACT_112785]. After the eligibility has been 
checked in IRT and confirmed that the patient is eligible for the trial, then the patient can b e 
enrolled into the treatment phase of the study.  
Please refer to and comply with detailed guidelines in the IRT manual.  
[IP_ADDRESS]  Information to be collected on screening failures  
Patients who sign an informed consent but fail to be started on treatment for any rea son will be 
considered a screen failure. The reason for not being started on treatment will be entered on the 
Screening Phase Disposition Page.  
The demographic  information, informed consent  and Inclusion/Exclusion pages must also be 
completed for Screen Fa ilure subjects.  
No other data will be entered into the clinical database for patients who are screen failures, 
unless the patient experienced a Serious Adverse Event during the Screening Phase (see Section 
8.2 for SAE reporting details).  
If the patient fails to be randomized, the IRT must be notified within 2 days of the screen fail 
that the patient was not randomized.  
[IP_ADDRESS]  Patient demographics and other baseline characteristics  
The following patient demograp hics and baseline characteristics will be collected on the eCRF:  
• Demography including date of birth, sex, predominant race and ethnicity (where permitted) . 
• Height, weight and waist circumference (see Section [IP_ADDRESS] ). 
• Medical history (e.g., important medical, surgical, and allergic conditions from the patient’s 
medical history which could have an impact on the patient’s evaluation) / current medical 
conditions (e.g., all relevant current medical condition s which are present at the time of 
signing informed consent) . Ongoing medical conditions, symptoms and disease s which are 
recorded on the Medical History eCRF should include the toxicity grade when applicable . 
• Information on the most recent prior medical therapy for CD will be collected and will 
include information on drug, dose, duration of therapy and outcomes pr ovided such data are 
available.  
• Where possible, diagnoses and not symptoms will be recorded. Cushing’s disease history 
together with the medication/treatment used will be collected.  
• Prior and concomitant medications . 
All assessments to be completed and doc umented during screening and at baseline are detailed 
in Table 7 -1a. 
[COMPANY_001]  Confidential  Page 83 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 Day 1 assessments / samples should be taken before the patient receives study drug as these 
values will be considered the baseline val ues for the study. Where multiple values are available 
for a parameter  prior to study drug, the last value prior to the start of study drug will be 
considered the baseline value.   
7.1.2  Run-in period  
The screening period should be viewed as a “run -in” period in which the treatment of co -
morbidities is optimized (see rescue medication plan in Section 6.1.3 ). For details of 
assessments, refer to Section 7.1.[ADDRESS_916465] be seen fo r all visits on the designated day with a visit window of ± 3 days 
for all visits , except Week 1 (Day 1)  where the window is +3 days . During Period 1 ( Weeks 1 
to 12), patients will attend  the site 2 week s after starting study medication, and then at Weeks 
5, 8 and 12 .  
During Period 2 ( Weeks 12 to 48), patients will attend  the site for the Week [ADDRESS_916466] the option to enter a separate long -term safety follow -up study or stop study treatment.  
Patients not entering the long -term safety follow -up study will complete the study with a 30 day 
follow -up. 
 
During study treatment phases , patients will be instructed to : 
• bring urine samples (collected as described in Section [IP_ADDRESS] ) to each study visit  
• complete a patient diary  collecting information on study drug , and  urine and salivary 
collections . The diary  will be reviewed a t each site visit by [CONTACT_6624] .  
For details of assessments, please refer to Table 7 -1a, Table 7 -1b and Table 7 -2 for the Core  
and Extension , respectively . 
7.1.4  Discontinuation  of Study  drug  
Patients  may voluntarily  discontinue  from  the study drug for any reason at any time. If a 
patient  decides  to discontinue  from  the study drug, the investigator  should  make a reasonable 
effort  (e.g. telephone,  e-mail, letter)  to understand  the primary  reason  for this decision while 
respecting the subjects rights and record  this information  in the patient ’s chart and  on the 
appropriate  eCRF  pages.  Patients  may be conside red withdrawn  if they state an inte ntion to 
withdraw,  fail to return for visits, or beco me lost  to follow -up for any  other  reason.  
[COMPANY_001]  Confidential  Page 84 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 In order to help retain patients in the placebo -controlled phase (Period 1, Weeks 1 - 12), rescue 
therapy for co -morbid conditions should be optimized before a decision is made to discontinued  
patients  from study drug or from the study .   
Patie nts who discontinue  study  drug should NOT  be considered withdrawn from  the study.  
For patients who discontinue treatment during Weeks 1 - 12, investigators should make 
reasonable efforts to follow patients  and perform all assessments identified for all visits up to 
and including  Week 1 2 as indicated in Table 7 -1a (Post -treatment follow -up) and Section 7.1.6 , 
even if study drug has been discontinue d and alternative cortisol -lowering therapy has been 
initiated.  Patient s discontinuing  study drug at any time before Week 48 of the Core 
phase  or  during the optional  Extension  phase , should be scheduled for an End of Treatment 
(EOT) visit as soon as possible, at which time the assessments l isted for the EOT visit will be 
performed ( Table 7 -1a, Table 7 -1b and Table 7 -2), with the following exceptions:  
• Patients  discontinuing treatment prior to the  Week [ADDRESS_916467] an EOT  
DXA scan  
• Patients discontinuing prior to the Week [ADDRESS_916468] an EOT  pi[INVESTIGATOR_299446] (or CT)  (i.e. scans are needed if patients 
discontinue within the 1 2 week period prior to the W eek 26 and W eek 48 visits) .  
The date and reason for stoppi[INVESTIGATOR_677379] . If a patient  
fails to return for the assess ments for unknown  reasons, reasonable  efforts  (e.g. telephone, 
email, letter)  shou ld be made to contact  [CONTACT_348444] 7.1.[ADDRESS_916469]  discontinue  study drug for a given  patient  if he/she  believes  that 
continu ation would be  detrimental  to the patie nt’s well-being.  The investigator must also contact 
[CONTACT_105253]’s discontinuation from study drug. 
Patients must discontinue study drug if any of the following occur:  
• Emergence of the following adverse events:  
• hypertension defined as office mean supi[INVESTIGATOR_677380] > 180 mmHg or mean supi[INVESTIGATOR_677381] > 110 mmHg (confirmed and persistent*).  
• Any of the following laboratory abnormalities (confirmed):  
• hyperkalemia (serum potassium > 6.0 mmol/L).  
• hypokalemia (serum potassium < 2.8 mmol/L).  
• Any of the following laboratory abnormalities (confirmed and persistent*):  
• hyperkalemia (serum potassium > 5.5 mmol/L).  
• hypokalemia (serum potassium < 3.0 mmol/L).  
• hyponatremia (serum sodium < 130 mmol/L).  
• hyperglycemia (fasting plasma glucose ≥ 15.0 mmol/L).  
* Persistent is defined as unresolved with osilodrostat dose change or after adjustments to 
other concomitant medication s targeting the co -morbidity in question.  
• Abnormal liver function as described i n Table 6 -2. 
• Mean QTcF > [ADDRESS_916470] (see Section 
[IP_ADDRESS] ). 
[COMPANY_001]  Confidential  Page 85 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 • Mean QTcF > [ADDRESS_916471] (see Section [IP_ADDRESS] ). 
• Mean increase in QTcF > [ADDRESS_916472] dose or 
the QTcF is > 480 msec at Day 1.  
• QTcF increase > 60 msec from the pre-dose measurement  earlier during the same visit . 
• Pi[INVESTIGATOR_621325], if symptomatic or complicated by [CONTACT_677452] (visual field loss, cranial nerve palsies, 
diplopia)  and confirmed by [CONTACT_621358][INVESTIGATOR_2117] (see Section 7. 2.2.5 ). 
• Pregnancy.  
• Use of prohibited treatment (refer to Section 6.4.3 ). 
• Any other  protocol  deviation  that results  in a significant risk to the patient’s  safety. 
The appr opriate per sonnel fr om the site and [COMPANY_001] will asse ss whether study drug should be 
discontinued for any patient  whose treat ment code  has been  broken  inadvertently  for any  reason.  
The investigator  must also contact [CONTACT_677453]’s  discontinuation  from 
study  drug within 2 days.  
[IP_ADDRESS]  Replacement policy  
Not applicable.  
7.1.[ADDRESS_916473] already  been collected may be 
retained  and analyzed  at a later date (or as required  by [CONTACT_427]).  
If a patient  withdraws  consent,  the investigator  should  make reasonable  effort  (e.g. telephone,  
e-mail, lette r) to determine the primary reason for this de cision while respecting the subject’s 
rights and rec ord this in formation.  
Study drug must be discontinued  and no further assess ments conducted.  
Further  attempts to  contact  [CONTACT_677454] -up. 
7.1.[ADDRESS_916474]-treatment follow -up visits through and including Week 1 2 (±3 days) as indicated 
in Table 7 -1a and Section 7.1.4 . If the 30 day follow -up evaluations should occur  at the time of 
a scheduled visit ; any assessment s common to both visits only need  to be performed once.   
[COMPANY_001]  Confidential  Page [ADDRESS_916475] to f ollow-up 
For patie nts whose  status is  unclear  because  they fail  to appear  for study visits without  stating 
an intention  to withdraw consent,  the investigator should  show  "due diligence"  by [CONTACT_15027], fa mily or  family physician  as agreed in  the infor med consent  and by [CONTACT_348446],  e.g. dates  of telephone  calls, 
registered letters, etc. A patie nt should not be considered  lost to follow -up until due diligence 
has been  completed. Patients  lost to follow -up should  be recorded  as such on the appropriate 
Disposition  eCRF.  
7.2 Assessment types  
7.2.1  Efficacy assessments  
Table 7-3 Disease and Imaging Assessment collection plan  
Procedure  Screening  During Treatment/Follow -up 
24-hour urine samples  to test for 
Urine Free Cortisol and 
creatinine  Mandated at screening 
(post washout)  Mandated  for Periods [ADDRESS_916476] Treatment 
Follow -up, as detailed in Table 7 -1a, Table 7 -
1b and Table 7 -2.  
*Every effort should be made to collect 
samples for p atients  discontin uing treatment  
prior to Week [ADDRESS_916477] Treatment 
follow -up, as detailed in Table 7 -1a, Table 7 -
1b and Table 7 -2. 
DXA scan   (lumbar spi[INVESTIGATOR_677382])  Mandated at screening  Mandated at End of Treatment Core  and End 
of Treatment Extension , unless EOT occurs 
less than 6 months before the scheduled 
Week 96 visit .  
* For patients who discontinued study drug during Period 1.  
All urine samples will be sent to the central laboratory designated by [CONTACT_18653]. 
During Period 1, o nce results are available, an alert (by [CONTACT_71345]) will be sent to the IE. The 
central laboratory and the IE will ensure that the sites and  [COMPANY_001] remain  blinded to the results.  
Starting from Week 1 4 in Period 2, UFC results will be sent directly by [CONTACT_677455].  
[COMPANY_001]  Confidential  Page 87 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 [IP_ADDRESS]  Urinary Free Cortisol  
The primary efficacy parameter , Urinary Free Cortisol (UFC) , will be assessed using a central 
laboratory. UFC will be measured in two or three 24 -hour urine samples  (Table 7 -1a, Table 7 -
1b, Table 7 -2, and Table 7 -3). Values from the individual samples for a visit will be averaged 
to obtain the mean UFC (mUFC) level . Urine creatinine levels will also be measu red to ensure 
validity of the [ADDRESS_916478] the 24-hour UFC samples preferably on consecutive 
days according to  Table 7 -1a, Table 7 -1b, Table 7 -2, and Table 7 -3 and will complete the patient 
diary . Patients are to bring both the urine samples and the patient diary to each study visit.   
Screening (post washout):  Three  24-hour UFC samples must be collected (preferably on 
consecutive days) and sent to central labo ratory at least 14 days prior to day 1 in order to ensure 
that sufficient time is allowed for central laboratory results to become available. These samples 
will be used to assess eligibility of the patient. A repeated evaluation within the screening 
window  is permitted for screening results out of the defined range. If the repeated laboratory 
result meets the criteria, that result may be used to determine eligibility. If the repeated 
laboratory result does not meet the criteria, the patient will be consider ed a screening failure.  
Baseline:  Three 24 -hour UFC samples will be collected  (preferably on consecutive days)  within 
[ADDRESS_916479] day  of treatm ent to serve as baseline value.   
Treatment period: Patients will collect t wo 24-hour UFC samples preferably over the [ADDRESS_916480] urine sample  should be 
collected the day prior to the site visit (collection may end on the  morning of the visit)  as defined 
in Table 7 -1a and Table 7 -1b for Periods 1  and 2 (Core phase), and Table [ADDRESS_916481] -treatment follow -
up visits .  If only one UFC value is available at a visit, this value will be used for dose decision 
making only and not for mUFC based analysis.  
[IP_ADDRESS]  Physical features of Cushing’s disease  
The following clinical signs (physical findings) of Cushing’s disease will be assessed clinically 
for severity at time points defined in  Table 7 -1a, Table 7 -1b, Table 7 -2 and Table 7 -3: facial 
rubor, hirsutism (female only), striae, supraclavicular and dorsal fat pads, proximal muscle 
wasting (atrop hy), central (abdominal) obesity, and ecchymoses (bruising). These clinical signs 
are to be rated on a semi -quantitative scale as follows: 0=absent; 1=mild; 2=moderate; and 
3=severe.  
Physical features of Cushing’s disease will also be documented by [CONTACT_677456]. A t otal of four 
photographs will be taken. Two photographs, one frontal and one lateral from the shoulders up 
will be taken to assess facial plethora (rubor), supraclavicular and dorsal fat pads. Two 
photographs, frontal and dorsal of the trunk with  patient in standing position will be taken to 
assess striae, proximal muscle wasting (atrophy), central (abdominal) obesity, and ecchymoses 
(bruising). In order to maintain confidentiality, photographs will not be published without the 
explicit written co nsent of the patient.  Photographs will be centrally collected and checked for 
quality by [CONTACT_677457]. The quality checks will be detailed in the vendor manual.  
[COMPANY_001]  Confidential  Page [ADDRESS_916482] be discussed with the sponsor on a case -by-case basis and sponsor 
approval will be required.  
[IP_ADDRESS]  Bone mineral density assessments  
Bone mineral density  (BMD)  of the lumbar vertebrae (L1 -L4) and left total hip are to be 
measured using Lunar or Hologic DXA (dual -energy X -ray absorptiometry ; DXA ) instruments . 
A patient should be scanned on the same DXA instrument throughout the study. If a scan of the 
left proxim al femur is not possible, then the right proximal femur can be used which is then to 
be used consistently throughout the study. Patients are to be positioned and scanning is to be 
performed according to the manufacturer ’s instructions  and the imaging acqui sition guidelines 
provided for this study. The image acquisition guidelines include detailed  instructions on 
scanning methods, calibration of individual DXA machines and cross -calibration of DXA 
machines at different sites. The BMD results must be reported  in actual density (gm/cm2) and 
standardized against the peak bone mass in a healthy young adult population  (BMD T -score). 
Analysis and reporting of BMD results will be conducted centrally by [CONTACT_677458] . This assessment will be done as defined in  Table 7 -1a, Table 7 -1b, Table 7 -2 and 
Table 7 -3. If EOT occurs less than 6 month s before the scheduled Week 96 visit, MRI (or CT) 
and DXA is not mandatory at EOT.  
Bone mineral density assessments will not be done in patients that are enrolled in [LOCATION_013].  
7.2.2  Safety and tolerability assessments  
Safety will be monitored by [CONTACT_217970], vital signs, laboratory evaluations, 
radiological assessments, imag ing assessments, cardiac assessments, as well as collecting of the 
adverse events at every visit. For details on AE collection and reporting, refer to Section 8 . The 
risk of suicide will be also collecte d and assessed as part of safety monitoring.  
[IP_ADDRESS]  Physical examination  
A complete physical examination will include the examination of general appearance, skin, 
neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, 
extrem ities, vascular and neurological. If indicated based on medical history and/or symptoms, 
rectal, external genitalia, breast, and pelvic exams will be performed.  This will be conducted at 
visits according to Table [ADDRESS_916483] be recorded 
in the Medi cal History page o f the patient’s eCRF. Significant new findings that begin or worsen 
after informed consent must be recorded on the Adverse Event eCRF.  
[IP_ADDRESS].1  Signs and symptoms of adrenal insufficiency  
Signs and symptoms of adrenal insufficiency (AI) should be assessed at every study visit and  / 
or contact  [CONTACT_677459] 7 -1a, Table 7 -1b and Table 7 -2. Signs and symptoms of AI are to  
be recorded on the Signs and symptoms  of AI  eCRF and in the AE eCRF  during Period 1, and 
in the AE eCRF only during all other study periods.  
Definition of s igns a nd symptoms of AI  (Charmandari, et al 2014 ):   
[COMPANY_001]  Confidential  Page 89 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 • Symptoms: Nausea, vomiting, diarrhea, fatigue, asthenia, dizziness, syncope, decreased 
appetite, myalgia, arthralgia, and pyrexia  
• Signs: hypotension, orthos tatic hypotension, and tachycardia . 
[IP_ADDRESS]  Vital Signs  
Vital signs include blood  pressure and pulse measurements , and body temperature will be 
assessed according to Table 7 -1a, Table 7 -1b and Table 7 -2. Pulse  and systolic and diastolic 
blood pressure will be measured using an automated validated device with an appropriately 
sized cuff  according to the following sequence and times  at each visit:  
1. Supi[INVESTIGATOR_050] : two separate recordings  after the patient has been supi[INVESTIGATOR_114926] a minimum of five 
minutes  
2. Standing: one recording  after the patient has been standing for 1 minute and  another 
recording  after the patient has been standing for 3 minutes.   
 These measurements will be used to assess the presence of orthostatic hypotension .  
A drop in systolic blood pressure of ≥20 mmHg, or in diastolic blood pressure of ≥10 mmHg  
in the supi[INVESTIGATOR_677383] , or presence of lightheadedness or dizziness is 
considered abnormal  and should be recorded on the appropriate form (see sect ion [IP_ADDRESS].1) . 
Vital sign assessments at screening may be repeated, if necessar y, up to a maximum of 3 times.  
[IP_ADDRESS]  Height and weight  and waist circumference  
Height in centimeters (cm) and body weight (to the nearest 0.1 kilogram [kg] in indoor clothing, 
but without shoes) will be measured. Body height will be measured at screening , and body 
weight and waist circumference will be measured at visits according to Table [ADDRESS_916484] to 
ensure the measuring tape is correctly positioned. Using  e.g. a cosmetic pencil, make a mark at 
the “natural waist” midway between the palpated iliac crest and the palpated lowest rib margin 
in the left and right mid -axillary lines. Place the non -stretchable tape evenly around the natural 
waist covering the lef t and right natural waist marks. The measurement scale should face 
outward, and there should be no twists in the tape. Ensure that the tape is just touching the skin 
but not compressing the soft tissue. Instruct patients to stand erect with abdomen relaxed , arms 
at sides, feet together, and weight divided equally over both legs.  
[IP_ADDRESS]  Laboratory evaluations  
Clinical laboratory analyses (hematology, chemistry,  coagulation, urinalysis, thyroid panel and 
additional tests mentioned in Table 7 -4 below) are to be performed by [CONTACT_2237].  
At any time during the study, abnormal laboratory parameters which are clinically significant 
and require an action to be taken with study drug (e.g., require dose modif ication and/or 
interruption of study drug, lead to clinical symptoms or signs, or require therapeutic 
intervention), whether specifically requested in the protocol or not, will be recorded on the AE 
eCRF page. Laboratory data will be summarized using the C TCAE version 4.[ADDRESS_916485] Name  
[CONTACT_6675], Hemoglobin, Platelets, Red blood cells, White blood cells, RBC 
Morphology , Differential (Basophils, Eosinophils, Lymphocytes, Monocytes, 
Neutrophils , Bands, Other (absolute value preferred , %s  are acceptable ) 
Chemistry  Albumin, Alkaline phosphatase, ALT, AST , Bicarbonate, Glucose, Cal cium, Chloride, 
Creatinine, Creatine phosphokinase (CPK), Gamma -glutamyl -transferase ( GGT ), 
Lactate dehydrogenase ( LDH), inorganic phosphorus, lipase, amylase, magnesium, 
potassium, sodium, Total Bilirubin, Direct Bilirubin, Indirect Bilirubin, Total Protein, 
Blood Urea Nitrogen (BUN) or Urea, Uric Acid  
Urinalysis   Macroscopic Panel (Bilirubin, Blood, Glucose, Ketones, Leukocytes esterase, pH, 
Protein, Specific Gravity)  
Coagulation  International normalized ratio (INR), Activated partial thromboplastin time (APTT)  
Thyroid  Free T4, Thyroid -Stimulating Hormone ( TSH) 
Additional tests  Pregnancy test : serum (central lab testing ) / Urine dipstick pregnancy testing (local lab 
testing ) 
Additional hormones:  
Serum testosterone, estradiol,  FSH  
Serum DHEAS, androstenedione and estrone  
Plasma r enin 
Plasma ACTH  
Serum aldosterone, cortisol and 11 -deoxycortisol  
Salivary cortisol (morning and late night) * 
Serum 11 -deoxycorticosterone   
LH 
Other parameters:   
Fasting serum insulin , fasting plasma glucose  and fasting lipid profile (including: Total 
Cholesterol, LDL, HDL, Triglycerides)  
HbA1c  
Hair cortisol  
* Salivary cortisol samples will be collected within the following intervals: Late night samples between 10:00 pm 
and 11:00  pm and morning samples between 8:00 am and 10:00 am. Late night salivary cortisol samples will 
be collected with each 24 -hr UFC collection  (or with the last two  24-hr UFC collections closest to the ne xt visit if 
3 samples are being collected ), and the mornin g salivary cortisol  sample will be collected with the last 24 -hr 
UFC collection.  
Details on the collections, shipment of samples and reporting of results by [CONTACT_339590] [Laboratory Manual] . 
[IP_ADDRESS].1  Hematology  
Hematology tests are to be performed by [CONTACT_677460] 7 -1a, Table 7 -1b, Table 7 -2, and 
Table 7 -4.  
[IP_ADDRESS].2  Clinical chemistry  
Chemistry tests  are to be performed by [CONTACT_677461] 7 -1a, Table 7 -1b, Table 7 -2, and 
Table 7 -4. 
[COMPANY_001]  Confidential  Page 91 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 [IP_ADDRESS].3  Urinalysis  
Urinalysis tests are to be performed according to the schedule of assessments and collection 
plan outlined respectively in  Table 7 -1a, Table 7 -1b, Table 7 -2, and Table 7 -4. 
A midstream urine sample (approx. 30 mL) will be obtained, in order to avoid contamination 
with epi[INVESTIGATOR_107183], and allow proper assessments.  
A semi -quantitative "dipstick" evaluation will be performed.  
[IP_ADDRESS].4  Coagulation  
Coagulation factors specified in Table 7 -4 will be assessed by [CONTACT_677462] 7 -1a, Table 7 -1b and Table 7 -2. 
[IP_ADDRESS].5  Thyroid Panel  
Thyroid Panel specified in Table 7 -4 will be assessed by [CONTACT_677463] 7 -1a, Table 7 -1b and Table 7 -2. 
[IP_ADDRESS].6  Additional hormones  
Additional hormones as specified in Table 7 -4 will be assessed by [CONTACT_677464] 7 -1a, Table 7 -1b and Table 7 -2. 
[IP_ADDRESS].7  Other laboratory parameters  
Other laboratory parameters as sp ecified in Table 7 -4 will be assessed by [CONTACT_677465] 7 -1a, Table 7 -1b and Table 7 -2. 
[IP_ADDRESS].[ADDRESS_916486] be received before the patient may be 
randomized . 
[IP_ADDRESS]  Radiological examinations  
Table 7-5 Imaging Assessment collection plan  
Procedure  Screening  During Treatment/Extension  
Pi[INVESTIGATOR_299446]  (or CT)  Mandated at screening  Mandated, approximately every [ADDRESS_916487] (gadolinium) i s contraindicated for 
a patient, then a non -contrast MRI scan should be performed. If the MRI cannot be performed 
at all, then a CT of the pi[INVESTIGATOR_2117] (with i.v. contrast if not contraindicated) may be performed. 
Regardless of imaging type, all regularly sch eduled pi[INVESTIGATOR_677384]. The modality should remain consistent to 
that used at baseline unless there is a development of a contraindication. Please see the study 
imaging manual fo r further information.  If EOT occurs less than 6 month s before  the scheduled 
Week 96 visit, MRI (or CT) and DXA is not mandatory at EOT.  
[IP_ADDRESS]  Cardiac assessments  
Cardiac monitoring will include [ADDRESS_916488] wash -out (up to Week -
3) up to -[ADDRESS_916489]-dose  12 Lead  Local  
48* 337* Anytime for patients 
not continuing in 
extension  [ADDRESS_916490] Treatment Follow -up 
week 2, 5, 8, 12** 15, 36, 57, 85** Anytime  [ADDRESS_916491] Treatment Follow -up 
week 2, 12** 15, 85** Anytime  24-hour 
Holter  Central  
Optional Extension:  48*, 60, 
72, 84, [ADDRESS_916492] ***  337*, 421, 505, [ADDRESS_916493] -dose  12 Lead  Local  
End of treatment  extension  
visit  Anytime  12 Lead  Local  
Optional Extension:  72 505 Start at Pre -dose  24-hour 
Holter  Central  
End of treatment extension 
visit****   24-hour 
Holter  Central  
Post Treatment Follow -up Last dose + 30d  Anytime  12 Lead  Local  
Unscheduled assessment  Anytime  12 Lead  Local  
[COMPANY_001]  Confidential  Page 93 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 Week  Day Time  point  ECG 
Type  Central or 
Local  reading  
reading  
*Patients will have only one ECG at Week 48 (Day 3 37). For patients not continuing in optional extension, ECG 
will be performed anytime during the visit. For patients continuing in optional extension, ECG will be performed 
at 1.[ADDRESS_916494] -dose, except for  EOT Ext. , if applicable  
**For patients  who discontinued study drug during Period 1 . 
***The patients who have completed Week [ADDRESS_916495].  
****End of treatment  optional  Extension visit assessment shoul d be completed at the time the patients are 
transitioning either to a  separate long -term safety follow -up study, a local alternative treatment option, or the 
completion of the study, whichever occurs first.  Note: Patients end participation in the optional extension period 
study within [ADDRESS_916496].  
[IP_ADDRESS].1  24-hour Holter Electrocardiogram  
Twenty -four hour continuous 12 -lead Holter recording with central reading of data are done on 
each patient according to the  Table 7 -1a, Table 7 -1b, Table 7 -2, and Table 7 -6. Patient s should  
be instructed to return  their 24 -hour Holter flash cards to the site at their next study visit in order 
to facilitate timely central reading of the Holter data.  
[IP_ADDRESS].2  Electrocardiogram  (ECG)  
Twelve -lead safety ECGs are collected at the study sites according to  Table [ADDRESS_916497] -dose (approximately at the time of Cmax).  
Twelve -lead safety ECG s are collected at the study site using ECG equipment provided by [CONTACT_677466]. This ECG must be read on site by a qualified physician (e.g., the 
investigator, or another qualified physician such as a consulting cardiologist) at the time they 
are collected  and documented on the ECG eCRF.   
Each [ADDRESS_916498] be labeled with the:  
• study number  
• patient initials  
• patient number  
• date and time  
and kept in the source documents at the study site. The clock on the ECG machine must be 
synchr onized with the central clock on a daily basis.  
Record t he following on the eCRF:  
• date and time of ECG  
• heart rate  
• PR interval  
• QT and QTcF interval  
• QRS duration  
[COMPANY_001]  Confidential  Page 94 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 The Fridericia QT formula (QTcF) to correct for variations in heart rate must be used for clinical 
decisions.  
The purpose of the safety ECG is to identify patients with clinically significant ECG 
abnormalities. On the day of the first study drug administration ( Day 1), pre -dose ECGs must 
be done in triplicate. The mean of the QTcF from these [ADDRESS_916499] be reported on the ECG eCRF. The overall 
interpretation will be collected with a Yes/No statement to confirm if any clinically si gnificant 
abnormalities are present which need to be specified further.  
A “notable ECG abnormality” is defined as:  
• Day 1 only: an increase in QTcF > [ADDRESS_916500] -dose, compared to the mean 
pre-dose baseline QTcF from the same day  
• QTcF > [ADDRESS_916501]  
• Any QTcF > [ADDRESS_916502]  
• QTcF increase > [ADDRESS_916503], followed by [CONTACT_18651], and then blood sampling for osilodrostat pharmacokinetic (PK) 
assessment ( Figure 7 -1). ECG procedu re may also be performed 30 minutes after PK sampling.  
Figure 7-1 Sequence of cardiovascular data collection  
 
Original ECG tracings, appropriately signed, will be archived at study site.  
[IP_ADDRESS]  QT monitoring  
QT monitoring will occur as follows:  

[COMPANY_001]  Confidential  Page 95 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 • On the first day of the first administration of osilodrostat ( Day 1), pre -dose baseline ECGs 
must be done in triplicate. The mean of the QTcF values from these three ECG tracings is 
used to  determine the mean baseline QTcF.  
• On Day 1, if the safety ECG (1.[ADDRESS_916504] dose of osilodrostat) shows an increase 
in QTcF > 30 msec from the mean baseline value, or the QTcF is > [ADDRESS_916505] be discontinued from study. The EC G reading should be performed in 
triplicate (to determine a mean value) and reviewed promptly by a consulting cardiologist 
before discontinuing the patient from osilodrostat therapy.  
• If at any follow ing visit, a QTcF > 480 msec is observed or an increase o f the QTcF of > 
60 msec compared to baseline mean QTcF assessment, then two additional ECGs, each 2 -
3 minutes apart, need to be taken after the initial ECG. The mean QTcF from the triplicate 
ECGs will be determined. If the mean QTcF is > 480 msec or the me an QTcF increase 
is > [ADDRESS_916506] consultation, the following should occur:  
• If a mean QTcF > 480 msec is NOT confirmed, no further action needs to be taken.  
• If the cardiologist confirms a mean QTcF > [ADDRESS_916507] remain under observation until the QTcF is 
< 480 msec and serum electrolytes, calcium, and magnesium are measured and the results 
normal. This observation may be done at the site, in an Emergen cy Room, or a cardiology 
clinic, as appropriate and depending upon local resources.  
• If the cardiologist confirms that QTcF > 480 msec, osilodrostat treatment is temporarily 
interrupted and a thorough evaluation is performed to assess the patient for acute 
cardiovascular risk, and for possible underlying heart disease that needs additional 
evaluation and management. In addition, an unscheduled PK sample will be collected.  
• If based upon the assessment by [CONTACT_72324], the investigator considers that there  
is an acute cardiovascular safety risk and that the subject should not continue with 
study medication, the subject needs to be discontinued immediately (discontinuation 
criteria described in Section 7.1 .4). 
• If based upon the assessment by [CONTACT_72324], the investigator considers that there 
is not an acute cardiovascular safety risk; the subject can continue to receive study 
medication.  
[COMPANY_001]  Confidential  Page 96 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 Figure 7-2 QT Monitoring Flow Chart  
 
7.2.3  Pharmacokinetics  
Blood samples for osilodrostat pharmacokinetic (PK) evaluation will be collected from all 
patients who receive at least one dose of study drug. Pharmacokinetic blood sampling will be 
performed in each study period as indicated in the Visit Evaluation Schedule ( Table 7 -1a, Table 
7-1b and Table 7 -2). Time points of blood sample collection for PK analyses are outlined in 
Table 7 -7.  
All ECG procedures should be taken prior to and/or [ADDRESS_916508] study drug dose prior to the sampling (24 -h 

[COMPANY_001]  Confidential  Page 97 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 clock time), must be obtained on all sampling days and recorded on the PK eCRF and/or 
Contract Research Organization (CRO) requisition form(s). Sampling problems will be noted 
in the relevant field in the eCRF.  
An additional blood sample (unscheduled) should be collected in the event that a patient 
experiences an AE which requir es premature termination from the study drug.  
[IP_ADDRESS]  Pharmacokinetic blood collection and  handling  
Complete instructions for sampling processing, h andling and shipment will be provided in the 
[Laboratory Manual] . 
Blood samples will be taken by [CONTACT_677467] 
a forearm vein at specified time points described in  Table 7 -7. Blood will be collected into tubes 
containing K2 -EDTA and gently inverted several times to thoroughly mix the anticoagulant. 
Tubes will be centrifuged to separate plasma and plasma will immediately be transferred into 
labeled screw -cap polypropylene, cryogenic, freezing vials (e.g. Sarstedt, part# 72.693, no 
skirt). Plasma samples will be placed in a freezer in an upright position until shipment on dry 
ice to the [COMPANY_001] assigned laboratory for analysis.  
Table 7-7 Pharmacokinetic blood collection log  
Week  Day Scheduled time 
pointa Dose reference 
IDb PK Sample 
No. Sample volume [mL]  
1 1 Pre-dose / [ADDRESS_916509]-dose 1 – 2 h 1  2 Approximately 3.0  
2 15 Pre-dose / [ADDRESS_916510]-dose 1 – 2 h 2  4 Approximately 3.0  
5 36 Pre-dose / [ADDRESS_916511]-dose 1 – 2 h 3  6 Approximately 3.0  
8 57 Pre-dose / [ADDRESS_916512]-dose 1 – 2 h 4  8 Approximately 3.0  
12 85 Pre-dose / [ADDRESS_916513]-dose 1 – 2 h 5  10 Approximately 3.0  
14 99 Pre-dose / [ADDRESS_916514]-dose 1 – 2 h 6  12 Approximately 3.0  
17 120 Pre-dose / [ADDRESS_916515]-dose 1 – 2 h 7  14 Approximately 3.0  
20 141 Pre-dose / [ADDRESS_916516]-dose 1 – 2 h 8  16 Approximately 3.0  
23 162 Pre-dose / 0 h  9 901 17 Approximately 3.0  

[COMPANY_001]  Confidential  Page 98 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 Week  Day Scheduled time 
pointa Dose reference 
IDb PK Sample 
No. Sample volume [mL]  
[ADDRESS_916517]-dose 1 – 2 h 9  18 Approximately 3.0  
26 183 Pre-dose / [ADDRESS_916518]-dose 1 – 2 h 10  20 Approximately 3.0  
29 204 Pre-dose / [ADDRESS_916519]-dose 1 – 2 h 11  22 Approximately 3.0  
32 225 Pre-dose / 0 h  12 1201  23 Approximately 3.0  
36 253 Pre-dose / 0 h  13 1301  24 Approximately 3.0  
40 281 Pre-dose / 0 h  14 1401  25 Approximately 3.0  
44 309 Pre-dose / [ADDRESS_916520] dose   
9801  98 Approximately 3.0        
 
Unscheduled sample    1001+  Approximately 3.0  
a The following PK assessment windows are acceptable: pre-dose sample within 0.5 h before dose 
administration, ±[ADDRESS_916521] dose in the 
extension phase  
b For the PK pre -dose (trough) samples, the actual date and time of administration of the previous dose of 
study medication should also be recorded with appropriate PK collection number as indicated in the above 
table. The PK collection number series “1, 2, 3…” is for the osilodrostat dose administered on study visit day, 
while PK collection number series “201, 301, 401…” is for the previous osilodrostat dose the subject received 
prior to the collection of the PK pre -dose (trough) sample  
[IP_ADDRESS]  Analytical method  
The plasma samples from all subjects treated with osilodrostat  will be assayed for osilodrostat 
concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC -
MS/MS). The lower limit of quantitation (LLOQ) will be 0.10 ng/mL fo r osilodrostat; values 
below LLOQ will be reported as zero ng/mL, and missing samples will be labeled accordingly. 
Concentrations of osilodrostat  will be expressed in mass per volume units (ng/mL). Placebo 
samples will not be analyzed.  

[COMPANY_001]  Confidential  Page [ADDRESS_916522] be completed in accordance with the schedules listed in  Table 
7-1a, Table 7 -1b, Table 7 -2 and Table 7 -11. Patient’s refusal to complete all or any part of a 
questionnaire should be documented in the study data ca pture system and should not be captured 

[COMPANY_001]  Confidential  Page [ADDRESS_916523] 
familiar to the patient. The patient should be given sufficient space and time to complete the 
questionnaire. The site personne l should check the questionnaire for completeness and ask the 
patient to complete any missing responses. The original questionnaire will be kept with the 
patient’s file as the source document.  
Completed questionnaire(s) and any unsolicited comments written  by [CONTACT_677468]. This assessment must be documented in study 
source records. If AEs or SAEs are confirmed, study  investigators must not encourage the 
patient to change responses reported in the completed questionnaires. Study investigators must 
follow reporting instructions outlined in Section 8  (e.g. reference “A dverse Events” section) of 
the study protocol.  
Table 7-11 Patient reported outcomes (PROs) collection plan  
Patient 
Questionnaires1 Week  Day Time 
C-SSRS  
 -[ADDRESS_916524] treatment follow -
up: Week 2**, 5**, 8**, 
12**.  -[ADDRESS_916525] dose +[ADDRESS_916526] treatment follow -up 
Day 15**, 36**, 57**,  85**. Prior to any clinical assessment s, 
drug dosing (predose)  or 
diagnostic testing. 
CushingQoL , 
Beck Depression 
Inventory -II 1, 2, 5, 8, 12, 14, 17, 
20, 23, 26, 36, 48, and 
at Post treatment follow -
up. 
Post treatment follow -up 
Week 2**, 5**, 8**, 12**. 1, 15, 36, 57, 85, 99, 120, 
141, 162, 253, 337, Last 
dose +[ADDRESS_916527] treatment follow -up 
Day 15**, 36**, 57**, 85**. Prior to any clinical assessment s, 
drug dosing (predose)  or 
diagnostic testing. 
EQ-5D-5L 1, 12, 14, 26, 36, 48, 
and at Post treatment 
follow -up. 
Post treatment follow -up 
Week 12**. 1, 85, 99, 183, 253, 337, 
Last dose +[ADDRESS_916528] treatment follow -up 
Day 85**. Prior to any clinical assessment s, 
drug dosing (predose)  or 
diagnostic testing. 
Cushing  QoL 
Beck Depression 
Inventory -II 
EQ-5D-5L Optional Treatment 
Extension:  
72, 96, end of treatment  
Extension visit ***, and 
at Post treatment follow -
up.  
505, 673, Last dose +30 
days .   
 Prior to any clinical assessment s, 
drug dosing (predose  for Week 
72) or diagnostic testing. 
[ADDRESS_916529] general: Cushing QoL 
→ Beck Depression Inventory -II → EQ -FD-5L 
** For patients  who discontinued study drug during Period 1  
*** End of treatment  Extension  visit assessmen t should be completed at the time the patients transitioning either to 
a separate long -term safety follow -up study, a local alternative treatment option, or the completion of the study, 
whichever occurs first.  Note: Patients to end study participation within [ADDRESS_916530]  
[COMPANY_001]  Confidential  Page 103 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 Columbia Suicide Severity rating Scale (C -SSRS)  
The Columbia -Suicide Severity Rating Scale (C -SSRS) is a questionnaire that prospectively 
assesses S uicidal Ideation and Suicidal Behavior using a semi -structured interview to probe 
patient responses.  
The eC-SSRS  is a validated version of the C -SSRS that captures self -reported C -SSRS data via 
a web-based system. The eC -SSRS uses a detailed branched logi c algorithm to perform the C -
SSRS subject answers in order to evaluate each subject’s suicidal ideation and behavior in a 
consistent manner. Data are handled as third party data. At the conclusion of each assessment, 
the investigator will receive a detaile d eC-SSRS Findings Report via e -mail or fax. If the system 
assesses the patient as having positive suicidal signs, the investigator will be immediately 
notified by [CONTACT_348195], email and/or via telephone.  
The “baseline/screening” version of the C -SSRS will be provided to patient at the first visit  by 
[CONTACT_15370] (see Table 7 -1a). This version assesses Suicidal Ideation and Suicidal Behavior 
during the subject’s lifetime and during a predefined period. Th e predefined period currently 
used in [COMPANY_001] trials is past six months for suicidal ideation and past two years for suicidal 
behavior. At subsequent visits , the “since last visit” version will be administered (see  Table 7 -
1a, Table 7 -1b).  
If the score is “yes” on item 4 or item 5 of the Suicidal Ideation section of the C -SSRS or “yes” 
on any item of the Suicidal Behavior section, the patient must be referred to a mental health 
care professional for further assessment and/or treatment. The decision on whether the study 
drug should be discontinued is to be taken by [CONTACT_677469].  
CushingQoL  
The Cushing’s Disease Health -Related Quality of Life Questionnaire (CushingQoL) (version 
1.0) that was developed to evaluate quality of life in patients with Cushing’s syndrome ( Webb 
et al 2008 ). The CushingQoL is comprised of 12 items that capture patient responses on seven 
concepts: daily activities, healing and pain, mood and self -confidence, social concerns, physical 
appearance, memory and concern about the future. Cont ent reliability, sensitivity to change and 
psychometric properties have been validated in patients with Cushing’s disease ( Nelson et al 
2013 ). 
For this study, the CushingQoL has been modified from the st andard four -week recall to a one -
week recall in order to be more sensitive to the changes in patient quality of life, during Study 
Periods 1 and 2 where it is believed that changes in Cushing’s disease symptoms will occur 
rapi[INVESTIGATOR_677385].  
BDI-II 
The Beck Depression Inventory II (BDI -II) is a patient reported instrument that consists of [ADDRESS_916531] of  four statements arranged in increasing severity about 
a particular symptom of depression.  
[COMPANY_001]  Confidential  Page 104 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 EQ-5D-5L 
The EQ -5D-5L questionnaire is a standardized measure of health status developed by [CONTACT_181273] a simple, generic measure of health  for clinical and 
economic appraisal. The EQ -5D-5L is applicable to a wide range of health conditions and 
treatments; it provides a simple descriptive profile and a single index value for health status that 
can be used in the clinical and economic evaluati on of health care as well as in population health 
surveys.  
The EQ -5D-5L is designed for self -completion by [CONTACT_677470], in clinics, and in face -to-face interviews. It is cognitively undemanding, taking 
only a few minutes to complete.  
Instructions to respondents are included in the questionnaire. The EQ -5D-5L measures 5 items 
on mobility, self -care, usual activities, pain/discomfort, anxiety/depression, measured on 5 
levels: no problems, slight problems, moderate problems, severe problems, and extreme 
problems. The EQ -5D-5L also includes a 20 cm vertical, VAS (visual analogue scale) with on 
a scale of 0 -100, with endpoints labeled ‘the best health you can imagine’ and ‘the worst health 
you can imagine’. A single index value is analyzed for the EQ -5D-5L and VAS score.  
8 Safety monitoring and reporting  
8.1 Adverse events  
8.1.1  Definitions and reporting  
An adverse event is defined as the appearance of (or worsening of any pre -existing) undesirable 
sign(s), symptom(s), or medical condition(s) that occur after patient’s signed informed consent 
has been obtained.  
Abnormal laboratory values or test results occurring after informed consent constitute adverse 
events only if they induce clinical signs or symptoms, are considered clinically significant, 
require therapy (e.g., hematologic abnormality that requires transfusion or hematological stem 
cell support), or require changes in study medication(s).  
Adverse events that begin or worsen after informed consent should be recorded i n the Adverse 
Events eCRF. Conditions that were already present at the time of informed consent should be 
recorded in the Medical History page of the patient’s eCRF. Adverse event monitoring should 
be continued for at least 30 days (or 5 half -lives, whiche ver is longer) following the last dose 
of study drug. Adverse events (including lab abnormalities that constitute AEs) should be 
described using a diagnosis whenever possible, rather than individual underlying signs and 
symptoms. When a clear diagnosis can not be identified, each sign or symptom should be 
reported as a separate Adverse Event.  
Adverse events will be assessed according to the Common Terminology Criteria for Adverse 
Events (CTCAE) version  4.03.  
If CTCAE grading does not exist for an adverse eve nt, the severity of mild, moderate, severe, 
and life -threatening, corresponding to  Grades 1 - 4, will be used. CTCAE Grade 5 (death) will 
[COMPANY_001]  Confidential  Page 105 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 not be used in this study but is collected as a seriousness criteria; rather, information about 
deaths will be collect ed though a Death form.  
Table 8-1 CTCAE v4.03 - General grading guideline  
Grade  Definition of Severity  
1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not 
indicated  
2 Moderate; minimal, local or noninvasive intervention indicated; limiting age -appropriate 
instrumental ADL*  
3 Severe or medically significant but not immediately life -threatening hospi[INVESTIGATOR_77081]; disabling; limiting self -care ADL**  
4 Life-threatening consequences; urgent intervention indicated  
Activities of Daily Living (ADL)  
*Instrumental ADL refer to preparing meals, shoppi[INVESTIGATOR_677386], using the telephone, managing 
money, etc.  
**Self -care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and 
not bedridden.  
Please refer to: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_201 0-06-14_QuickReference_8.5x11.pdf  
The occurrence of adverse events should be sought by [CONTACT_105] -directive questioning of the patient 
(subject) during the screening process after signing informed consent and at each visit during 
the study. Adverse events also may be detected when they are volunteered by [CONTACT_102] 
(subject) during the screening process or between visits, or through physical examination, 
laboratory test, or other assessments. As far as possible, each adverse event should be evaluated 
to de termine:  
• The severity grade (CTCAE Grade 1 -4) 
• Its duration (Start and end dates)  
• Its relationship to the study drug (Reasonable possibility that AE is related: No, Yes)  
• Action taken with respect to study or investigational treatment (none, dose adjusted, 
temporarily interrupted, permanently discontinued, unknown, not applicable)  
• Whether medication or therapy was given  
• Outcome (not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequelae , fatal, unknown)  
• Whether it is serious, where a serious adverse event (SAE) is defined as in Section 8.2.[ADDRESS_916532] been met.  
All adverse events should be treated appropriately. If a concomitant medication  or non -drug 
therapy is given, this action should be recorded on the Adverse Event eCRF.  
Once an adverse event is detected, it should be followed until its resolution or until it is judged 
to be permanent, and assessment should be made at each visit (or mo re frequently, if necessary) 
of any changes in severity, the suspected relationship to the study drug, the interventions 
required to treat it, and the outcome.  
[COMPANY_001]  Confidential  Page [ADDRESS_916533] abnormalities  
[IP_ADDRESS]  Definitions and reporting  
Laboratory abnormalities that constitute  an Adverse event in their own right (are considered 
clinically significant, induce clinical signs or symptoms, require concomitant therapy or require 
changes in study drug), should be recorded on the Adverse Events eCRF. Whenever possible, 
a diagnosis, ra ther than a symptom should be provided (e.g. anemia instead of low hemoglobin). 
Laboratory abnormalities that meet the criteria for Adverse Events should be followed until 
they have returned to normal or an adequate explanation of the abnormality is found.  When an 
abnormal laboratory or test result corresponds to a sign/symptom of an already reported adverse 
event, it is not necessary to separately record the lab/test result as an additional event.  
Laboratory abnormalities, that do not meet the definition o f an adverse event, should not be 
reported as adverse events. A Grade 3 or 4 event (severe) as per CTCAE does not automatically 
indicate a SAE unless it meets the definition of serious as defined below and/or as per 
investigator’s discretion. A dose hold o r medication for the lab abnormality may be required by 
[CONTACT_217974], by [CONTACT_108], be an adverse event 
and must be reported as such.  
8.1.[ADDRESS_916534]  
Some AEs are predicted by [CONTACT_171101] (MoA) of osilodrostat or by [CONTACT_677471] , specifically in subjects with Cushing’s disease. Many, but not all, of these AEs have 
been observed in preclinical and/or clinical studies.  
These “AEs of Special Interest” are listed under the f ollowing mechanistic groups:  
• Adrenal Hormone Precursor Accumulation -related AEs  
• Hypocortisolism related AEs  
• Pi[INVESTIGATOR_677387] -related AEs  
• QT-prolongation -related AEs  
• Arrythmogenic potential AEs  
Two of the AEs of special interest, the potential fo r QT prolongation and glucocorticoid 
withdrawal/adrenal insufficiency are described in greater detail below.  
[IP_ADDRESS]  Risk of QT Prolongation  
Preclinical cardiac safety studies have revealed a signal of QT prolongation with osilodrostat 
that is consistent across in vitro  and in vivo  studies. Preliminary clinical data suggest that there 
is a risk for QT prolongation in patients, at doses above th e therapeutic range, but this requires 
further investigation to quantify the effect of osilodrostat and preliminary clinical data indicate 
that QT prolongation is a risk associated with osilodrostat therapy . Relevant QTc data from 
study [LCI699C2201]  is presented in this section on the risk of QT prolongation.  

[COMPANY_001]  Confidential  Page 107 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 Study [LCI699C2201] . Although  the PoC study was not designed to control adequately for 
changes in the QT interval, locally read 12 -lead EKGs were p erformed. In the 10 -week analysis, 
the mean (± SD) for QTcF at screening was 388.60 ± 62.80 msec, and at the end of study was 
412.31 ± 28.861msec [CLCI699C2201 PT -Listing 16.2.9 -1.2.2] . No conclusion can be drawn 
because of the high variability of results,  the absence of correlation with osilodrostat plasma 
concentration, and the potential for several concomitant risk factors for QT prolongation. In 
addition, the end of study ECGs were performed [ADDRESS_916535] dose of osilodrostat was 
administered. There were no patients with QTcB > 480 msec, and no reported QT -related AEs 
or cardiac arrhythmias in this POC study.  
Study [LCI699C2105] . This study was an ICH E -14 compliant thorough QT/QTc study  
conducted in healthy volunteers  (see Section [IP_ADDRESS].4  for a summary of the results ). The results 
support the use of osilodrostat in doses up to 30 mg.    
[IP_ADDRESS]  Glucocorticoid withdrawal and adrenal insufficiency  
Important and closely related AEs of  special interest are glucocorticoid withdrawal and 
hypocortisolism (adrenal insufficiency). These AEs are a consequence of the potent activity of 
osilodrostat to inhibit cortisol synthesis. In patients Cushing’s disease, the relatively rapid 
correction of  hypercortisolism can result in symptoms of glucocorticoid withdrawal. If the 
inhibition of cortisol synthesis is excessive, hypocortisolism with or without symptoms of 
adrenal insufficiency may develop.  
Although symptoms of frank adrenal insufficiency wer e not reported in the 10 -week analysis 
of study [LCI699C2201] , four patients did reports symptoms suggestive of glucocorticoid 
withdrawal. These symptoms were managed successfully by [CONTACT_677472].  
[IP_ADDRESS]  Definitions and reporting  
Designated e vents of special interest will be collected through routine AE collection. These 
events will be presented and discussed separately in the CSR.  

[COMPANY_001]  Confidential  Page 108 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 8.2 Serious adverse events  
8.2.1  Definitions  
Serious adverse event (SAE) is defined as one of the following:  
• Is fatal or li fe-threatening  
• Results in persistent or significant disability/incapacity  
• Constitutes a congenital anomaly/birth defect  
• Is medically significant, i.e., defined as an event that jeopardizes the patient or may require 
medical or surgical intervention to prev ent one of the outcomes listed above  
• Requires inpatient hospi[INVESTIGATOR_1081],  
• Note that hospi[INVESTIGATOR_14944]:  
• Routine treatment or monitoring of the studied indication, not associated with  any 
deterioration in condition  
• Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent  
• Social reasons and respi[INVESTIGATOR_064]’s 
general condition  
• Note that treatment on an emergency outpatient basis that does not result in hospi[INVESTIGATOR_677388] a SAE given above 
is not a serious adverse event . 
8.2.[ADDRESS_916536] be reported as follow -up to the original ep isode within 24 hours of 
the investigator receiving the follow -up information. An SAE occurring at a different time 
interval or otherwise considered completely unrelated to a previously reported one should be 
reported separately as a new event.  
Any SAEs ex perienced after this 30 days period should only be reported to [COMPANY_001] if the 
investigator suspects a causal relationship to the study drug.  
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sec tions of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess and record the relationship of each SAE to each 
specific study drug (if there is more than one study drug), complete the SAE Report Form in 
English, and submit the completed form within [ADDRESS_916537] as the original SAE Report.  Each re -
occurrence, complication, or progression of the original event should be reported as a follow -
up to t hat event regardless of when it occurs. The follow -up information should describe 
whether the event has resolved or continues, if and how it was treated, whether the blind was 
broken or not, and whether the patient continued or withdrew from study particip ation.  
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new 
occurrence) and is thought to be related to the [COMPANY_001] study drug, an oncology [COMPANY_001] Drug 
Safety and Epi[INVESTIGATOR_623] (DS&E) department associate may urgently require further 
information from the investigator for Health Authority reporting. [COMPANY_001] may need to issue 
an Investigator Notification (IN), to inform all investigators involved in any study with the same 
drug that this SAE has been reported. S uspected Unexpected Serious Adverse Reactions 
(S[LOCATION_003]Rs) will be collected and reported to the competent authorities and relevant ethics 
committees in accordance with Directive 2001/20/EC or as per national regulatory requirements 
in participating countries.  
8.[ADDRESS_916538] often, study drug discontinuation and knowledge of the possible treatment 
assignments are suffici ent to treat a study patient who presents with an emergency condition. 
Emergency code breaks are performed using the IRT. When the investigator contacts the IRT 
to unblind a patient, he/she must provide the requested patient identifying information and 
confirm the necessity to unblind the patient. The investigator will then receive details of the 
drug treatment for the specified patient and a fax confirming this information. The system will 
automatically inform the [COMPANY_001] monitor for the site and the Stud y Lead that the code has 
been broken.  
It is the investigator’s responsibility to ensure that there is a procedure in place to allow access 
to the  IRT in case of emergency. The investigator will inform the patient how to contact [CONTACT_5657]/her 
backup in cases of e mergency when he/she is unavailable. The protocol number, study drug 
name [CONTACT_90228], subject number, and instructions for contact[CONTACT_144957] (or 
any entity to which it has delegated responsibility for emergency code breaks) will be provid ed 
to the patient in case emergency unblinding is required at a time when the investigator and 
backup are unavailable. However, if a mechanism is already in place to ensure that the 
investigator and/or back -up can always be reached in case of emergency the n the procedure 
above is not required.  
Study drug must be discontinued once emergency unblinding  has occurred . 
An assessment will be done by [CONTACT_677473]/Medical Lead 
after an emergency unblinding to assess whether or n ot study drug should be discontinued for 
a given patient and, if applicable, whether the patient can continue to receive study drug and be 
followed as described in the protocol.  
[COMPANY_001]  Confidential  Page [ADDRESS_916539] be 
reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy should be 
followed up to determine outcome, including spontaneous or voluntary termination, details of 
the birth, and the presence or absence of a ny birth defects, congenital abnormalities, or maternal 
and/or newborn complications.  
Pregnancy should be recorded on a Clinical Trial Pregnancy Form and reported by [CONTACT_36926][INVESTIGATOR_066] (DS&E). 
Pregnancy follow -up should be recorded on the same form and should include an assessme nt 
of the possible relationship to the study drug any pregnancy outcome. Any SAE experienced 
during pregnancy must be reported on the SAE Report Form.  
8.5 Warnings and precautions  
No evidence available at the time of the approval of this study protocol indicat ed that special 
warnings or precautions were appropriate, other than those noted in the provided Investigator 
Brochure. Additional safety information collected between IB updates will be communicated 
in the form of Investigator Notifications. This informat ion will be included in the patient 
informed consent and should be discussed with the patient during the study as needed.  
8.6 Data Monitoring Committee  
This study will institute a data monitoring committee (DMC) which will function independently 
of all other i ndividuals associated with the conduct of this clinical trial, including the site 
investigators participating in the study. The DMC will be constituted prior to the randomization 
of the first patient. The DMC will be responsible to review safety data at a frequency to be 
decided jointly by [CONTACT_677474] . This includes but does not limit the role of the DMC 
to evaluate these data and to provide recommendations to the sponsor to continue  the study 
without change, modify  the study , or stop the study ear ly.  
It is expected that the DMC will consist of a minimum of two physicians with appropriate 
disease area qualifications, one cardiologist, and one statistician. There will be a meeting with 
the DMC describing their roles and responsibilities and discussi ng potential data format and 
process issues prior to the finalization of DMC charter.  
A DMC subcommittee consisting of a group of  Independent Endocrinologists (IEs) will be 
responsible for dose titration during the double -blind, placebo -controlled period o f the study.  
The DMC members who are not IEs have a responsibility to oversee the function of the IEs, 
specifically as it relates to reporting accurate and timely UFC information to the IEs, capturing 
and communicating the dose recommendation of the IE to the study sites, and showing that 
study drug information was actually received at the study sites.   
A charter will be prepared and approved by [CONTACT_677475]. This will occur prior 
to the enrollment of the first patient. The DMC charter will specify the format and conduct of 
the meetings, conference calls, the role and responsibilities of Core  and extended members,  the 
type of data to be reviewed, and the timing and frequency of meetings.   
[COMPANY_001]  Confidential  Page 111 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 8.7 Steering Committee  
A Steering Committee (SC) will be established prior to the enrollment of the first patient . Most 
members will be  investigators participating  in the trial . [COMPANY_001] representatives from the 
Clinical Trial Team  may be present at SC meetings as non -voting participants.  
The SC will ensure transparent management of the study according to the protocol through 
recommending and approving modifications  as circumstances require. The SC will review 
protocol amendments as appropriate. Together with the clinical trial team, the SC will also 
develop recommendations for publications of study results including authorship rules. The 
details of the role of the S teering Committee will be defined in a Steering Committee charter, 
which must be approved and signed by [CONTACT_677476].  
[ADDRESS_916540] of the following:  
• What protected health information (PHI) will be collected from subjects in this study  
• Who will have access to that informa tion and why  
• Who will use or disclose that information  
• The rights of a research subject to revoke their authorization for use of their PHI.  
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
[CONTACT_5151], retains th e ability to use all information collected prior to the revocation of subject 
authorization. For subjects that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permission to collect follow -up safety information (e.g. has the subject 
experienced any new or worsened AEs) at the end of their scheduled study period.  
The data collection system for this study uses built -in security features to encrypt all data for 
transmission in both directions, preventing unauthorized access t o confidential participant 
information. Access to the system will be controlled by a sequence of individually assigned 
user identification codes and passwords, made available only to authorized personnel who have 
completed prerequisite training.  
9.2 Site monitoring  
Before study initiation, at a site initiation visit or at an investigator’s meeting, [COMPANY_001] 
personnel (or designated CRO) will review the protocol and eCRFs with the investigators and 
their staff. During the study, the field monitor will visit  the site regularly to check the 
completeness of patient records, the accuracy of entries on the eCRFs, the adherence to the 
protocol to Good Clinical Practice, the progress of enrollment, and to ensure that study drug is 
being stored, dispensed, and accou nted for according to specifications. Key study personnel 
must be available to assist the field monitor during these visits.  
[COMPANY_001]  Confidential  Page [ADDRESS_916541] maintain source documents for each patient in the study, consisting of 
case and visit notes (hospi[INVESTIGATOR_677389]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information recorded on eCRFs must be traceable to source documents in the 
patient's file. The i nvestigator must also keep the original signed informed consent form (a 
signed copy is given to the patient).  
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency with the eCRF entries. [COMPANY_001] monito ring standards require full verification for 
the presence of informed consent, adherence to the inclusion/exclusion criteria and 
documentation of SAEs. Additional checks of the consistency of the source data with the eCRFs 
are performed according to the st udy-specific monitoring plan.  
9.3 Data collection  
Designated investigator staff will enter the data required by [CONTACT_37290] (eCRF). The eCRFs have been built using fully validated secure web -
enabled software that conforms to [ADDRESS_916542] been trained. Automatic validation programs 
check for data discrepancies in the eCRFs and, allow modification or verification of the  entered 
data by [CONTACT_6649].  
The Principal Investigator [INVESTIGATOR_217914], accurate, and that entry and updates are performed in a timely manner.  
Pharmacokinetic (PK)  samples drawn during the course of the 
study will be collected from the investigator sites and analyzed by [CONTACT_15035] a central 
laboratory contracted by [CONTACT_5343]. The site staff designated by [CONTACT_677477] e protocol onto the PK and Biomarker Sample Collection eCRFs, as 
well as onto the designated CRO’s requisition form. One copy of the requisition form will be 
sent to the CRO with the relevant information (including study number, subject ID, etc.) and 
one c opy will be retained by [CONTACT_779].  
ECG tracings , and Imaging (MRI and DXA) will be transferred to central readers. Method s for 
data collection will be described in respective manuals. A [Laboratory Manual]  will also be 
available for Central Laboratory.  
9.4 Data base management and quality control  
[COMPANY_001] personnel (or designated CRO) will review the data entered by [CONTACT_49432]. Electronic data queries stating the nature of the problem and 
requesting clarification will be c reated for discrepancies and missing values and sent to the 
investigational site via the EDC system. Designated investigator site staff is  required to respond 
promptly to queries and to make any necessary changes to the data.  
Concomitant treatments and pri or medications entered into the database will be coded using the 
WHO Drug Reference List, which employs the Anatomical Therapeutic Chemical classification 
system. Medical history/current medical conditions and adverse events will be coded using the 
Medical  dictionary for regulatory activities (MedDRA) terminology.  

[COMPANY_001]  Confidential  Page [ADDRESS_916543], additional hormones and others laboratory parameters as specified in Table 7 -4 will be 
performed by a Central Laboratory. Results of analysis tested centrally will be sent 
electronically to [COMPANY_001] (or a designated CRO).  
Samples and/or data for PK sampling, imaging , ECG  readings and IRT will 
be processed centrally and the results will be sent electronically to [COMPANY_001] (or a designated 
CRO).  
Diary data will be entered into a paper diary by [CONTACT_677478].  
Randomization c odes and data about all study drugs dispensed to the patient and all IRT 
assigned dosage changes will be tracked using an Interactive Response Technology. The system 
will be supplied by a vendor(s), who will also manage the database. The data will be sent 
electronically to [COMPANY_001] personnel (or designated CRO).  
At the conclusion of the study, the occurrence of any emergency code breaks will be determined 
after return of all code break reports and unused drug supplies to [COMPANY_001] personnel (or 
designated CR O). The occurrence of any protocol violations will be determined. After these 
actions have been completed and the data has been verified to be complete and accurate, the 
database will be declared locked and the treatment codes will be unblinded and made av ailable 
for data analysis. Authorization is required prior to making any database changes to locked data, 
by [CONTACT_15044].  
For EDC studies, after database lock, the investigator will receive a CD -ROM or paper copi[INVESTIGATOR_5322].  
[ADDRESS_916544] complete d the Core  
phase of study (Period 1  and 2) or have prematurely withdrawn from the study prior to the end 
of the Core  phase.  After the Core  study phase, patients may continue in the  optional  extension 
phase. The additional data collected in the extension phase, will be further summarized in a 
final study report once these patients completed the study.  
[COMPANY_001] or designated CRO will analyze all data using the SAS System for data analysis V9.3 
or higher. Any data analyses carried out independently  by [CONTACT_677479].  
The data from all centers participating in the trial will be combined, so that an adequate number 
of patients will be available for analysis. The statistic al analysis methods described in this 
section will focus on the analysis of the data in the Core  study. Similar methods will be applied 
to the analyses in the extension phase as appropriate.  

[COMPANY_001]  Confidential  Page 114 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 10.1 Analysis sets  
10.1.1  Full Analysis Set  
The Full Analysis Set (FAS) compr ises all randomized  patients who have received at least one 
dose of study drug ( osilodrostat or placebo). According to the intent -to-treat (ITT)  principle, 
patients will be analyzed according to the treatment and stratum they have been assigned to 
during t he randomization. This is the default analysis set for efficacy.   
10.1.2  Safety Set  
The Safety Set (SS) includes all patients who received at least one dose of study drug 
(osilodrostat or placebo). Patients will be analyzed according to the study drug received, where 
treatment received is defined as the randomized/assigned treatment if the patient took at least 
one dose of that treatment or the first treatment received if t he randomized/assigned treatment 
was never received.  
10.1.3  Per-Protocol Set  
Per-Protocol Set (PPS) consists of a subset of the patients in the FAS who are compliant with 
the requirements of the Clinical Study Protocol and have no CSR -reportable protocol deviatio n.  
The criteria for CSR -reportable protocol deviation will be defined prior to database lock.  
10.1.4  Pharmacokinetic analysis set  
The pharmacokinetic analysis set (PAS) consists of all patients who receive d at least one dose 
of osilodrostat and have at least one  evaluable pharmacokinetic concentration (post -first-dose) 
at any visit.  
10.1.5  Other analysis sets  
Not applicable  
10.2 Patient demographics/other baseline characteristics  
Demographic and other baseline data will be summarized descriptively for the FAS  and the 
safety set (if not the same).  
Categorical data will be presented as frequencies and percentages. For continuous data, mean, 
standard deviation, median, minimum, and maximum will be presented.  For selected 
parameters, 25th and 75th percentiles will  also be presented.  
Relevant medical histories and current medical at baseline will be summarized by [CONTACT_59134], by [CONTACT_677480].  
10.3 Treatments (study drug , concomitant therapi[INVESTIGATOR_014], compliance)  
When appropriate, p atients in a given analysis set can be classified into mutually exclusive 
treatment arms as described below:  
For patients in FAS/PPS  
[COMPANY_001]  Confidential  Page 115 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 Osilodrostat arm: patients randomized to osilodrostat for the placebo control period of the 
study  
Placebo arm: patients ran domized to placebo for the placebo control period of the study  
For patients in SS  
Osilodrostat arm: patients receiving osilodrostat for the placebo control period of the study  
Placebo arm: patients receiving placebo for placebo control period of the study  
Exposure to study drug will be summarized descriptively using SS by [CONTACT_677481] . The actual and planned doses administered and reason for dose change will be listed.  
The number of patients with dose adjustments will be summarized by [CONTACT_5268], and all 
dosing data will be listed.  
Concomitant medications and significant non -drug therapi[INVESTIGATOR_677390], preferred term, treatment arms 
and study periods for the safety set.  The usage of concomitant medications for the treatment of 
hypertension, diabetes, and dyslipi[INVESTIGATOR_677391].  
10.4 Primary objective  
The primary objective is to demonstrate the superiority of osilodrostat compared to placebo in 
achieving a complete response (mUFC ≤ ULN)  at week 12. 
10.4.1  Variable  
The primary efficacy variable is the proportion of randomized patients in each treatment arm 
who are complete responders at Week 12.  
10.4.2  Statistical hypothesis, model, and method of analysis  
The primary analysis will be based on a Cochran –Mantel –Haenszel (CMH ) exact test stratified 
by [CONTACT_677420][INVESTIGATOR_585643] (yes/no) using the FAS. Following the ITT principle, 
patients are analyzed according to the drug and stratum they were assigned to at randomization.  
The statistical null hypothesis states tha t the complete response rates at the end of the 12-week 
placebo -controlled period (i.e., at Week 12) are the same between the two randomized arms. To 
test this hypothesis, if the 1 -sided p -value is ≤ 0.025,  and the odds ratio ( osilodrostat  vs. 
Placebo) is > 1, the null hypothesis will be rejected and the complete response rate in the 
osilodrostat  arm will be considered higher than that in the placebo arm.   
10.4.3  Handling of missing values/censoring/discontinuations  
It is scheduled to collect three individual 24 h ours Urine Free Cortisol (UFC) samples at visits 
Week s 1, 12, 36, [ADDRESS_916545] -treatment Follow -up, and two UFC samples at all other 
visits. For a given visit, Mean Urine Free Cortisol (mUFC) is the mean of all available (need to 
be ≥2) individual U FC values determined at a central laboratory . In case only one or no 
individual UFC value is available, the mUFC will be considered missing for that visit.  
During the double blind period, early discontinued patients (prior to Week 12) will be followed 
at regular visits and have assessments performed as indicated in Table 7 -1a (post -treatment 
[COMPANY_001]  Confidential  Page 116 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 follow -up). Patients who discontinued prior to Week 12 or had a missing mUFC assessment at 
Week 12 will be considered as non -responder in the primary analysis. No imputation will be 
used.  
10.4.4  Supportive and sensitivity analyses  
As a supportive analysis to the primary analysis, an un-stratified Fisher’s exact test of the 
primary endpoint will be performed using FAS.  
In addition, both stratified CMH exact test and un -stratified Fisher’s exact test of the primary 
endpoint will be performed using PPS.  
To deal with potential missing mUFC at Week 12, imputation methods such as multiple 
imputation will be used as sensitivi ty analysis. For patients who discontinued the study early, 
mUFC  collected during the follow -up visit at Week 12 will also be used for sensitivity analysis. 
If mUFC during the follow up visit is missing at Week 12, patient will be considered as non -
respond er.  
10.5 Secondary objectives  
10.5.1  Key secondary objective(s)  
The key secondary objective is to assess the complete response rate (proportion of enrolled 
patients with mUFC ≤ ULN) in both arms combined at Week 36 in patients receiving 
osilodrostat treatment .   
The statistical null hypothesis states that the proportion of complete response rate at Week 36 
is < 30%. The analysis of the key secondary objective will be based on the 2 -sided 95% exact 
confidence interval (CI) constructed using the Clopper -Pearson method in FAS  patients 
receiving osilodrostat treatment . Patients with missing mUFC at Week 36 will be counted as 
non-responders . If the lower bound of this 95% confidence interval is ≥ 30%, the null hypothesis 
will be rejected and the complete response rate will be considered at least 30%  at Week 36 . 
Patients randomized to placebo who do not switch to osilodrostat will not be included in this 
analysis.  
The above testing on the key secondary objective will only be carried out if the null hypothesis 
for the primary objective is rejected.  This sequential procedure will ensure preservation of the 
overall 2 -sided type 1 error at 5%.  
As supportive analysis of the key secondary objective, analysis will be repeated using  PPS 
patients  receiving osilodrostat treatment . In addition, the same analysis will be performed in the 
patients randomized to osilodrostat arm only.  For each supportive analysis, the 2 -sided 95% 
exact confidence interval of the complete response rate at Week [ADDRESS_916546] of missing mUFC, imputation method such 
as multiple imputations will be considered as sensitivity analyses.    
[COMPANY_001]  Confidential  Page 117 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 10.5.2  Other secondary efficacy objectives  
[IP_ADDRESS]  Assess the overall response rate at  Week 12,  Week 36, and Week 48 
Proportion of overall responder s (enrolled patients with mUFC ≤ ULN or have at least 50% 
reduction in mUFC from baseline   and > ULN ) at Week 12, Week 36 and Week 48 will be 
summar ized using point estimates and  Clopper -Pearson  95% C is by [CONTACT_677482] . For the osilodrostat arm, denominator will be the number of patient randomized 
to osilodrostat ; whereas for placebo arm, denominator will be number of random ized patients 
switched to osilodrostat.  
[IP_ADDRESS]  Assess the change in mUFC during the Core and optional Extension 
period s of the study  
For the actual and percentage change in mUFC from baseline, descriptive summaries will be 
provided for every visit in Core  and optional extension  phase  at which UFC is collected. 95% 
CIs for the percentage change from baseline will also be provided  by [CONTACT_677483] . 
[IP_ADDRESS]  Compare the time -to-first control of mUFC during the placebo -
control led period between patients randomized to osilodrostat and 
placebo  
Time -to-first control of mUFC during the placebo control period will be analyzed usi ng Kaplan -
Meier plots and the logrank test. Time -to-first control of mUFC is defined as the time (in days) 
from randomization to the time of the first post-baseline mUFC collection that was ≤ ULN 
(based on central lab result) before discontinuation or comp letion of placebo -control led period, 
whichever is earlier.  
[IP_ADDRESS]  Assess the time -to-escape during treatment of osilodrostat up to 
Week 48  
For patients who attained normal mUFC (≤ ULN), time -to-escape will be analyzed using 
Kaplan -Meier plots. This will be perfo rmed by [CONTACT_677484]. Time -to-escape is defined as the time (in weeks) from the first 
collection of post-baseline normal mUFC (≤ ULN) to the first mUFC > 1.[ADDRESS_916547] dose interruption.   
[IP_ADDRESS]  Assess the change from baseline in cardiovascular and metabolic 
related parameters associated with  Cushing’s disease during the core 
period of the study  
For cardiovascular and metabolic parameters associated with Cushing’s disease (e.g. fasting 
glucose, HbA1c, fasting lipid profile, SBP, DBP, weight and waist circumference):  
[COMPANY_001]  Confidential  Page [ADDRESS_916548] available 
measurement of the placebo contr ol period, whichever occurs earlier, in addition to the 
descriptive summary, the mean difference between two randomized arm and associated 2 -sided 
95% C.I. will be estimated with adjustment for corresponding baseline parameter value. In 
addition, shift tab les using normal/abnormal categories for BP (SBP, DBP), FPG, HbA1c, 
fasting lipid profile, weight and waist circumference from baseline at Week 12, 36, and 48 by 
[CONTACT_677485]. Normal for these parameters is 
defined as shown in  Appendix 3 . 
[IP_ADDRESS]  Assess the change from baseline in physical features of Cushing’s 
disease  
For each of physical features of Cushing’s disease: facial rubor, hirsutism (female only), striae, 
supraclavicular fat pad, dorsal fat pad, proximal muscle wasting (atrophy), central (abdominal) 
obesity, and ecchymoses (bruises), Likert scores will be measured.  The change from baseline 
at Weeks 12, 36 and 48 will be assessed using by [CONTACT_677486] .  
[IP_ADDRESS]  Assess the change from baseline in bone mineral density by [CONTACT_677487] 48  
For bone mineral density measured by [CONTACT_677428][INVESTIGATOR_390066], descriptive 
summaries of actual and percentage change f rom baseline at Week 48 will be provided by 
[CONTACT_677488].  
[IP_ADDRESS]  Assess the change from baseline in serum, salivary and hair cortisol 
levels  
Change in  the actual and percentage change  from baseline  to each post -baseline visit for serum 
cortisol, late night salivary cortisol, morning salivary cortisol and hair cortisol  levels  will be 
assessed . Descriptive summaries will be provided for every visit in the Core and Extension  
phase s at which the biomarkers of hypercortisolism are collected.  Salivary cortisol samples will 
only be included if they are collected within the correct time window . 95% CIs for the 
percentage change from baseline will also be provided  by [CONTACT_677410] . 
10.5.3  Safety objectives  
[IP_ADDRESS]  Analysis set and groupi[INVESTIGATOR_677392] -determined ranges. Other safety data (e.g. 
ECG, vital signs, and special tests)  will also be presented. All safety outputs will use the SS, 
which consists of all patients that received at least one dose of osilodrostat or placebo. Safety 
data will be presented in two different periods as defined below.  
• Placebo -controlled period: patients randomized to osilodrostat, patients randomized to 
placebo, and overall patients  
[COMPANY_001]  Confidential  Page 119 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 • Overall study period: patients randomized to osilodrostat, patients randomized to placebo, 
and overall patients  
• The overall observation period wi ll be divided into three mutually exclusive segments:  
• pre-treatment period: from day of patient’s informed consent to the day before first dose 
of study medication  
• on-treatment period: from day of first dose of study medication to [ADDRESS_916549] dose 
of study medication  
• post-treatment period: starting at day 30+[ADDRESS_916550] dose of study medication.  
[IP_ADDRESS]  Adverse events (AEs)  
Summary tables for adverse events (AEs) have to include only AEs that started or worsened 
during the on -treatment period, the treatment -emergent  AEs. However, all safety data 
(including those from the pre and post -treatment periods) will be listed and those collected 
during the pre -treatment and post -treatment period are to be flagged.  
The incidence of treatment -emergent adverse events (n ew or worsening from baseline) will be 
summarized by [CONTACT_30826], severity (based on CTCAE version 
4.03 grades), type of adverse event, relation to study treatment.  
Serious adverse events, non -serious adverse events and adverse  events of special interest  
(AESI)  during the on -treatment period will be tabulated.  
All deaths (on -treatment and post -treatment) will be summarized.   
All AEs, deaths and serious adverse events (including those from the pre and post -treatment 
periods) wil l be listed and those collected during the pre -treatment and post -treatment period 
will be flagged.  
[IP_ADDRESS]  Laboratory abnormalities  
Grading of laboratory values will be assigned programmatically as per NCI Common 
Terminology Criteria for Adverse Events (CTCAE) ve rsion 4.03 .  The calculation of CTCAE 
grades will be based on the observed laboratory values only, clinical assessments will not be 
taken into account.  
CTCAE Grade 0 will be assigned for all non -missing values not graded as 1 or higher. Grade  5 
will not be used.  
For laboratory tests where grades are not defined by [CONTACT_3989] v4.03, results will be categorized 
as low/normal/high based on laboratory normal ranges . 
The following summaries will be generated separately for hematology, and biochemistry t ests: 
• Listing of all laboratory data with values flagged to show the corresponding CTCAE 
v4.03 grades if applicable and the classifications relative to the laboratory normal ranges  
For laboratory tests where grades are defined by [CONTACT_3989] v4.03   
• Worst post-baseline CTCAE grade (regardless of the baseline status). Each patient will be 
counted  only once for the worst grade observed post -baseline.  
[COMPANY_001]  Confidential  Page 120 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 • Shift tables using CTCAE  v4.[ADDRESS_916551] s where grades are not defined by [CONTACT_3989] v4.03,  
• Shift tables using the low/normal/high/ (low and high)  classification to compare baseline 
to the worst on-treatment  value.  
[IP_ADDRESS]  Other safety data  
ECG  
ECG data will be summarized with  
• shift table baseline to worst o n-treatment result for overall assessments  
• Number and percentage of patients with clinically notable QT/QTcF interval values will 
be summarized.  
• listing of ECG evaluations for all patients with at least one abnormality.  
Vital signs  
Vital signs (supi[INVESTIGATOR_30991], HR & temperature) reporting of results will include  
• shift table baseline to worst on -treatment result  
• table with descriptive statistics at baseline, one or several post -baseline time points and 
change from baseline to this/these post -baseline time points.  
Tumor volume  and longest dimension   
Tumor volume and longest dimension will be evaluated as defined in Section [IP_ADDRESS]  
The longest dimension (in mm) will be summarized as absolute values and actual and perc ent 
change from baseline in longest dimension. The tumor invasiveness  is also evaluated, in terms 
of the prevalence of tumors with extension outside sella tur cica and/or invasion into surrounding 
structures at baseline and during the study  (new onset/disappearance) . 
In addition, if the  tumor volume is evaluated, a descriptive summary of actual tumor volumes 
as well as actual and percent change from baseline in tumor volumes will be provided.   
Columbia Suicide Severity Reporting Scale (C -SSRS) 
C-SSRS data will be mapped to Columbia Classification Algorithm for Suicide Assessment 
(C-CASA) as per FDA guidance on suicidality ( Food and Drug Administration 2010 ). The 
proportion of patients who have completed suicide, suicide attempt, preparatory actions 
toward imminent suicidal behavior, suicidal ideation, and self -injurious behavior without 
suicidal intent will be summarized by [CONTACT_2939]. The number of pati ents with SAEs 
referring to a positive suicidal evaluation will be summarized by [CONTACT_2939]. 
[IP_ADDRESS]  Supportive analyses for secondary objectives  
Not applicable  
[COMPANY_001]  Confidential  Page 121 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 [IP_ADDRESS]  Tolerability  
Tolerability will be studied in terms of dose reductions or drug interruption due to an  AE. 
10.5.[ADDRESS_916552], visit, incident dose and nominal sampling times. 
Descriptive statistics of plasma concentrations will be provided by [CONTACT_677489], visit and 
nominal sampling times, and will include arithmetic and geometric mean, median, SD, CV, 
geometric CV, minimum and maximum. Zero concentrations will not be included in the 
geometric mean calculation.  Graphical depi[INVESTIGATOR_182513] (mean and individual) for osilodrostat 
concentrations and/or profiles  (if applicable) during the course of the study will be performed 
by [CONTACT_677490]. Additional details on PK data analysis will be specified in the 
statistical analysis plan . 
[IP_ADDRESS]  Data handling principles  
Plasma concentrations of osilodrostat will be expressed in ng/mL. Missing concentration values 
will be labeled as such in data listings. Concentrations below the limit of quantitation (LLOQ) 
will be treated as zero in summary statistics and reported as zero in data listings.  
10.5.[ADDRESS_916553]. EQ -5D utility 
index and visual analogue scale (VAS) scores, and Beck Depression Inventory -II (BDI) total 

[COMPANY_001]  Confidential  Page [ADDRESS_916554] square means between osilodrostat and placebo arm, and the 
corresponding 2 -sided 95% confidence interval (CI) at each time point  will be presented. 
Descriptive statistics will be used to summarize the raw and absolute change from baseline for  
the scores at each scheduled assessment  including critical time points such as from baseline to 
Week 12 and Week 48, from Week 12 to Week 36 and from Week 36 to Week 48 etc.  during 
both Core  phase (Study Period 1  and 2) and the optional extension phase.  
Similar analyses will be performed for EQ -5D utility index and visual analogue scale (VAS) 
scores, and Beck Depression Inventory -II (BDI) total score.  
Missing items data in a scale will be handled based on each instrument  manual. Additional 
details for handling missing items data will be specified in the analysis plan for instruments 
with no missing data handling criteria in the instrument manual.  
No imputation will be applied if the total scores are missing at a visit. Pa tients with baseline 
and at least one non -missing post -baseline assessments during the Core  phase will be included 
in the linear mixed effect model analysis. All available data until completion or early 
discontinuation during Core  phase will be used in the  linear mixed effect models analyses with 
missing scores at any time point are assumed to be missing -at-random (MAR).  

[COMPANY_001]  Confidential  Page [ADDRESS_916555] periodic 
safety data reviews as outlined in Section 8.6 . 
10.8 Sample size calculation  
Eligible patients will be stratified at randomization according to histo ry of pi[INVESTIGATOR_585643] 
(yes/no). Based on the LCI699C2201 study,  it is assumed that approximately 20% of 
randomized patients will have a history of pi[INVESTIGATOR_677393].   
With 2:[ADDRESS_916556] a difference of 45% in complete response rate between 
60% in osilodrostat arm and 15% in placebo arm (equivalent odds ratio equals 8.5), a sample 
size of 42 patients in osilodrostat arm and 21 patients in placebo arm will provide 91% power 
based on a [ADDRESS_916557] for drop -outs, an 
additional 10% patients will be enrolled. Thus a total of approximately 69 patients will be 
enrolled in the study.  
10.9 Power for analysis of key secondary variables  
The analysis of the key secondary objective will be based on the 2 -sided 95% confidence 
interval constructed using the Clopper -Pearson exact method. If the lower bound of this 95% 
confidence interval is ≥ 30%, the null hypothesis will be rejected and the complete response 
rate will be considered at least 30%  at Week  36 . Both t he SOM230G2304 trial of Pasireotide 
LAR and the SOM230B2305 trial of Pasireotide s.c. were powered to show a response rate 

[COMPANY_001]  Confidential  Page 124 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 where the lower bound of the 95% confidence interval was ≥15%. Therefore an increase in this 
lower bound of the 95% confi dence interval to a threshold of ≥30% would provide a significant 
improvement in clinical benefit to this patient arm. 
The above testing on the key secondary objective will only be carried out if the null hypothesis 
for the primary objective is rejected.  This sequential procedure will ensure preservation of the 
overall 2 -sided type 1 error at 5%.  
Assuming a 60% complete response rate at Week 3 6, and less than 50% discontinuation rate of 
patients in placebo arm prior to Week 12. For the 69 patien ts in the pooled population, there is 
higher than 98% chance that the lower bound of 2 -side 95% exact CI (based on Clopper -Pearson 
method) of the observed response rate is larger than 30%.  
11 Ethical considerations and administrative procedures  
11.1 Regulatory and  ethical compliance  
This clinical study was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC and US Code of Federal Regulations 
Title 21), and with the ethical principles laid down in the Declaration of Helsinki.  
11.2 Responsibilities of the investigator and IRB/IEC/REB  
The protocol and the proposed informed consent form must be reviewed and  approved by a 
properly constituted Institutional Review Board/Independent Ethics Committee/Research 
Ethics Board (IRB/IEC/REB) before study start. Prior to study start, the investigator is required 
to sign a protocol signature [CONTACT_5389]/her agre ement to conduct the study in 
accordance with these documents and all of the instructions and procedures found in this 
protocol and to give access to all relevant data and records to [COMPANY_001] monitors, auditors, 
[COMPANY_001] Clinical Quality Assurance represen tatives, designated agents of [COMPANY_001], 
IRBs/IECs/REBs and regulatory authorities as required.  
11.3 Informed consent procedures  
Eligible patients may only be included in the study after providing written (witnessed, where 
required by [CONTACT_6617]), IRB/IEC /REB -approved informed consent  
Informed consent must be obtained before conducting any study -specific procedures (i.e. all of 
the procedures described in the protocol). The process of obtaining informed consent should be 
documented in the patient source d ocuments. The date when a subject’s Informed Consent was 
actually obtained will be captured in their eCRFs.  
[COMPANY_001] will provide to investigators, in a separate document, a proposed informed consent 
form (ICF) that is considered appropriate for this study  and complies with the ICH GCP 
guideline and regulatory requirements. Any changes to this ICF suggested by [CONTACT_5381]/IEC/REB, and a copy of the 
approved version must be provided to the Novar tis monitor after IRB/IEC/REB approval.  
[COMPANY_001]  Confidential  Page [ADDRESS_916558] adhere to the contraception requirement for the 
duration of the study. If there is any question that the patient will not reliably comply, they 
should not be entered in the study.  
11.4 Discontinuatio n of the study  
[COMPANY_001] reserves the right to discontinue this study  under the conditions specified in the clinical 
study agreement. Specific conditions for terminating the study are outlined in  
Section  4.4. 
11.5 Publication of study protocol and results  
[COMPANY_001] assures that the key design elements of this protocol will be posted in a publicly 
accessible database such as clinicaltrials.gov. In addition, upon study completion and 
finalization of the study rep ort the results of this study will be either submitted for publication 
and/or posted in a publicly accessible database of clinical study results.  
11.5.[ADDRESS_916559] ethical  standards for reporting the results of 
medical research, including the timely communication and publication of clinical trials results, 
whatever their outcome.  
[COMPANY_001] complies with the authorship guidelines of the International Committee of Medical 
Journal Editors (ICMJE) uniform requirements for manuscripts submitted to biomedical 
journals and other specific guidelines of the journal or congress to which the document will be 
submitted. These guidelines apply to any clinical trial publication including b ut not limited to 
manuscripts, abstracts, posters, and oral presentations. For more information regarding the 
ICMJE guidelines, visit http://www.ICMJE.org/index.html#author.  
Accordingly, ALL AUTHORS MUST HAVE:  
• Contributed substantially to the study concept , design and/or conduct of the study or to the 
acquisition, analysis, and interpretation of the data AND  
• Drafted or critically revised the proposed clinical publication for important intellectual 
content AND  
• Approved the final proposed clinical publication  for submission AND  
• Have intimate knowledge of trial implementation/analysis  

[COMPANY_001]  Confidential  Page [ADDRESS_916560] attended the majority of the steering committee meetings 
and recruited patients into the trial from his/her own center to be included a s an author. Study 
investigators must have significant contribution to patient recruitment based on number of 
eligible patients upon study entry and data quality.  
11.[ADDRESS_916561] keepi[INVESTIGATOR_677394] m aintain appropriate medical and research records for this trial, in 
compliance with Section 4.9 of the ICH E6 GCP, and regulatory and institutional requirements 
for the protection of confidentiality of subjects. As part of participating in a [COMPANY_001] -spons ored 
study, each site will permit authorized representatives of the sponsor(s) and regulatory agencies 
to examine (and when required by [CONTACT_1289], to copy) clinical records for the purposes of 
quality assurance reviews, audits and evaluation of the st udy safety and progress.  
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Examples 
of these original documents and data records include, but are not limited to, hospi[INVESTIGATOR_1097], 
clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation 
checklists, pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_644663], microfiches, 
photographic negatives, microfilm or magnetic media, x -rays, and subject files and records kept 
at the pharmacy, at the laboratories, and medico -technical departme nts involved in the clinical 
trial. 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of 
the site Principal Investigator. The study case report form ( eCRF) is the primary data collection 
instrument for the study. The investigator should ensure the accuracy, completeness, legibility, 
and timeliness of the data reported in the eCRFs and all other required reports. Data reported 
on the eCRF, that are derived from source documents, should be consistent with the source 
documents or the discrepancies should be explained. All data requested on the eCRF must be 
recorded. Any missing data must be explained. For electronic CRFs an audit trail will be 
maintained by [CONTACT_1190]. The investigator should retain records of t he changes and corrections 
to eCRFs.  
The investigator/institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by [CONTACT_5383]/or guidelines. Th e investigator/institution should take measures to prevent 
accidental or premature destruction of these documents.  
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the completion of the C linical Trial unless Sponsor provides written 
permission to dispose of them or, requires their retention for an additional period of time 
because of applicable laws, regulations and/or guidelines . 
[COMPANY_001]  Confidential  Page [ADDRESS_916562] ensure anonymity of the patients; patients must not be identified by [CONTACT_5384]. Signed informed consent forms and patient enrollment 
log must be kept strictly confidential to enable patient i dentification at the site.  
11.8 Audits and inspections  
Source data/documents must be available to inspections by [CONTACT_5385].  
11.[ADDRESS_916563] be 
considered a protocol amendment , and unless such an amendment is agreed upon by [CONTACT_5386]/IEC/REB it cannot be implemented. All significant protocol 
deviations will be recorded and reported in the CSR.  
12.[ADDRESS_916564] be approved by [CONTACT_5343], Health Authorities where required, and the IRB/IEC/REB. Only 
amendments that are required for patient safety may be implemented prior to IRB/IEC/REB 
approval. Notwithst anding the need for approval of formal protocol amendments, the 
investigator is expected to take any immediate action required for the safety of any patient 
included in this study, even if this action represents a deviation from the protocol. In such cases , 
[COMPANY_001] should be notified of this action and the IRB/IEC at the study site should be informed 
according to local regulations (e.g. [LOCATION_006] requires the notification of urgent safety measures 
within 3 days) but not later than 10 working days.  
[COMPANY_001]  Confidential  Page 128 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 13 References (ava ilable upon request)  
Alvarez -Madrazo S, MacKenzie S, Davies E, et al (2013) Common Polymorphisms in the 
CYP11B1 and CYP11B2 Genes: Evidence for a Digenic Influence on Hypertension. 
Hypertension; 61: 232 -239. 
Alwani RA , Schmit Jongbloed LW,  de Jong FH, et  al (2014) Differentiating between 
Cushing’s disease and pseudo -Cushing’s syndrome: comparison of four tests. Eur J 
Endocrinol. 170:477 –486. 
American Diabetes Association (2015) Standards of Medical Care in Diabetes. J Clin Applied 
research and education 3 8 (suppl 1): 1 -93. 
Arnaldi G, Angeli A, Atkinson AB, et al (2003) Diagnosis and Complications of Cushing’s 
Syndrome: A Consensus Statement. J Clin Endocrinol Metab; 88(12):5593 -5602.  
Arnaldi, et al (2012) Advances in the epi[INVESTIGATOR_623], pathogenesis, and man agement of 
Cushing’s syndrome complications. J. Endocrinol. Invest. 35: 434448.  
Assie G, Bahurel H, Coste J, et al (2007)  Corticotroph tumor progression after adrenalectomy 
in Cushing’s disease: a reappraisal of Nelson’s syndrome. J Clin Endocrinol Metab 
92(1):172 –179. 
Ayuk J. (2012) Does Pi[INVESTIGATOR_621327], if so, What 
Preventative Actions Should be Taken? Clin Endocrinol. 76(3):328 -331. 
Biller BMK, Grossman AB, Stewart PM, et al (2008) Treatment of 
adrenocorticotropi[INVESTIGATOR_677395]’s Syndrome: a consensus statement. J Clin Endocrinol 
Metab; 93(7):2454 -62. 
Bochicchio D, Losa M, Buchfelder M, et al (1995) Factors influencing the immediate and late 
outcome of Cushing's disease treated by [CONTACT_303597]: a retro spective study by [CONTACT_677491]'s Disease Survey Group. Journal of Clinical Endocrinology and 
Metabolism; 80, 3114 -3120.  
Chan K, Lit L, Tai M, et al. (2004)  Diminished urinary free cortisol excretion in patients with 
moderate and severe renal impai rment. Clinical Chem 50 (4): 757 -9. 
Charmandari E, Nicolaides NC, Chrousos GP (2014) Adrenal insufficiency. Lancet; 383, 
2152 –2167.  
Chobanian A, Bakris GL, Black HR, et al (2003)  Seventh report of the joint national 
committee on prevention, detection, evaluation, and treatment of high blood pressure. 
Hypertension;  42, 1206 –1252 . 
Clayton R, et al (2011) Mortality and Morbidity in Cushing’s Disease over 50 Years in Stoke -
on-Trent, [LOCATION_006] : Audit and Meta -Analysis of Literature. J Clin Endocrinol Metab. 96(3): 632 -
642.  
FDA ( 2010 ) Guidance for Industry - Suicidality: Prospective assessment of occurrence in 
clinical trials.  
Feelders RA, Pulgar SJ, Kempel A, Pereira  AM (2012) The burden of Cushing's disease: 
clinical and health -related quality of life aspects. Eur J Endocrinol;167(3): 311 -26.  
[COMPANY_001]  Confidential  Page 129 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 Fleseriu M, Loriaux DL, Ludlam WH  (2007)  Second -line treatment for Cushing's disease 
when initial pi[INVESTIGATOR_677396]. Curr Opin Endocrinol Diabetes Obes; 
14(4):323 -8. 
Friedman R, et al (1989) Repeat transsphenoidal surgery for Cushing’s disease. J 
Neurosurgery 71(4):520 –527. 
Issa B, Page M, Read G, et al (1999) Undetectable urinary free cortisol concentrations in a 
case of Cushing’s disease.  Eur J Endocrinol, 140: 148 –151. 
Loeffler JS and Shih HA (2011) Radiation therapy in the management of pi[INVESTIGATOR_239572]. 
J  Clin Endocrinol Metab. 2011 Jul;96(7):1992 -2003  
Losa M, et al (2010) Pi[INVESTIGATOR_677397]’s Disease. Neuroendocrinology 92 
(suppl 1):107 –110. 
Manenschijn L, Koper JW, van den Akker EL, et al (2012) A novel tool in the diagnosis and 
follow -up of (cyclic) Cushing's syndrome: measurement of long -term cortisol in scalp hair. J 
Clin Endocrinol Me tab.; 97(10):E1836 -43. 
Masri -Iraqi H, Robenshtok E, Tzvetov G, et al (2014) Elevated white blood cell counts in 
Cushing’s disease: association  with hypercortisolism. Pi[INVESTIGATOR_2117]. 17: 436 -440. 
Minniti G, et al. (2007) Long -term follow -up results of postoperat ive radiation therapy for 
Cushing’s disease. J Neurooncol 84(1):79 –84. 
Monaghan PJ, Owen LJ, Trainer PJ, et al (2011) Comparison of serum cortisol measurement 
by [CONTACT_677492] -tandem mass spectrometry in patients receiving 
the 11 -hydroxylase inhibitor metyrapone. Ann Clin Biochem.;48:441 –446. 
Nelson L, Forsythe A, McLeod L, et al (2013) Psychometric Evaluation of the Cushing’s 
Quality -of-Life. The Patient - Patient -Centered Outcomes Research; 6(2): 113 -124. 
Newell -Price J, Bertagna X , Grossman AB, et al (2006) Cushing’s syndrome. Lancet 2006; 
367(9522): 1605 –17. 
Sedney C, et al (2012) Radiation -associated sarcoma of the skull base after irradiation for 
pi[INVESTIGATOR_296953]. Rare Tumors. 4(7), 18 -20. 
Sharp N, Devlin J, Rimmer J (1996) Ren al failure obfuscates the diagnosis of Cushing’s 
disease.  JAMA; 256 (18): 2564 -5. 
Sheehan, et al (2013) Results of gamma knife surgery for Cushing's disease.  J Neurosurg. 
2013 Dec;119(6):1486 -92. doi: 10.3171/2013.7.JNS13217. Epub 2013 Aug 9.  
Sonino N, Z ielezny M, Fava G, et al (1996)  Risk factors and long -term outcome in pi[INVESTIGATOR_2117] -
dependent Cushing’s disease. Journal of Clinical Endocrinology and Metabolism; 81(7), 
2647 -2652.  
Trainer P (2014) Next Generation Medical Therapy for Cushing’s Syndrome - Can We 
Measure a Benefit?  J Clin Endocrinol Metab, 99(4):1157 –1160.   
Valassi E, et al (2012) Clinical consequences of Cushing’s syndrome. Pi[INVESTIGATOR_2117]. 15: 319 -329. 
[COMPANY_001]  Confidential  Page 130 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 Webb S, Badia X, Barahona M, et al (2008) Evaluation of health -related quality of life in 
patient s with Cushing’s syndrome with a new questionnaire. European Journal of 
Endocrinology; 158: 623 –630. 
 
 
  
Zhang G, Wang B, Ouyang J, et al (2010) Polymorphisms in CYP11B2 and CYP11B1 genes 
associated with primary hyperaldosteronism. Hypertension Research; 33: 478 –484. 

[COMPANY_001]  Confidential  Page 131 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 14 Appendices  
Appendix 1: List of drugs to be used with cauti on with osilodrostat  
Table 14-[ADDRESS_916565] of medications with potential drug -drug interactions with 
osilodrostat – to be used with caution  
CYP1A2 
substrates  CYP2C19 
substrates  CYP2D6 substrates  CYP3A4/5 substrates  CYP2E1 substrates  
Atypi[INVESTIGATOR_91874] : 
Clozapi[INVESTIGATOR_677398]:  
Caffaine1 
Theophylline2 
Others : 
Nabumetone  
Riluzole  
Ropi[INVESTIGATOR_677399]1 
Duloxetine1 
Melatonin1 
Ramelteon1 
Tacrine1 
Tizanidine1,2 
 Anti-epi[INVESTIGATOR_23698] : 
Diazepam  
Phenytoin  
Phenobarbitone  
S-mephenytoin1,2 
Benzodiazepi[INVESTIGATOR_1651]:  
Clobazam1 
Proton pump 
inhibitors : 
Lansoprazole1 
Omeprazole1 
Pantoprazole  
Rabeprazole  
Esoprazole  
Antidepressants : 
Amitriptyline  
Clomipramine  
Others : 
Clopi[INVESTIGATOR_677400] : 
Aripi[INVESTIGATOR_677401]1 
Thioridazine2 
Antiarrhythmics : 
Encainide  
Flecaninide  
Mexilletine  
Prajmaline  
Procainamide  
Propafenone  
Sparteine  
Vernakalant  
Alpha/Beta -
adrenergic 
antagonists : 
Metoprolol1 
Nebivolol1 
Carvedilol  
Propranolol  
Tamsulosin  
Timolol  
Serotonin 
modulators : 
Venlafaxine1 
Citalopram  
Duloxetine  
Fluoxetine  
Fluvoxamine  
Nefazodone  
Ondansetron  
Paroxetine  
Repi[INVESTIGATOR_677402]:  
Quinidine2 
Dronedarone1 
Antihistimines:  
Astemizole2 
Ebastine1 
Terfenadine1,2 
Benzodiazepi[INVESTIGATOR_1651] : 
Brotizolam1 
Midazolam1 
Triazolam1 
Alprazolam  
Diazepam  
Calcium channel 
blockers : 
Felodipi[INVESTIGATOR_050]1 
Nisoldipi[INVESTIGATOR_050]1 
Amlodipi[INVESTIGATOR_677403] : 
Brecanavir1 
Capravirine1 
Darunavir1 
Indinavir1 
Lopi[INVESTIGATOR_054]1 
Saquinavir1  
Tipranavir1 
Boceprevir  
Ritonavir  
Telaprevir  
HMG CoA reductase 
inhibitors:  
Atorvastatin1 
Lovastatin1 
Simvastatin1 
Antibiotics : 
Clarithromycin  
Erythromycin  
Telithromycin  
Antipsychotics :  Enflurane  
Halothane  
Isoflurane  
Methoxyflurane  
Sevoflurane  
Acetaminophen  
Chlorzoxazone  
Ethanol  
N, N-
Dimethylformamide  
Theophylline  
[COMPANY_001]  Confidential  Page 132 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 CYP1A2 
substrates  CYP2C19 
substrates  CYP2D6 substrates  CYP3A4/5 substrates  CYP2E1 substrates  
Tricyclics/ 
tetracyclics : 
Desipramine1 
Amitriptyline  
Clomipramine  
Doxepin  
Imipramine  
Maprotiline  
Mianserin  
Mirtazapi[INVESTIGATOR_677404] : 
Codeine  
Dihydrocodeine  
Hydrocodone  
Methadone  
Oxycodone  
Tramadol  
Others : 
Atomoxetine1 
Dextromethorphan1 
Tolterodine1 
 Amiflamine  
Brofaromine  
Chlorpheniramine  
Debrisoquine  
Dexfenfluramine  
Donepezil  
Fesoterodine  
Gefitinib  
Lasofoxifene  
Loratadine  
Methamphetamine  
Methoxyphenamine  
Methylphenidate  
Nicergolin  
Pactimibe  
Phenformin  
Ranolazine  
Ratonavir  
Sabeluzole  
Tamoxifen  
Traxoprodil  Aripi[INVESTIGATOR_677405]1  
Perospi[INVESTIGATOR_5331]1 
Pi[INVESTIGATOR_3924]2  
Quetiapi[INVESTIGATOR_050]1 
Immune Modulators:  
Cyclosporine2  
Everolimus1 
Sirolimus1,2  
Tacrolimus1,2 
Tyrosine Kinase 
Inhibitors : 
Dasatinib1 
Neratinib1 
Imatinib  
Nilotinib  
Opi[INVESTIGATOR_2438] :  
Alfentanil1,2 
Fentanyl2 
Levomethadyl1 
Methadone  
Others:  
Quinine  
Tamoxifen  
Trazodone  
Vincristine  
Ergot derivatives:  
Diergotamine/  
Dihydroergotamin2 
Ergotamine2 
Corticosteroids:  
Budesonide1 
Fluticasone1 
Erectile dysfunction 
agents:  
Sildenafil1 
Vardenafil1 
Antiemetics:  
Aprepi[INVESTIGATOR_053]1 
Casopi[INVESTIGATOR_053]1 
Others: 
Alpha -
dihydroergocryptine1 
Aplaviroc1 
Buspi[INVESTIGATOR_5331]1 
Cisapride2 
Conivaptan1 
Darifenacin1 
[COMPANY_001]  Confidential  Page 133 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 CYP1A2 
substrates  CYP2C19 
substrates  CYP2D6 substrates  CYP3A4/5 substrates  CYP2E1 substrates  
Eletriptan1 
Eplerenone1 
Lumefantrine1 
Maraviroc1 
Ridaforolimus1 
Ticagrelor1 
Tolvaptan1 
Vicriviroc1 
1 Sensitive substrates: drugs that exhibit an AUC ratio (AUCi/AUC) of 5 -fold or more when co -administered with a 
known potent inhibitor.  
2 Substrates with narrow therapeutic index: drugs whose exposure -response indicates that increases in their 
exposure levels by [CONTACT_64128].  
This database of CYP substrates was compi[INVESTIGATOR_677406] e Indiana University School of Medicine’s “Clinically 
Relevant” Table; from the FDA’s “Guidance for Industry, Drug Interaction Studies” and from the University of 
Washington’s Drug Interaction Database.  
[COMPANY_001]  Confidential  Page 134 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 Appendix 2: Medications with a “ Known risk to cause TdP” and with a 
“Possible risk to cause TdP”  
The following e -link provides a list of medications with a “ Known risk to cause TdP” and with 
a “Possible risk to cause TdP”.  These medications are prohibited to be used concomitantly with  
osilodrostat : www.crediblemeds.org.  
Investigators are advised to utilize this website when considering the addition of a new 
concomitant medication, as the lists are periodically updated. If necessary, a discussion can be 
held with the [COMPANY_001] Medical Mo nitor  when considering the use of medications with a 
“Known risk to cause TdP” and with a “Possible risk to cause TdP”.  
[COMPANY_001]  Confidential  Page 135 
Amended Protocol Version 0 2 Clean   Protocol No. CLCI699C2302  
 
 Appendix 3: Normal ranges for cardiovascular risk factors  
Parameter  Conventional Units  SI Units  Comment  
Systolic blood 
pressure (SBP)  90-139 mmHg  90-139 mmHg  Conventional and SI units   
are the same  
Diastolic blood 
pressure (DBP)  60-90 mmHg  60-90 mmHg  Conventional and SI units   
are the same   
Fasting plasma 
glucose (FPG)  70-115 mg/dL                     
70-125 mg/dL  3.9-6.4 mmol/L  
3.9-6.9 mmol/L  Age 13 -49 years  
Age ≥ 50 years  
HbA1c  < 6.5 %  < 6.5 %  Percent of total hemoglobin  
Total cholesterol  < 170 mg/dL  
< 200 mg/dL  0.00-4.35 mmol/L                      
0.00-5.15 mmol/L  Age 3 -19 years  
Age ≥ 20 years  
HDL cholesterol  > 34 mg/dL  > 0.89 mmol/L  All adult ages  
LDL cholesterol  0-110 mg/dL  
0-130 mg/dL  0.00-2.85 mmol/L                       
0.00-3.35 mmol/L  Age 3 -19 years  
Age ≥ 20 years  
Triglycerides  < 200  mg/dL  2.24 mmol/L  All adult ages  
SI: Age13 -64 years  
SI: Age ≥ 65 years  
Source: Chobanian A, et al JNC 7 (2003) .  FPG, HbA1c  :  ADA Diabetes Standards 2015    . 
Lipi[INVESTIGATOR_805]: Central Labora tory Reference Ranges as of writing of original version of this protocol 
(consult Laboratory Manual for most current information).  